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A B S T R A C T
Background
Chronic obstructive pulmonary disease (COPD) is a respiratory disease that causes progressive symptoms of breathlessness, cough and
mucus build-up. It is the fourth or fifth most common cause of death worldwide and is associated with significant healthcare costs.
Inhaled long-acting beta2-agonists (LABAs) are widely prescribed to manage the symptoms of COPD when short-acting agents alone
are no longer sufficient. Twice-daily treatment with an inhaled LABA is aimed at relieving symptoms, improving exercise tolerance and
quality of life, slowing decline and even improving lung function and preventing and treating exacerbations.
Objectives
To assess the effects of twice-daily long-acting beta2-agonists compared with placebo for patients with COPD on the basis of clinically
important endpoints, primarily quality of life and COPD exacerbations.
Search methods
We searched the Cochrane Airways Group trials register, ClinicalTrials.gov and manufacturers’ websites in June 2013.
Selection criteria
Parallel, randomised controlled trials (RCTs) recruiting populations of patients with chronic obstructive pulmonary disease. Studies
were required to be at least 12 weeks in duration and designed to assess the safety and efficacy of a long-acting beta2-agonist against
placebo.
Data collection and analysis
Data and characteristics were extracted independently by two review authors, and each study was assessed for potential sources of bias.
Data for all outcomes were pooled and subgrouped by LABA agent (formoterol 12 µg, formoterol 24 µg and salmeterol 50 µg) and
then were separately analysed by LABA agent and subgrouped by trial duration. Sensitivity analyses were conducted for the proportion
of participants taking inhaled corticosteroids and for studies with high or uneven rates of attrition.
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Main results
Twenty-six RCTs met the inclusion criteria, randomly assigning 14,939 people with COPD to receive twice-daily LABA or placebo.
Study duration ranged from three months to three years; the median duration was six months. Participants were more often male
with moderate to severe symptoms at randomisation; mean forced expiratory volume in 1 second (FEV1) was between 33% and 55%
predicted normal in the studies, and mean St George’s Respiratory Questionnaire score (SGRQ) ranged from 44 to 55 when reported.
Moderate-quality evidence showed that LABA treatment improved quality of life on the SGRQ (mean difference (MD) -2.32, 95%
confidence interval (CI) -3.09 to -1.54; I2 = 50%; 17 trials including 11,397 people) and reduced the number of exacerbations requiring
hospitalisation (odds ratio (OR) 0.73, 95% CI 0.56 to 0.95; I2 = 10%; seven trials including 3804 people). In absolute terms, 18
fewer people per 1000 were hospitalised as the result of an exacerbation while receiving LABA therapy over a weighted mean of 7
months (95% CI 3 to 31 fewer). Scores were also improved on the Chronic Respiratory Disease Questionnaire (CRQ), and more
people receiving LABA treatment showed clinically important improvement of at least four points on the SGRQ.
The number of people who had exacerbations requiring a course of oral steroids or antibiotics was also lower among those taking LABA
(52 fewer per 1000 treated over 8 months; 95% CI 24 to 78 fewer, moderate quality evidence).
Mortality was low, and combined findings of all studies showed that LABA therapy did not significantly affect mortality (OR 0.90,
95% CI 0.75 to 1.08; I2 = 21%; 23 trials including 14,079 people, moderate quality evidence). LABA therapy did not affect the
rate of serious adverse events (OR 0.97, 95% CI 0.83 to 1.14; I2 = 34%, moderate quality evidence), although there was significant
unexplained heterogeneity, especially between the two formoterol doses.
LABA therapy improved predose FEV1 by 73 mL more than placebo (95% CI 48 to 98; I
2 = 71%, low quality evidence), and people
were more likely to withdraw from placebo than from LABA therapy (OR 0.74, 95% CI 0.69 to 0.80; I2 = 0%). Higher rates of
withdrawal in the placebo arm may reduce our confidence in some results, but the disparity is more likely to reduce the magnitude
of difference between LABA and placebo than inflate the true effect; removing studies at highest risk of bias on the basis of high and
unbalanced attrition did not change conclusions for the primary outcomes.
Authors’ conclusions
Moderate-quality evidence from 26 studies showed that inhaled long-acting beta2-agonists are effective over the medium and long term
for patients with moderate to severe COPD. Their use is associated with improved quality of life and reduced exacerbations, including
those requiring hospitalisation. Overall, findings showed that inhaled LABAs did not significantly reduce mortality or serious adverse
events.
P L A I N L A N G U A G E S U M M A R Y
Long-acting beta2-agonists for people with COPD
We wanted to know whether twice-daily treatment with an inhaled long-acting beta2-agonist was better than treatment with a dummy
inhaler for people with chronic obstructive pulmonary disease (COPD).
Background to the review
COPD is a disease of the lungs that causes airways to narrow. As a result, people with COPD experience symptoms of breathlessness,
cough and mucus buildup, which worsen over time. Cigarette smoking is the most common cause of COPD, and it is the fourth or
fifth most common cause of death worldwide.
Inhaled salmeterol and formoterol, known as long-acting beta2-agonists (LABAs), are widely used to manage the symptoms of COPD,
so it is important to understand their benefits and side effects. They are often introduced when inhaled treatments for quick relief from
symptoms (e.g. salbutamol) are no longer helpful. LABAs are designed to be taken twice a day to control symptoms and reduce the
likelihood of flare-ups.
What did we find?
Twenty-six studies (including 14,939 people with moderate to severe symptoms of COPD) compared twice-daily salmeterol or for-
moterol with a dummy inhaler. The evidence gathered for this review is current up to June 2013. Results within studies were described
most often after six months of treatment, but some were reported at three months and others after as long as three years. More men
than women took part, and they had moderate to severe symptoms when they began treatment.
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People who took LABA inhalers showed greater improvement on quality of life scales than those taking dummy inhalers, and they had
fewer serious flare-ups that resulted in a hospital stay (18 fewer per 1000). They also had better lung function than people who had
taken placebo. LABA inhalers did not reduce the number of people who died, and no significant difference was noted in the number
who had serious adverse events while taking the medication.
These studies were most often sponsored by drug companies and were generally well designed. People in the studies did not know which
treatment they were getting, and neither did the people doing the research. Several studies did not describe flare-ups, hospital stays
or lung volume, so there is a chance that evidence obtained in future studies would change the strength of what has been concluded.
Additionally, quite a lot of variation was noted between studies in the effects of LABA inhalers on quality of life, serious side effects
and lung function. This may be explained in part by variation in study methods regarding what medications people could continue to
take.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Long-acting beta2-agonists compared with placebo for chronic obstructive pulmonary disease
Patient or population: people with chronic obstructive pulmonary disease
Intervention: long-acting beta2-agonists
Comparison: placebo
Setting: community
Outcomes
Follow-
up: weighted means pre-
sented for each outcome
Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Long-acting beta2-ago-
nists
Quality of life1
St George’s Respiratory
Questionnaire (SGRQ);
lower scores are better
16 months
45.3
(mean of
reported placebo
endpoints)
Mean score in the inter-
vention groups was
2.32 units lower
(3.09 to 1.54 lower)
MD -2.32
(-3.09 to -1.54)
11,397
(17 studies)
⊕⊕⊕©
moderate21
A difference of 4 points is
generally accepted to be
of clinical significance
Severe exacerbations
(hospitalisations)
7 months
71 per 1000 53 per 1000
(40 to 68)
OR 0.73
(0.56 to 0.95)
2859
(7 studies)
⊕⊕⊕©
moderate3
I2 = 10%, P = 0.35
Moderate exacerbations
(course of antibiotics or
oral steroids)
8 months
238 per 1000 186 per 1000
(160 to 214)
OR 0.73
(0.61 to 0.87)
3375
(7 studies)
⊕⊕⊕©
moderate3
I2 = 8%, P = 0.37
Severe/moderate exac-
erbations (hospitalisa-
tion or course of medi-
cation or ER visit)
8 months
336 per 1000 308 per 1000
(278 to 340)
OR 0.88
(0.76 to 1.02)
3968
(7 studies)
⊕⊕⊕©
moderate3
I2 = 0%, P = 0.80
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Mortality (all-cause)
14 months
5 per 1000 5 per 1000
(4 to 5)
OR 0.90
(0.75 to 1.08)
14,079
(23 studies)
⊕⊕⊕©
moderate4
I2 = 21%, P = 0.21
Participants with one or
more serious adverse
event (non-fatal)1
15 months
86 per 1000 84 per 1000
(74 to 97)
OR 0.97
(0.83 to 1.14)
12,446
(20 studies)
⊕⊕⊕©
moderate5
Predose FEV1 (mL)
1
7 months; higher is better
1221 mL
(mean of
reported placebo
endpoint scores)
Mean predose FEV1 in the
intervention groups was
73 mL higher
(48 to 98 mL higher)
MD 73 mL
(48 to 98 mL)
6125
(14 studies)
⊕⊕©©
low6,7
Subgroup differences (I
2 = 84%) discussed in
high heterogeneity within
subgroups, with potential
baseline differences
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
n.b. Unless otherwise stated, significant subgroup differences were not found.
1 Quality of life, serious adverse events and FEV1 were analysed with random effects as the result of heterogeneity.
2 I2 = 50%, P <0.01 (-1 for inconsistency)
3 Several studies did not report exacerbations in a form that could be included in any of the three outcomes included in this review (-1
for publication bias)
4 Confidence intervals include important benefit and potential harm (-1 for imprecision)
5 I2 = 34%, P = 0.06; opposite direction of effect observed for the two formoterol doses (-1 for inconsistency)
6 I2 = 71%, P <0.01 (-1 for inconsistency)
7 Several studies did not report the outcome in a way that could be included in the meta-analysis
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B A C K G R O U N D
Description of the condition
Chronic obstructive pulmonary disease (COPD) is a respiratory
disease characterised by chronic and progressive breathlessness,
cough, sputum production and airflow obstruction, which leads
to restricted activity and poor quality of life (GOLD 2013). The
World Health Organization (WHO) has estimated that COPD,
which includes emphysema, chronic bronchitis and small airways
disease, is the fourth or fifth most common single cause of death
worldwide, and that the treatment and management costs asso-
ciated with COPD present a significant burden to public health.
In the United Kingdom (UK), the annual cost of COPD for the
National Health Service (NHS) is estimated to be £1.3million per
100,000 people (NICE 2011). Furthermore, because of its slow
onset and under-recognition of the disease, it is heavily under-
diagnosed (GOLD 2013).
COPD comprises a combination of bronchitis and emphysema
and involves chronic inflammation and structural changes in the
lung. Cigarette smoking is the most important risk factor, but air
pollution and occupational dust and chemicals are also recognised
risk factors. COPD is a progressive disease that leads to decreased
lung function over time, even with the best available care. No cure
for COPD is known, although it is a preventable and treatable
disease. As yet, apart from smoking cessation and non-pharma-
cological treatments such as long-term oxygen therapy in hypoxic
patients, and pulmonary rehabilitation, no intervention has been
shown to reduce mortality (GOLD 2013; Puhan 2011). Manage-
ment of the disease is multifaceted and includes interventions for
smoking cessation (van der Meer 2001), pharmacological treat-
ments (GOLD 2013), education (Effing 2007), and pulmonary
rehabilitation (Lacasse 2006; Puhan 2011). Pharmacological ther-
apy is aimed at relieving symptoms, improving exercise tolerance
and quality of life, slowing decline and even improving lung func-
tion, and preventing and treating exacerbations. COPD exacer-
bations impair patients’ quality of life (GOLD 2013), and a large
part of the economic burden of COPD is attributed to the cost of
managing exacerbations, particularly those resulting in the use of
acute care services, or hospitalisations (Hutchinson 2010). In the
UK, one in eight emergency admissions to hospital is for COPD,
which makes it the second largest cause of emergency admissions,
and one of the most costly conditions treated by the NHS (NICE
2011). Appropriate pharmacological management of the disease
is therefore important, particularly for reducing and preventing
exacerbations.
Description of the intervention
Pharmacological management of COPD tends to begin with one
treatment, and additional therapies are introduced as necessary to
relieve symptoms and reduce the frequency and severity of exac-
erbations (ATS/ERS 2011; GOLD 2013). The first step often in-
volves a short-acting bronchodilator for control of breathlessness
when needed: either a short-acting beta2-agonist (SABA), such
as salbutamol, or the short-acting muscarinic antagonist (SAMA)
ipratropium. For persistent or worsening breathlessness associated
with lung function decline, long-acting bronchodilators may be
introduced (ATS/ERS 2011; GOLD 2013). These comprise twice
daily long-acting beta2-agonists (LABAs; duration of action 12
hours); once-daily long-acting beta2-agonists (sometimes referred
to as ultra long-acting; duration of action 24 hours); and the once-
daily long-acting anticholinergic agent tiotropium. Regular treat-
ment with long-acting bronchodilators is preferred over treatment
with regular short-acting bronchodilators on the basis of efficacy
and side effects (Beeh 2010; GOLD 2013). Theophylline, an oral
phosphodiesterase (PDE) inhibitor, is an alternative when bron-
chodilators are not available or affordable. However, theophylline
is less effective and is less well tolerated than inhaled long-acting
bronchodilators. For patients with severe or very severe COPD
(i.e. with forced expiratory volume in 1 second (FEV1) < 50%
predicted) and with repeated exacerbations, GOLD 2013 rec-
ommends the addition of inhaled corticosteroids (ICS) to bron-
chodilator treatment. ICS are anti-inflammatory drugs that are
licenced as combination inhalers with LABAs. This group of pa-
tients with severe COPD may also benefit from treatment with
the PDE4 inhibitor roflumilast, which may reduce the risk of ex-
acerbations (GOLD 2013).
How the intervention might work
LABAs are widely used in the management of COPD, alone or
in combination with other bronchodilators, ICS or both. Com-
monly used LABAs include twice-daily salmeterol and formoterol
and the newonce-daily preparation, indacaterol. All inhaled beta2-
agonists activate beta2-receptors on different cells in the lung. Ac-
tivation of the receptor on airway smooth muscle leads to a cas-
cade of reactions that result in dilation of the airways. However,
the exact mechanism of action differs between the various LABAs,
and different efficacy and safety profiles can be expected between
them. LABAs are commonly used to relieve symptoms and re-
duce exacerbations in stable COPD (Rodrigo 2008). Possible side
effects of LABAs include cardiac effects such as arrhythmia and
palpitations, muscle tremors, headache and metabolic imbalances
such as hypokalaemia and increased glucose levels (Berger 2008).
Why it is important to do this review
LABAs are used widely and play a central role in the management
of COPD (ATS/ERS 2011;GOLD2013;NICE 2010). An earlier
Cochrane systematic review has presented evidence on the effects
of LABAs for patients with poorly reversible COPD (Appleton
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2006). However, in this systematic review, we summarised the ev-
idence regarding the efficacy and safety of twice-daily LABAs (i.e.
those with a 12-hour duration of action) comparedwith placebo in
all patients with COPD. The efficacy and safety of the once-daily
LABA indacaterol in comparison with other LABAs and placebo
will be assessed in another Cochrane systematic review (Geake
2012).
This review formspart of a suite of reviews on long-acting therapies
for COPD, including long-acting anticholinergics, long-acting
beta2-agonists, ultra-long-acting beta2-agonists, PDE4 inhibitors,
and ICS (Cheyne 2012; Chong 2011; Chong 2012; Geake 2012;
Karner 2011; Karner 2011a; Karner 2012; Karner 2012a; Karner
2012b; Nannini 2010; Nannini 2010a; Nannini 2012; Spencer
2011;Welsh 2011; Yang 2012). These reviews, which look at long-
term treatment for COPD, will ultimately be summarised in an
overview.
O B J E C T I V E S
To assess the effects of twice-daily long-acting beta2-agonists com-
pared with placebo for patients with COPD on the basis of clin-
ically important endpoints, primarily quality of life and COPD
exacerbations.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) with a parallel-
group design, of at least 12 weeks’ duration. We did not exclude
studies on the basis of blinding. We excluded cross-over trials, as
we were looking at long-term effects including adverse events.
Types of participants
We included RCTs that recruited participants with a clinical di-
agnosis of COPD based on the following (GOLD 2013).
1. Forced expiratory volume after one second (FEV1)/forced
vital capacity (FVC) ratio < 0.7, which confirms the presence of
persistent airflow limitation.
2. Several of the following key indicators:
i) Progressive and/or persistent dyspnoea
(breathlessness);
ii) Chronic cough;
iii) Chronic sputum production; and
iv) History of exposure to risk factors (tobacco smoke,
smoke from home cooking and heating fuels, occupational dusts
and chemicals).
We excluded RCTs in which participants had to have asthma as
well as COPD to be included.
Types of interventions
We included studies in which participants were randomly assigned
to receive the following.
1. Salmeterol 50 µg or placebo twice daily.
2. Formoterol 12 µg or placebo twice daily.
3. Formoterol 24 µg or placebo twice daily.
We included studies that allowed concomitant short-acting bron-
chodilators, provided they were not part of the trial treatment un-
der study. We did not include studies in which most participants
were receiving other COPD treatments.
Types of outcome measures
Primary outcomes
1. Quality of life; mean difference and responders analysis
(number of participants with clinically significant improvement
or worsening); measured with a scale validated for COPD, such
as St George’s Respiratory Questionnaire (SGRQ) or the
Chronic Respiratory Disease Questionnaire (CRQ).
2. Severe COPD exacerbations (COPD exacerbations leading
to hospitalisation).
Secondary outcomes
1. Moderate COPD exacerbations.a
2. Mortality; all-cause.
3. Non-fatal serious adverse events; all-cause.
4. Trough (predose) FEV1.
5. Withdrawals from study treatment.
aA sample definition of COPD exacerbation is “an acute event
characterised by a worsening of the patient’s respiratory symptoms
that is beyond normal day-to-day variations and leads to a change
in medication” (GOLD 2013).
Search methods for identification of studies
Electronic searches
We identified trials from the Cochrane Airways Group Spe-
cialised Register of trials (CAGR), which is derived from system-
atic searches of bibliographic databases including the Cochrane
Central Register of Controlled Trials (CENTRAL), MEDLINE,
EMBASE, CINAHL, AMED and PsycINFO, and conference ab-
stracts found through handsearching (see Appendix 1 for further
7Long-acting beta2-agonists for chronic obstructive pulmonary disease (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
details). We searched all records in the CAGR coded ’COPD’ us-
ing the following terms:
(*formoterol or salmeterol or Serevent or Foradil or Oxis or LABA
or long-acting* or “long acting*”)
We also searched ClinicalTrials.gov using search terms described
in Appendix 2. We searched all databases up to June 2013, with
no restriction on date or language of publication.
Searching other resources
We checked reference lists of all primary studies and review articles
for additional references.We searched the manufacturers’ websites
(GlaxoSmithKline and AstraZeneca) for additional information
on studies identified through the electronic searches.
Data collection and analysis
Selection of studies
Two review authors independently screened the titles and abstracts
of citations retrieved through literature searches and obtained in
full text those deemed to be potentially relevant.We assigned each
reference to a study identifier and assessed each against the inclu-
sion criteria of this protocol (see Criteria for considering studies
for this review). Any disagreements were resolved by consensus.
Data extraction and management
Two review authors independently extracted information from
each study to record the following characteristics.
• Design (design, total study duration, number of study
centres and location).
• Participants (number randomly assigned to each treatment,
mean age, gender, baseline lung function, smoking history,
reversibility, inclusion criteria and exclusion criteria).
• Interventions (run-in, intervention and control treatments
including concentration and formulation).
• Outcomes (definition of exacerbation and outcome data
using end of study as time of analysis for all studies).
In the event that treatment arms of interest with different doses
were included, these findings were combined when possible ac-
cording to recommendations outlined in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2009). If the data
could not be combined, we used the trial arm with the dose of-
fering greatest homogeneity with other trials regarding dose. We
also subgrouped primary outcome data according to dose. Any
discrepancies in the data were resolved by discussion, or by con-
sultation with a third party when necessary.
Assessment of risk of bias in included studies
For the following items, two review authors independently assessed
the risk of bias and graded each potential source of bias as high
risk, low risk or unclear risk and resolved disagreements by con-
sensus, according to recommendations outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2009).
• Random sequence generation.
• Allocation concealment.
• Blinding of participants and personnel.
• Blinding of outcome assessment.
• Incomplete outcome data.
• Selective outcome reporting.
Measures of treatment effect
Dichotomous data:We analysed dichotomous data variables (such
as mortality and withdrawals) using Mantel-Haenzsel odds ratios
(ORs) with 95% confidence intervals (CIs). If events were rare, we
employed the Peto odds ratio. If count data were not available as
the number of participants experiencing an event but rather were
reported as rate ratios, we transformed them into log rate ratios
and analysed the data using generic inverse variance (GIV).
Continuous data: We analysed continuous outcome data as fixed-
effect mean differences (MDs) with 95% CIs unless excessive het-
erogeneity was found.
Unit of analysis issues
We analysed dichotomous data using participants as the unit of
analysis. For continuous data, the MD based on change from
baseline was preferred over the MD based on absolute values.
Dealing with missing data
If outcome data or key study characteristics were not reported
in the primary publication, we searched clinical trial reports and
contacted study authors and sponsors for additional information.
We used intention-to-treat (ITT) analysis on outcomes from all
randomly assignedparticipantswhenpossible.We also considered,
as part of the sensitivity analysis, the impact of the unknown status
of participants who withdraw from the trials.
Assessment of heterogeneity
We assessed clinical and methodological heterogeneity by record-
ing differences in study design and participant characteristics be-
tween individual studies. We assessed the extent of statistical vari-
ation among study results by using the I2 measurement.
Assessment of reporting biases
We tried tominimise reporting bias fromnon-publication of stud-
ies or selective outcome reporting by using a broad search strategy,
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checking references of included studies and relevant systematic re-
views and contacting study authors to request additional outcome
data. We visually inspected funnel plots when 10 or more studies
were included.
Data synthesis
For all outcomes, we analysed each LABA and dose separately;
however for our primary outcomes, we also pooled the three com-
parisons. We analysed data using a fixed-effect model, but when
heterogeneity was noted (I2 > 30%), we used a random-effects
model and explored the heterogeneity (see Subgroup analysis and
investigation of heterogeneity). We presented the findings of our
primary outcomes in a ’Summary of findings’ table generated with
the use of GradePro software and according to recommendations
provided in the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2009).
Subgroup analysis and investigation of heterogeneity
When substantial heterogeneity was identified among the studies
(I2 > 30%), we explored it by analysing the data by the following
subgroups.
• Duration of LABA therapy (≤ 1 year; > 1 year).
• Disease severity at baseline (FEV1 < 50% predicted; FEV1
≥ 50% predicted).
Sensitivity analysis
We assessed the robustness of our analyses by performing sensi-
tivity analyses and systematically excluding the following studies
from the overall analysis.
• Those at high risk of bias.
• Those with high and/or uneven withdrawal rates
• Concurrent use of inhaled steroids*
*Studies where more than fifty percent of patients continued tak-
ing ICS or other COPD medications were excluded. However,
included studies in which a significant proportion (but not the
majority) of patients continued taking ICS or other COPD med-
ications were removed in a sensitivity analysis.
R E S U L T S
Description of studies
Results of the search
Nine hundred and seventy-two references were identified through
searches of online databases, and 63 additional references were
found by searching other resources (drug company websites, ref-
erence lists of systematic reviews, clinicaltrials.gov). After 16 du-
plicates were removed, 802 of the remaining 1019 references were
excluded by sifting titles and abstracts. The most common reasons
for exclusion were that no LABA versus placebo comparison was
performed (n = 359) and that the study used a cross-over design
(n = 184). Full reasons for exclusion are listed in Figure 1. Full
texts were consulted for the remaining 217 references, and 191
were found to meet all of the inclusion criteria, representing 26
studies. The main reason for exclusion at this stage was that more
than 50% of participants in the trials were taking concomitant
COPDmedications (n = 22). Full details of the search history can
be found in Appendix 1 and Appendix 2.
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Figure 1. Study flow diagram.
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Included studies
Twenty-six studies met the inclusion criteria, randomly assigning
14,939 people with a diagnosis of COPD to LABA or placebo. All
but one of the trials (Watkins 2002) contributed data to at least
one analysis. Calverley 2007 [TORCH] contributed the greatest
number of people to the analyses, with 3087 people randomly
assigned to the two groups of interest. A small industry-funded
trial, SLMF4010 2005 included the smallest number of people,
with 17 people randomly assigned to each group.
Design and duration
All twenty-six studies were randomised, double-blind, parallel-
group controlled trials. Nine trials lasted for three months, 10 for
six months and six for a year.The remaining trial (Calverley 2007
[TORCH]) was a three-year study. In accordance with the proto-
col, separate analyses of the three included LABA doses were sub-
grouped according to length of trial (three, six, 12 and 36months).
Distribution of studies among the four duration categories and
descriptive statistics of age and sex are given in Table 1.
Participant inclusion and exclusion criteria
Full details of the inclusion and exclusion criteria for each trial
can be found in Characteristics of included studies. Inclusion and
exclusion criteriawere largely similar across trials. Participantswere
required to be over the age of 40 (35 in three studies) and to have
a smoking history of at least 10 pack-years.
Baseline characteristics of participants
Full details of the baseline characteristics of participants in each
study can be found in Characteristics of included studies. Partici-
pants’ mean age was similar across trials, ranging from58.8 to 67.2
years in individual trial arms. Trial participants were most often
male (range 50% to 94%, median 75%) and Caucasian (range
46% to 100%, median 92%). Seventeen trials reported mean or
median smoking pack-years; medians ranged from 40 to 60, and
means ranged from 35.4 to 52.5, pack-years. Twenty studies re-
porting percentage predicted FEV1 indicated that the populations
were of moderate to high disease severity, with baseline means
ranging from 32.6% to 54.7%. Distribution of mean percent-
age predicted FEV1 at baseline within studies and mean baseline
SGRQ (when reported) are presented in Table 2.
Descriptive statistics were analysed separately for the formoterol
and salmeterol studies to check for systematic differences between
trials of drugs made by different manufacturers. Percentage re-
versibility was reported in only 12 studies (46%), of which only
two were studying salmeterol. Within the ten formoterol studies
(both doses), reversibility reported for each arm ranged from 4.7%
to 19.5%, with a mean value of 8.8. For the salmeterol studies,
the mean was 7.9 and ranged from 4 to 13 in individual trial
arms. Mean percentage predicted FEV1 was better reported (77%
of studies), and no differences in baseline severity were apparent
between formoterol and salmeterol; the formoterol studies had a
mean of 44.7, ranging from 32.6 to 54.7, and the salmeterol stud-
ies a mean of 43.0, ranging from 37.7 to 53. Given the relative
homogeneity of these metrics between subgroups and between the
individual trials, it was not deemed appropriate to subgroup re-
sults on the basis of severity.
Characteristics of the interventions
Fourteen studies included the comparison of formoterol 12 µg
twice daily (or metered dose equivalent) and placebo. Three of
these studies (Aalbers 2002; Dahl 2001; Rossi 2002) also included
a formoterol 24µg twice-daily arm. One additional study,Wadbo
2002, used only the comparison of formoterol 24 µg. Most for-
moterol studies used matching dry powder Turbuhaler devices to
deliver blinded study medication. The remaining 11 studies com-
pared salmeterol 50 µg twice daily (or equivalent) with placebo,
primarily using blinded Diskus dry powder inhalers. Studies al-
lowed the use of a short-acting beta2-agonist as relievermedication
during the study period (salbutamol or terbutaline).
Outcomes and analysis structure
Health-related quality of life measured on the St George’s Respira-
tory Questionnaire (SGRQ) was reported in most of the studies.
The SGRQ is a well-validated and widely used measure of health
status in patients with chronic airflow limitation; the total score
ranges from 0 (perfect health) to 100 (most severe status) and in-
cludes three components of symptoms, activity and impacts. Only
three of these studies (Bogdan 2011; Brusasco 2003; Kornmann
2011) reported the number of people improving by four or more
points on the SGRQ, which is generally accepted to be the mini-
mal clinically important difference. In two studies (Doherty 2012
and Szafranski 2003), variance was not given for the comparison
of interest. In these cases, standard deviations of 14.5 were im-
puted on the basis of population variance and on that of other
arms within the studies to increase the number of studies in the
analysis. Four additional studies reported quality of life data using
the Chronic Respiratory Diseases Questionnaire (CRQ) (Hanania
2003; Mahler 1999; Mahler 2002; Rennard 2001), of which two
reported mean change with no measure of variance. All four were
analysed separately from the main SGRQ analysis to reduce possi-
ble sources of heterogeneity, with missing variances imputed from
those reported in Mahler 1999 and Rennard 2001. Because these
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four studies all compared salmeterol with placebo and were of
three months’ and six months’ duration, results for the CRQ were
not part of the subgroup analyses. Therefore, the quality of life
data could be presented in a more clinically meaningful format
by using mean differences on the SGRQ scale. For this outcome
and predose FEV1, mean change and endpoint data were analysed
together, and footnotes were entered to clarify which data were
available.
The second primary outcome, severe COPD exacerbations re-
quiring hospitalisation, was quite poorly reported. Seven studies
(nine comparisons) reported this as an outcome, of which five
also reported the number of people with one or more moderate
COPD exacerbations (those requiring a course of antibiotics or
oral steroids). Rennard 2001 and Calverley 2003b [TRISTAN] re-
ported data that could be included in the moderate exacerbations
analyses but not hospitalisations. Two additional studies, Mahler
1999 and Nelson 2007, did not explicitly define exacerbations
but were included in the moderate exacerbations analysis because
rates were more consistent with these rates in other studies. Data
for hospitalisations are collated in Analysis 1.4 and for moderate
exacerbations in Analysis 1.6.
Seven additional studies reported the overall number of people
who had either one or more moderate or severe exacerbations dur-
ing the study, and these data are presented separately in Analysis
1.5. Overall, 18 studies reported exacerbation count data that
could be included in at least one of these three analyses. Four
studies presented no data related to exacerbations (Aalbers 2002;
Kornmann 2011; Wadbo 2002; Watkins 2002), and four fur-
ther studies reported data as rate ratios or yearly patient rates
that could not be incorporated with data from the other studies
(Calverley 2007 [TORCH]; SLMF4010 2005; Szafranski 2003;
Tashkin 2008 [SHINE]).
Mortality was well reported and was missing only in Aalbers
2002, Wadbo 2002 and Watkins 2002. Watkins 2002 did not
contribute data to any analysis. Calverley 2007 [TORCH], the
largest and longest study, was unique in tracking the status of all
participants at endpoint, regardless of how long they stayed in the
study. For this reason, the nature and quality of mortality data
from this study are likely to differ from those of other studies
in the analysis. The number of participants experiencing one or
more serious adverse events was reported in slightly fewer studies.
Within the six studies that could not be included, one reported
only the number of serious cardiac adverse events, and the others
reported overall serious and non-serious events combined.
Lung function as measured by predose FEV1 was not consistently
reported. Half of the studies reported data that could be used
in meta-analysis as mean change or endpoint scores with corre-
sponding variance. Two studies reported absolute means at end-
point, and all other studies reported mean change from baseline.
Two studies reporting change did not report a measure of variance
(Calverley 2003a; Tashkin 2012), so standard deviations were im-
puted by calculating themean of the change variances from the re-
maining nine studies.The remaining studies either reported other
lung function measures that could not be analysed with predose
FEV1 (e.g. peak expiratory flow, postbronchodilator FEV1) or did
not present the data in a format that could be incorporated in
the meta-analysis. Rennard 2001 aimed to detect differences of
effect between participants with high or low reversibility, and so
the merged results may represent a heterogeneous population that
is different from that seen in other studies.
Three trials-Aalbers 2002, Dahl 2001 and Rossi 2002-included
two LABA arms that met inclusion criteria for the review, and in
these cases, all three arms were included and the placebo arm of
each was split in comparison 1. In these cases, the power of the
overall analysis is accurate, but the power to detect subgroup dif-
ferences may be reduced. In comparisons 2, 3 and 4, where LABA
doses are split into different analyses, no adjustments were made
to the participant totals. When studies reported data at more than
one time point of interest, we reported only the duration subgroup
totals-not the pooled effect (i.e. data for the same participants were
not double counted, but power to detect subgroup differencesmay
be increased). For this reason, slight discrepancies may be evident
between a subgroup result in comparison 1 and the corresponding
effect in the following comparisons subgrouped by trial duration.
Sensitivity analyses
Use of inhaled corticosteroids (ICS) during the study period
As stated in the protocol, we intended to exclude trials in which
more than 50% of participants were taking other COPD med-
ications. Most available data in the study reports related to ICS
use during the randomised period, and this was used as a proxy
in cases where the preferred data were not available. Ten stud-
ies required that other medications, including ICS, were stopped
during the run-in. Eight further studies did not explicitly report
the proportion of participants taking other medications, and in-
ferences based on pharmacological exclusion criteria could not be
made. Hanrahan 2008 reported that 28.6% and 23.9% of par-
ticipants in the salmeterol and placebo groups, respectively, were
taking regular ICS during the study period, and so the study was
included. Similarly, Nelson 2007 reported that 33% and 38%
of participants in the formoterol and placebo groups were taking
COPDmedications during the study period that were not part of
the randomised interventions. Because ICS use fell just above or
just below the predefined 50% threshold in the remaining six stud-
ies (Campbell 2005; Dahl 2001; Dahl 2010; Kornmann 2011;
Rossi 2002; Vogelmeier 2008), these studies were removed from
the primary outcomes in a sensitivity analysis.
Studies at high risk of bias/those with high or uneven
withdrawal rates
Because no studies were rated at high risk of bias for either of the
selection bias parameters, or for detection or performance bias, a
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sensitivity analysis was performed to remove the eight studies that
were rated at high risk of bias due to attrition (Dahl 2010;Hanania
2003; Mahler 1999; Mahler 2002; Nelson 2007; Rennard 2009;
SLMF4010 2005; Szafranski 2003). Given that high risk judge-
ments in the reporting bias parameter usually were made because
studies were already missing from analyses, it was not appropriate
to perform a sensitivity analysis on selective outcome reporting.
Reporting bias is reflected in the grade ratings of the affected out-
comes.
Excluded studies
Details of why studies were excluded from the review, including
exact percentages of participants taking additional COPD med-
ications, can be found in Characteristics of excluded studies. Six
studies (22 citations) were excluded because a clear majority of the
participants were taking other COPD medications (Boyd 1995;
Celli 2003; Chapman 2002;Dal Negro 2003; Rutten-vanMolken
1999; Stockley 2006). One additional trial (two publications) was
excluded because the inclusion criteria allowed for participants
with asthma or COPD, and data for diagnostic subgroups were
not presented (Steffensen 1996).
Risk of bias in included studies
The methodological quality of the included trials was good. None
of the studies were at high risk of selection, performance or de-
tection bias, but there was high risk of bias for attrition in eight
studies and selective reporting of outcomes in 11 studies. More
detailed descriptions by domain (allocation generation, allocation
concealment, blinding and incomplete data) are given below. De-
tails of the risk of bias rating for each study and the reasons for
each rating can be found in Characteristics of included studies and
a summary of judgements by study and domain can be found in
Figure 2. When studies funded by the same company were rated
as unclear for one or more domain, we attempted to clarify study
methods with the funder.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
None of the included studies were rated as having high risk of
bias for either of the two allocation parameters (random sequence
generation and allocation concealment).
With the exception of Watkins 2002 (which was not a full trial
report and hence was rated as unclear), all of the trials were rated as
having low risk of bias for random sequence generation. Although
several of the trials did not adequately describe the methods of
sequence generation used, the authors agreed that this was likely
due to variations in reporting standards. All of the studies were
industry sponsored; therefore the authors deemed it reasonable to
assume that standardised drug company methods were used (i.e.
computerised random list generators).
Nine studies (Aalbers 2002; Brusasco 2003; Calverley 2003b
[TRISTAN]; Calverley 2007 [TORCH] Campbell 2005; Dahl
2010; Kornmann 2011; Rennard 2009; Tashkin 2012) fully de-
scribed methods used for allocation concealment and were thus
rated as having low risk of bias. Although some drug companies
might have standard protocols for concealing allocation, the au-
thors agreed that studies would be rated as unclear unless themeth-
ods used were properly described for this parameter. The remain-
ing 17 studies were rated as unclear for this reason.
Blinding
None of the studies were rated as having high risk of bias for either
of the two blinding parameters (participants and personnel, and
outcome assessment).
When a study was described as double-blind and no specific details
were reported in the original report, trial registrations most often
confirmed that the blind applied to participants and investigators.
As a result, all trials were rated as having low risk of bias for this
parameter. Twelve studies specifically described double-dummy
procedures and matched inhalers.
Studies were not rated as having low risk of bias for blinding of
outcome assessors unless blinding was explicitly stated in the trial
report or the protocol registration. This was the case for only nine
of the studies; therefore most were rated as unclear.
Incomplete outcome data
More than half of the included studies were rated as having low
risk of bias for this parameter (N = 16), either because dropout was
deemed to be low and even between groups, or because dropout
was considered acceptable given the methods of imputation de-
scribed in the report. Two studies were rated as unclear: Calverley
2003b [TRISTAN] had high and even dropout in both arms but
did not sufficiently describe the method of imputation to warrant
a ’low’ rating, and Watkins 2002 provided no information related
to attrition. The remaining eight studies were considered to be at
high risk of bias, either because dropout was very high in both
groups, or because dropout was deemed excessive or uneven given
the method of imputation or the analysis method used (i.e. per
protocol or completers only).
Selective reporting
Twenty studies could be linked with their protocol registration
on clinicaltrials.gov or with their industry report, allowing com-
parison of prespecified outcomes with published or unpublished
results. Of these, ten reported all stated outcomes in a way that
allowed them to be combined in meta-analysis (Bogdan 2011;
Calverley 2003a; Calverley 2003b [TRISTAN]; Calverley 2007
[TORCH]; Dahl 2010; Hanania 2003; Mahler 2002; Rennard
2001; SLMF4010 2005; Tashkin 2008 [SHINE]). Five studies
that could not be linked to their trial registration documents
but did not show clear evidence of selective outcome reporting
were rated as unclear (Campbell 2005; Dahl 2001; Rossi 2002;
Szafranski 2003; Tashkin 2012). Eleven studies were rated as hav-
ing high risk of bias either because outcomes that were stated in
the protocol were not reported in sufficient detail in the results,
or because key outcomes expected in COPD trials were not in-
cluded, regardless of whether they were named in a protocol (e.g.
mortality, adverse events, exacerbations).
Funnel plots were constructed for the primary outcomes. Figure
3 is not suggestive of any serious publication bias of the SGRQ.
However, some evidence suggests a small study effect on severe
exacerbations (those resulting in hospitalisation), which might be
due to publication bias, as shown in Figure 4.
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Figure 3. Funnel plot of comparison: 1 All LABA versus placebo [subgrouped by drug], outcome: 1.1
Quality of life (SGRQ total score).
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Figure 4. Funnel plot of comparison: 1 All LABA versus placebo [subgrouped by drug], outcome: 1.4 Severe
exacerbations (hospitalisations).
Other potential sources of bias
No other sources of bias were identified in the included studies.
Effects of interventions
See: Summary of findings for themain comparison Long-acting
beta2-agonists compared with placebo for chronic obstructive
pulmonary disease
Full details of the analyses and their GRADE ratings can be found
in Data and analyses and Summary of findings for the main
comparison.The first comparisonpresents results for all outcomes,
with studies subgrouped according to the type and dose of LABA.
Comparisons 2, 3 and 4 show results for formoterol 12 µg, for-
moterol 24 µg and salmeterol 50 µg, respectively (all twice daily),
subgrouped according to study duration. The final comparison
presents data for the two primary outcomes, excluding six studies
in which relatively large proportions of the population were taking
regular COPD therapies other than the study medication (see ’Use
of inhaled corticosteroids (ICS) during the study period’ in Included
studies).
Primary outcomes
Health-related quality of life
Improvement on the St George’s Respiratory Questionnaire
(SGRQ) was greater with LABA therapy than with placebo (MD
-2.32, 95% CI -3.09 to -1.54; I2 = 50%, P = 0.007; Analysis
1.1), based on data from 11,397 people in 17 studies. Results were
analysed using a random-effects model because heterogeneity was
high, and the outcome was downgraded from high to moderate
quality for this reason. Heterogeneity could not be explained by
differences between the effects of LABA drug and dose (test for
subgroup difference, I2 = 0%, P = 0.45). The difference between
LABA and placebo was significant for all three LABA agents sep-
arately, but important heterogeneity was noted within the for-
moterol 12 µg and salmeterol 50 µg subgroups (I2 = 57% and
48%, respectively).
More people taking a LABA showed clinically important improve-
ment of at least four points on the SGRQ (OR 1.58, 95% CI
1.32 to 1.90; I2 = 86%, P = 0.0007; Analysis 1.2) based on 1871
people in three studies. Data were insufficient to allow conclusions
regarding the difference between formoterol and salmeterol.
Four salmeterol studies reporting the Chronic Respiratory Dis-
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ease Questionnaire (CRQ) were analysed separately and showed
a significant benefit of LABA therapy (MD 3.10, 95% CI 1.22
to 4.98; I2 = 0%, P = 0.58; Analysis 1.3) with no heterogeneity.
Because so few trials reported the CRQ and the number of people
achieving a minimally clinically important difference (MCID) on
the SGRQ of 4 units, we did subgroup and sensitivity analyses on
the SGRQ continuous data only.
A test for subgroup differences suggested that some of the het-
erogeneity within the 12 trials which randomised people to either
formoterol or placebo may be explained by differences in study
duration (I2 = 75%, P = 0.02; Analysis 2.1). The effect of twice-
daily formoterol 24 µg was significant when analysed separately
but lacked precision because only three studies compared the dose
with placebo (MD -2.32, 95% CI -4.52 to -0.13; I2 = 0%, P =
0.76; Analysis 3.1). No difference was detected between the two
three-month trials (Dahl 2001; Wadbo 2002) and the year-long
Rossi 2002 study. With so few studies, no heterogeneity was evi-
dent between or within subgroups. Unlike the formoterol 12 µg
analysis, trial duration did not appear to be an important source
of heterogeneity in the salmeterol included trials (I2 = 0%, P =
0.41; Analysis 4.1).
The overall pooled effect and drug subgroup effects were largely
consistent with the original analysis after removal of five studies
identified as having a high proportion of ICS use during the trial
(see Included studies-Use of inhaled corticosteroids (ICS) during
the study period). The magnitude of improvement due to LABA
therapywas reduced after the studies were removed, but somewhat
tighter confidence intervals and less between-study heterogeneity
were noted (MD -1.53, 95% CI -2.08 to -0.98; I2 = 34%, P =
0.12; Analysis 5.1).
Four of the eight studies rated as having high risk of bias reported
the SGRQ: three from the formoterol 12 subgroup and one from
the salmeterol subgroup. After these studies were removed, the
pooled difference betweenLABAandplacebo remained significant
but was again reduced (MD -1.60, 95% CI -2.15 to -1.05; I2 =
42%, P = 0.04; Analysis 6.1).
Severe COPD exacerbations (requiring hospitalisation)
Whendata from seven studies were combined (nine comparisons),
the number of people hospitalised for COPD exacerbations was
lower among LABA-treated participants than in those receiving
placebo (OR 0.73, 95% CI 0.56 to 0.95; Analysis 1.4). Although
little evidence was found for explicit selective outcome reporting
within trials, the outcome was downgraded for publication bias
and was rated as having moderate quality; more than half of the
studies did not report the outcome of high interest to patients and
clinicians, and the estimate might have been different if all studies
could have been included in the analysis (see Included studies-
Outcomes and analysis structure). No heterogeneity was noted be-
tween trials, and the results of a test for subgroup differences be-
tween drugs/doses were not significant (I2 = 57.5%, P = 0.10).
No evidence of a statistically significant effect of trial duration was
observed in the formoterol 12µg trials (six studies across three du-
ration subgroups). Similarly, no significant differencewas observed
between the three-month Dahl 2001 study and the 12-month
Rossi 2002 study comparing formoterol 24µg with placebo. Only
one six-month study comparing salmeterol and placebo reported
hospitalisation rates, so no assumptions could be made regarding
relative effects of trial duration.
The pooled effect of LABA versus placebo decreased in magni-
tude and was no longer significant after four studies with a high
percentage of participants taking inhaled corticosteroids (six com-
parisons) were removed. This effect was based on only three re-
maining trials (OR 0.85, 95% CI 0.62 to 1.16; Analysis 5.2), and
the change in effect could be explained by another variable. None
of the eight studies rated as having high risk of bias reported the
number of participants with exacerbations requiring hospitalisa-
tion, so the outcome does not appear in the sensitivity analysis.
Secondary outcomes
Moderate COPD exacerbations (requiring a course of antibi-
otics and/or oral steroids)
LABA treatment reduced the number of people who had one or
more exacerbations requiring a course of antibiotics, oral steroids
or both compared with placebo (OR 0.73, 95% CI 0.61 to 0.87;
I2 = 8%, P = 0.37; Analysis 1.6), with minimal heterogeneity.
The quantity of data for the outcome was similar to that provided
for severe COPD exacerbations, so the outcome was downgraded
for publication bias for the same reasons and was rated as having
moderate quality. No evidence suggested important subgroup dif-
ferences on the basis of which LABA/dose was used (I2 = 0%, P
= 0.68). The three studies that compared formoterol 12 µg with
placebo showed no significant benefit (OR 0.78, 95% CI 0.56 to
1.07; I2 = 7%, P = 0.34; Analysis 2.3) with little heterogeneity,
and no evidence was found of differential effectiveness related to
study duration. The higher-dose formoterol 24 µg did show a
significant reduction relative to placebo (OR 0.57, 95% CI 0.38
to 0.88; Analysis 3.3), although this was based on a total of 124
events in one study (Rossi 2002). Four studies that compared sal-
meterol with placebo showed an overall reduction in moderate ex-
acerbations with the study drug (OR 0.75, 95% CI 0.60 to 0.94;
I2 = 40%, P = 0.17; Analysis 4.3), with some non-significant het-
erogeneity and no observed differences related to study duration.
Moderate/severe COPD exacerbations (requiring hospitalisa-
tion or a course of antibiotics/oral steroids or ER visit)
Around half of the studies did not report rates of moderate and
severe COPD exacerbations as separate outcomes, as we had de-
fined in the protocol, but rather reported a composite rate, which
could not be combined with the other data; therefore we decided
to present these data separately in the review. As with the other
two exacerbation outcomes, the outcome was rated of moderate
quality after it was downgraded for publication bias.
LABA treatment did not significantly reduce the number of people
withmoderate or severe exacerbations comparedwith placebo (OR
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0.88, 95% CI 0.76 to 1.02; I2 = 0%, P = 0.80; Analysis 1.5), as
determined on the basis of seven studies with 1142 participants.
No between-study or between-drug heterogeneity was observed.
Since the outcome was added, post hoc and subgroup analyses
have been reported for the other two exacerbation outcomes, and
we did not perform separate subgroup analyses of trial duration
for this outcome.
Mortality; all-cause
Study deaths were relatively uncommon; therefore the analyses
were conducted using Peto odds ratio, as this method does not
require adjustment for zero cells. LABA treatment did not signif-
icantly reduce mortality compared with placebo (OR 0.90, 95%
0.75 to 1.08; I2 = 21%, P = 0.21; Analysis 1.7), and a degree of
between-study heterogeneity was noted. The outcome was down-
graded for imprecision and was rated as having moderate qual-
ity because the confidence intervals for the pooled effect included
important benefit and potential harm. A test for subgroup differ-
ences between drugs was not statistically significant (I2 = 55%, P =
0.11). Results of a test for subgroup differences related to the du-
ration of the formoterol trials were not significant (Analysis 2.4).
In the two formoterol 24 µg trials that reported all-cause mortal-
ity, only one death occurred in the LABA group of Rossi 2002;
the confidence intervals were too wide to allow interpretation of
direction or magnitude of effects (Analysis 3.4) or assumptions
based on trial length. Four studies with no events did not con-
tribute to the salmeterol analysis (Analysis 4.4), and the effect was
largely influenced by the large Calverley 2007 [TORCH] study
(93% of total weight). This large study was unique because it was
much longer than the other trials (at three years), and investigators
logged mortality for all participants, regardless of how long they
stayed in the study. Between-trial heterogeneity was not significant
in the salmeterol analysis (I2 = 29%, P = 0.22); a test for subgroup
differences regarding trial duration also was not significant (I2 =
0%).
Non-fatal serious adverse events; all-cause
All studies included in the analysis reported this outcome with
participants as the level of analysis (i.e. number of people who had
serious adverse events as opposed to the number of adverse events
in total). When findings of all studies were pooled, no difference
was observed between LABA and placebo (OR 0.97, 95%CI 0.83
to 1.14; I2 = 34%, P = 0.06; Analysis 1.8). Heterogeneity was
significant at P = 0.1, and unexplained differences between the
two formoterol doses showed opposite directions of effect. A test
for subgroup differences indicated that some of the heterogeneity
may be explained by these differences in individual drugs/doses,
which were significant (I2 = 83%, P = 0.002). It is unclear whether
formoterol 12 µg significantly increases rates of serious adverse
events, as the confidence interval touched the line of no effect (OR
1.20, 95% CI 1.00 to 1.43; I2 = 14%, P = 0.32; Analysis 2.5),
and differences in trial duration were not statistically significant.
Three formoterol 24µg studies showed that serious adverse events
were lowered by LABA use (OR 0.53, 95% CI 0.36 to 0.79; I2
= 0%, P = 0.67; Analysis 3.5) with no significant heterogeneity,
although confidence intervals were quite wide. Studies that com-
pared salmeterol 50 µg with placebo showed no significant differ-
ences between groups (OR 0.94; 95% CI 0.83 to 1.06; I2 = 13%,
P = 0.33; Analysis 4.5) based on nine studies with 1608 events.
Some statistically insignificant heterogeneity between trial results
was noted and could not be explained by reliable differences in
trial duration.
Predose forced expiratory volume in one second (troughFEV1 )
The predose FEV1 of participants taking LABA was 73 mL higher
at the end of the trials than that of participants taking placebo
inhalers (95% CI 48 to 98; I2 = 71%, P < 0.0001; Analysis 1.9);
this finding was based on data from 6125 participants in thirteen
studies that reported the outcome. A large degree of heterogeneity
was noted, so the analysis was downgraded for inconsistency. Half
of the studies did not report the outcome or reported the outcome
in a way that could not be entered in meta-analysis; therefore it
was downgraded for publication bias and was rated as having low
quality. A test for subgroup differences suggested that the hetero-
geneity may be accounted for by differences between formoterol
12 µg and salmeterol 50 µg (no formoterol 24 studies reported
trough FEV1) (I
2 = 84%, P = 0.01). Individually, formoterol 12
µg (MD 45 mL, 95% CI 29 to 60) and salmeterol 50 µg (MD
101 mL, 95% CI 60 to 142) were associated with improved pre-
dose FEV1 relative to placebo.
No heterogeneity was observed between the formoterol 12 µg
studies (I2 = 0%, P = 0.57), and no observable differences related
to trial duration were reported. In the salmeterol 50 µg studies,
heterogeneity was substantial (I2 = 69%, P = 0.003), and a test for
subgroup differences of study duration suggested that the benefits
of LABA treatment over placebo become less distinct over time
(I2 = 87%, P = 0.0005; Analysis 4.6). Some of the heterogeneity
may have been introduced by within-subgroup variation in the
recruited populations. For example, Rennard 2001 split the pop-
ulation by high and low reversibility to compare the effects of sal-
meterol on different participant groups, and the data entered into
the analysis represent the population as a whole.
Withdrawal from study treatment
Withdrawal rateswere higher for placebo than for LABA treatment
(OR 0.74, 95%CI 0.69 to 0.80; I2 = 0%, P = 0.75; Analysis 1.10),
as determined on the basis of data from all studies except Watkins
2002. The formoterol 24 µg studies contributed the least data to
the analysis and showed no difference between LABA and placebo,
although subgroup differences between drugs and doses were not
significant (I2 =0%,P=0.66).Noheterogeneity between trialswas
noted, and no evidence showed significant subgroup differences
between dose categories. No clear effects of trial duration were
evident.
D I S C U S S I O N
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Summary of main results
Twenty-six studies including nearly 15,000 people with moderate
to severe COPD were included in the review. Participants in the
studies were more often male with mean baseline FEV1 between
33% and 55% predicted normal and mean SGRQ ranging from
44 to 55.
LABA treatment significantly improved quality of life and re-
duced hospitalisations relative to placebo, although unexplained
variation was noted within the quality of life data. Exacerbations
were not consistently defined in trials, but across three definitions
(those leading to hospitalisation, requiring a course of antibiotics
or steroids or either), good evidence suggested that LABA therapy
was effective. In terms of adverse events, no significant difference
was observed in rates of mortality or serious adverse events be-
tween LABA and placebo.
Most subgroup differences between drugs and between dose
groups were not significant. Significant differences in serious ad-
verse events data were complicated by the unexplained disparity
of effect direction for the two formoterol doses, and the differ-
ence in FEV1 between formoterol and salmeterol is complicated
by substantial heterogeneity within the salmeterol studies for that
outcome. Systematic differences between drug company method-
ology and recruitment procedures may preclude comparisons be-
tween salmeterol and formoterol.
Participants were more likely to withdraw from placebo than from
LABA therapy (OR0.74, 95%CI 0.69 to 0.80; I2 = 0%), although
sensitivity analyses removing studies at highest risk of bias for this
reason did not change conclusions for the primary outcomes.
Overall completeness and applicability of
evidence
The current review expanded and updated a previous Cochrane
review that looked only at patients with poorly reversible COPD
(Appleton 2006). Because the inclusion criteria were widened to
include all patients with a diagnosis of COPD, findings are likely
to apply to a larger group of patients for whom LABA therapy
is indicated. Trials were largely consistent in their inclusion of
moderately to severely affected participants, as confirmed through
smoking and medication history and spirometric indices.
Because of variation in study protocols regarding the use of other
COPD medications, it is difficult to accurately judge to which
groups of patients the evidence accurately applies. However, the
sensitivity analysis removing studies in which a large proportion
of participants were taking other COPD medications goes some
way to dispel this uncertainty, given that results were very similar
to those of the original pooled analysis. Similarly, systematic dif-
ferences may be noted between trials of salmeterol and those of
formoterol because differentmanufacturers conductedmost of the
trials for these two drugs. However, analysis of descriptive statis-
tics for the baseline measurements showed that the populations
recruited to trials of salmeterol were similar to those enrolled in
the formoterol trials (percentage reversibility and percentage pre-
dicted FEV1). Outlier studies (those recruiting unusually severe or
mild participants) may still have introduced heterogeneity within
analyses, and differences may have been masked by inconsistent
reporting of severity metrics across the data set and the lack of in-
dividual participant data. Additionally, significantly higher with-
drawal in the placebo groups is likely to be due primarily to lack of
efficacy leading to protocol violations (Calverley 2003). This may
have reduced the effectiveness of randomisation and decreased the
magnitude of difference between groups by removing from the
analysis participants with themost severe conditionswho had been
assigned to placebo.
Only three trials tested the higher dose of formoterol (24 µg twice
daily) against placebo, of which two also included an arm that
received the more commonly prescribed 12 µg dose. The higher
dose is the maximum indicated by the British National Formulary
(BNF) for additional symptom relief (BNF 2009), and, in this
sense, the tendency for trials to use the lower dose is consistent
with licensing and practice. Similarly, the use of 12 µg twice daily
is consistent and hence comparable with the dose received through
combination preparations of budesonide and formoterol. In ad-
dition, little variation in inhaler devices was seen within the for-
moterol or salmeterol studies, with most formoterol studies using
masked Turbuhaler devices, and most salmeterol trials using the
Diskus. However, fact that inhaler devices differed fairly system-
atically between the two drugs may have contributed to subgroup
differences.
It is unclear whether unpublished trials are missing from the re-
view or, in some cases, whether all data are reported in the available
papers and unpublished industry summaries. Attempts to ascer-
tain with GlaxoSmithKline, AstraZeneca and Novartis whether all
conducted studies and measures within them were included were
not fruitful in time for publication.
Quality of the evidence
The methodological quality of the included trials was good, and
the single conference abstract of unknown quality did not con-
tribute any data to the analysis. All studies were double-blind,
and so results are unlikely to be compromised by detection or
performance biases. Similarly, most studies controlled adequately
for selection bias or were presumed to do so, in accordance with
industry protocol. Although evidence suggested bias from high
and unbalanced attrition in some trials and significantly higher
withdrawal in the placebo arm when analysed, sensitivity analyses
showed that conclusions did not change when studies at highest
risk of bias were removed from the primary outcomes. It is possi-
ble that higher attrition in the placebo group across many of the
trials could have diluted the true difference between LABA and
placebo for some outcomes; if we accept that people who drop out
of studies have a less positive outcome than those who do not, the
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placebo estimate could appear more favourable than if everyone
had contributed endpoint data, depending on the method used to
impute values for missing data points (i.e. last observation carried
forward or other imputation models).
As described above, some evidence of selective reporting bias was
found, both within trials that failed to report key outcomes or
those stated in the prospectively registered protocols, and in terms
of the possibility that trials (industry funded or independent) may
remain unpublished (Song 2010). Several studies did not report
exacerbations or trough FEV1 in a way that could be included in
the review, so additional evidence obtained in future studies might
change our confidence in these results.
Most studies were sponsored by drug companies, and they gener-
ally were of good quality. A lot of variation between studies was
noted in the effect of LABA inhalers on quality of life, serious side
effects and lung function. Although studies with around half of
people taking additional medications were removed in a sensitivity
analysis, the variation in allowed co-medications and the numbers
taking them may explain some of the variation in reported find-
ings.
Potential biases in the review process
Review authors made every effort to identify all relevant published
and unpublished studies by using additional methods to catch
anything that might not have been found in the main electronic
search (e.g. searching drug company databases and clinical trial
registration sites, checking reference lists). However, attempts to
obtain data directly from drug companies were not successful, and
we did not routinely contact individual trial authors for additional
data unless outcomes were clearly selectively reported. Unpub-
lished studies (industry funded or otherwise) may exist that might
change our confidence in the conclusions. All authors adhered to
themost recent best practice guidelines in terms of study selection,
resolution of disagreements, data extraction and analysis to reduce
bias and errors.
Agreements and disagreements with other
studies or reviews
Five previous reviews were identified that specifically analysed
LABA versus placebo. Results of this review were consistent
with results for salmeterol 50 µg as reported in the previous
Cochrane review specifically looking at patients with poorly re-
versible COPD (Appleton 2006). Specifically, benefit was associ-
ated with twice-daily salmeterol 50 µg in terms of FEV1, quality
of life and exacerbations. This review found that formoterol 12µg
also improves these outcomes-a fact that was previously unclear.
The benefits of formoterol 24 µg remain unclear, and salmeterol
100 µg was not included in the current review, as this dose is not
recommended in current clinical practice.
Kliber 2010 concluded that mortality was not significantly re-
duced by LABA therapy, and this conclusion was consistent with
this review, despite some differences in trial inclusion criteria. Sim-
ilarly, Rodrigo 2008 found comparable benefits of LABA on exac-
erbation frequency, spirometry and quality of life, and again, no
significant effect on mortality.
Upon looking solely at salmeterol, Stockley 2006a found that
study participants were less likely to withdraw when taking the
study drug than when taking placebo, and that key efficacy mea-
sures were improved at three, six and 12 months.
Wang 2012 concluded that formoterol did not improve exacer-
bations unless used in conjunction with inhaled corticosteroids.
However,Wang 2012 did not include trials of less than sixmonths,
excluded small trials and included trials of indacaterol, which may
explain why the results differ.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review and meta-analysis provide moderate-quality evidence
that inhaled long-acting beta2-agonists are effective over medium
and long term for use in patients with moderate or severe COPD.
Excluding trials inwhich about half of people were receiving ongo-
ing treatmentwith inhaled corticosteroids or othermedications for
COPD gave similar effect estimates and reduced variation in the
results. LABA therapy is associated with improved patient qual-
ity of life and reduced exacerbations, including those requiring
hospitalisation. Overall, it was found that inhaled LABAs did not
significantly reduce mortality or serious adverse events.
Implications for research
More consistent reporting of exacerbations in clinically and finan-
cially meaningful categories is needed (i.e. those requiring hospi-
talisation as distinct from those requiring changes to medication).
We have found plenty of evidence for the comparison between
the LABAs salmeterol and formoterol and placebo in relation to
quality of life, and we would not suggest that any further research
is needed. However, for new and emerging LABAs (such as in-
dacaterol), trials will be needed to determine whether they are
safe, effective and cost-effective. Future clinical trials on LABAs
in COPD should focus on head-to-head comparisons with other
long-acting agents.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aalbers 2002
Methods Design: randomised, multi-centre, double-blind, parallel-group study
Duration: 3 months (+ 2 weeks run-in period)
Location: The study took place in 86 centres in nine countries (Australia, Belgium,
Denmark, Germany, Hungary, The Netherlands, Norway, Poland and UK)
Participants Population: 516 participants were randomly assigned to formoterol 12 µg twice daily
(166), formoterol 24 µg twice daily (177) and placebo (173)
Baseline characteristics:
Mean age (years): formoterol 12 µg, 63.3; formoterol 24 µg, 61.9; placebo, 61.8
% Male: formoterol 12 µg, 71.7; formoterol 24 µg, 69.5; placebo, 65.3
% Reversibility: formoterol 12 µg, 5.8; formoterol 24 µg, 6.5; placebo, 6.7
% FEV1 predicted: formoterol 12 µg, 54.5; formoterol 24 µg, 54.7; placebo, 53.8
Inclusion criteria: male or female current or former smokers with a history of at least
10 pack-years and a clinical diagnosis of COPD
Prebronchodilator FEV1 had to be > 0.7 L and 40% to 70% of predicted, FEV1/forced
vital capacity (FVC) ratio < 89% pred normal for females and < 88% for males and the
total symptom score had to be 2 or greater on at least 7 days of the run-in period
Exclusion criteria: history of asthma or seasonal rhinitis before age 40; current respira-
tory tract disorder other than COPD; significant or unstable heart disease; other signif-
icant gastro, hepatic, renal or endocrine disease
Interventions • Formoterol 12 µg twice daily
• Formoterol 24 µg twice daily
• Placebo
Inhaler device: dry powder inhaler
Co-medication: terbutaline (0.5mg), prednisolone (10mg),methylprednisolone (8mg)
and betamethasone (1 mg) were allowed during the study period. Excluded medications
included inhaled and oral beta2-agonists, inhaled anticholinergics, xanthine derivatives,
leukotriene antagonists, ephedrine and parenteral glucocorticosteroids
Outcomes Lung function: FEV1, FVC and dyspnoea (TDI)
Adverse events: non-fatal serious adverse events
Other: withdrawal, symptom scores and % of symptom-free days, shuttle walking test,
use of relief medication
Notes Funding: AstraZeneca
Study number: unknown
Definitions: none (exacerbations not reported)
Risk of bias
Bias Authors’ judgement Support for judgement
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Aalbers 2002 (Continued)
Random sequence generation (selection
bias)
Low risk Participants were randomly assigned to the
four treatments in balanced blocks using
a computer-generated schedule after com-
pleting the run-in period
Allocation concealment (selection bias) Low risk Individually sealed treatment codes indi-
cating the allocated treatment for each par-
ticipant were available at each clinic for
emergency situations
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind study-all inhalers used in the
study were of identical appearance, and
active and placebo inhalers were indistin-
guishable in taste
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No specific details regarding blinded out-
come assessment were found
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal rates were similar and below
20% in each group (formoterol 12 µg 18.
1%, formoterol 24 µg 15.3%, placebo 15.
6%)
Selective reporting (reporting bias) High risk Results for all specified outcomes were re-
ported, but key outcomes expected for
COPD were omitted (HRQoL, exacerba-
tions, mortality)
Bogdan 2011
Methods Design: randomised, double-blind, placebo-controlled, parallel-group, multinational
phase III study
Duration: 3 months (+ 2 weeks run-in period)
Location: 65 centres in Japan, Romania, Russia and Ukraine
Participants Population: 407 participants were randomly assigned to formoterol 12 µg twice daily
(199) and placebo (208)
Baseline characteristics:
Mean age (years): formoterol 12 µg, 66.7; formoterol 24 µg, 67.2; placebo, 66.3
% Male: formoterol 12 µg, 85.4; placebo, 89.4
% White: formoterol 12 µg, 45.7; placebo, 47.1
% Reversibility: formoterol 12 µg, 10.7; placebo, 11.3
Pack-years: formoterol 12 µg, 46.5; placebo, 47.4
% FEV1 predicted: 50.4; formoterol 12 µg, 51.5; placebo, 52.5
Inclusion criteria: > 40 years old; clinical diagnosis of COPD (postbronchodilator FEV1
< 80% predicted, and postbronchodilator FEV1/FVC < 70%); history of at least 10
pack-years; symptom score of at least 2 points on at least 6 of the last 10 days of the run-
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Bogdan 2011 (Continued)
in period
Exclusion criteria: history of asthma; history of clinical diagnosis of atopic disease such
as allergic rhinitis; significant or unstable ischaemic heart disease or other cardiovascular
conditions, other respiratory tract disorders or significant disease
Interventions • Formoterol 12 µg twice daily
• Placebo
Inhaler device: dry powder inhaler
Co-medication: salbutamol (100 µg pMDI) and short-acting anticholinergics were
allowed as rescuemedication. Excludedmedication included long-acting anticholinergics
and glucocorticoid treatment (including inhaled corticosteroids)
Outcomes HRQoL: St George’s Respiratory Questionnaire (SGRQ)
COPD exacerbations: number requiring hospitalisation and/or a course of antibiotics
and/or systemic steroid therapy
Lung function: change (ratio) from baseline to end of treatment period in FEV1 60
minutes postdose, FVC 60 minutes postdose, FEV1 and FVC predose and 5 minutes
postdose
Adverse events: all-cause mortality and non-fatal serious adverse events
Other: withdrawal, use of salbutamol as reliever medication (measured as inhalations/
day), COPD symptom scores (night-time awakenings due to symptoms, breathlessness
and cough)
Notes Funding: AstraZeneca
Study number: AstraZeneca ID D5122C00001; registration NCT00628862
Definitions: Exacerbations were defined as requiring hospitalisation and/or a course of
antibiotics and/or systemic steroid therapy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly assigned to
treatment. No details of sequence gener-
ation methods but assumed to adhere to
usual AstraZeneca methods
Allocation concealment (selection bias) Unclear risk No details reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial registration states masking was dou-
ble-blind for subject, caregiver and investi-
gator
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No specific details regarding blinded out-
come assessment
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Bogdan 2011 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was uneven but relatively low in
all groups (formoterol 12, 8.5%; placebo,
10.6%)
Selective reporting (reporting bias) Low risk Checkedpaper against protocol. Results for
all specified outcomes were reported and
could be included
Brusasco 2003
Methods Design: pooled results from two randomised, double-blind, double-dummy, parallel-
group design studies
Duration: 6 months (+ 2 weeks run-in period)
Location: The studies were performed in 18 countries
The only difference in the two studies was the duration of serial spirometry in the clinic
(12 hours in one study, 3 hours in the second)
Participants Population: 805 participants were randomly assigned to salmeterol 50 µg twice daily
(405) and placebo (400)
Baseline characteristics:
Mean age (years): salmeterol, 64.1; placebo, 64.6
% Male: salmeterol, 75.1; placebo, 76.3
Pack-years: salmeterol, 44.8; placebo, 42.4
% FEV1 predicted: salmeterol, 37.7; placebo, 38.7
Inclusion criteria: Participants were required to have relatively stable airway obstruction
with FEV1 < 65% of predicted normal and < 70% of FVC, > 40 years of age, with a
smoking history of > 10 pack-years
Exclusion criteria: Patients with a history of asthma, allergic rhinitis or atopy or with
an increased total eosinophil count were excluded. Other exclusion criteria included
use of supplemental oxygen or an upper respiratory tract infection in the six weeks
before screening. Patients with a significant disease other than COPD were not enrolled.
Significant disease was defined as a disease that, in the opinion of the investigator, would
put the patient at risk because of participation in the study, or a disease that would
influence the results of the study
Interventions • Salmeterol 50 µg twice daily
• Combination of salmeterol and tiotropium placebos
Inhaler device: dry powder inhaler
Co-medication: Participants were allowed to continue previously prescribed regular
inhaled steroids or regular oral steroids, not exceeding a dose equivalent to approximately
10 mg prednisone daily. The number of participants taking these medications during
the study was not located
Outcomes HRQoL: mean change from baseline on the SGRQ and number whose score decreased
by at least 4 units
COPD exacerbations: number of exacerbations, number of exacerbation days, percent-
age of participants with at least one COPD exacerbation, time to first COPD exacer-
bation, hospital admissions for any reason and for an exacerbation, days hospitalised,
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Brusasco 2003 (Continued)
percentage of participants with at least one hospital admission for a COPD exacerbation,
time to first hospital admission due to a COPD exacerbation
Lung function: FEV1, FVC, dyspnoea (evaluated using the Baseline Dyspnoea Index
(BDI) and the TDI)
Adverse events: all-cause mortality
Other: withdrawal, non-scheduled contacts with physicians and other healthcare
providers (use of the intensive care unit), disability days (days unable to perform daily
activities) and employment status
Notes Funding: Boehringer Ingelheim
Study number: Boehringer Ingelheim 205.130/205.137
Definitions: Exacerbations were defined as a complex of respiratory symptoms (new
onset or an increase in at least one of cough, sputum, dyspnoea, wheeze or chest discom-
fort) lasting at least 3 days and usually associated with a therapeutic intervention
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation list was generated by
Boehringer Ingelheim with the use of a val-
idated system, which involved a pseudo-
random number generator, so that the re-
sulting treatment sequence was both repro-
ducible and non-predictable
Allocation concealment (selection bias) Low risk All investigational medication for each par-
ticipant was identified by a unique med-
ication number. Each eligible participant
was assigned the lowest medication num-
ber available to the investigator at the time
of randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Boehringer Ingelheim was responsible for
preparing and coding study medication in
a blinded fashion (Boehringer Ingelheim
study drug and control were indistinguish-
able). Participants, investigators and study
personnel remained blinded with regard
to treatment assignments up to database
lock. Double-dummy technique was used
to blind different application devices
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk In all studies, a selection of standard respi-
ratory endpoints, such as pulmonary func-
tion, SGRQ, TDI, treadmill, exacerba-
tions, etc., were used. Outcome assessors
remained blinded with regard to treatment
assignments up to database lock
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Brusasco 2003 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal rates were relatively even be-
tween groups (salmeterol, 18.8%, placebo,
25.8%)
Selective reporting (reporting bias) High risk FEV1 [secondary outcome] was not re-
ported in a way that could be included in
the qualitative synthesis, and no data were
reported for serious adverse events
Calverley 2003a
Methods Design: randomised, double-blind, placebo-controlled, parallel-group study
Duration: 12 months (+ 2 weeks run-in period)
Location: 109 centres in 15 countries or regions
Participants Population: 511 participants were randomly assigned to formoterol 12 µg twice daily
(255) and placebo (256)
Baseline characteristics:
Mean age (years): formoterol 12 µg, 63; placebo, 65
% Male: formoterol 12 µg, 75; placebo, 75
% Reversibilty: formoterol 12 µg, 6.0; placebo, 6.0
Pack-years: formoterol 12 µg, 38; placebo, 39
% FEV1 predicted: formoterol 12 µg, 36; placebo, 36
% taking ICS: formoterol 12 µg, 0; placebo, 0
Inclusion criteria: Males and females > 40 years old; history of at least 10 pack-years;
COPD for at least 2 years; < 70% FEV1/FVC, FEV1 < 50% predicted; 1+ COPD
exacerbations requiring medication in previous 2 to 12 months
Exclusion criteria: history of asthma or seasonal allergic rhinitis before age 40; any
relevant cardiovascular disorders or other disease
Interventions • Formoterol 12 µg twice daily
• Placebo
Inhaler device: dry powder inhaler
Co-medication: terbutaline (0.5 mg) as needed; maximum 3-week course of oral corti-
costeroids and antibiotics were allowed in the event of exacerbations; parenteral steroids
and/or nebulised treatment were allowed at emergency visits. Medications excluded dur-
ing the study period were oxygen therapy; beta-blocking agents; inhaled corticosteroids;
disodiumcromoglycate; leukotriene antagonists or 5-lipoxygenase inhibitors; other bron-
chodilators; antihistamines and medications containing ephedrine
Outcomes HRQoL: St Georges Respiratory Questionnaire (SGRQ)
COPD exacerbations: number of ’severe’ exacerbations, time to first severe exacerbation
and mild exacerbations
Lung function: FEV1, FVC, morning and evening PEF
Adverse events: all-cause mortality and non-fatal serious adverse events
Other: withdrawal, diary cards, rescue medication use, use of antitussives and other
COPD medication, symptom scores, night-time awakenings due to COPD, healthcare
contacts and sick leave related to COPD
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Calverley 2003a (Continued)
Notes Funding: AstraZeneca
Study number: AZ study ID SD-039-0670
Definitions: ’Severe’ exacerbations were defined as intake of a course of oral steroids
and/or antibiotics and/or hospitalisation due to respiratory symptoms (coded as severe
and moderate in the review); ’mild’ exacerbations were described as the number of days
with intake of 4 or more puffs of rescue medication
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly assigned to
treatment. No details of sequence gener-
ation methods but assumed to adhere to
usual AstraZeneca methods
Allocation concealment (selection bias) Unclear risk No details reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study reported as double-blind (partici-
pants and investigators)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No specific details regarding blinded out-
come assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal even but high in both groups
(formoterol, 43.5%; placebo, 41.4%). An
intention-to-treat analysis was used for all
hypothesis testing
Selective reporting (reporting bias) Low risk All relevant outcomes were reported and
could be included. Only an inexact P-value
was given for quality of life [primary out-
come], which was included as an approxi-
mation in the analysis
Calverley 2003b [TRISTAN]
Methods Design: randomised, double-blind, placebo-controlled, parallel-group design
Duration: 12 months (+ 2 weeks run-in period)
Location: 196 centres in 25 countries (Australia, Austria, Belgium, Canada, Czech Re-
public, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Italy,
Lithuania, TheNetherlands,NewZealand,Norway, Poland, Russia, South Africa, Spain,
Sweden, Switzerland and United Kingdom)
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Calverley 2003b [TRISTAN] (Continued)
Participants Population: 733 participants were randomly assigned to salmeterol 50 µg twice daily
(372) and placebo (361)
Baseline characteristics:
Mean age (years): salmeterol, 63.2; placebo 63.4
% Male: salmeterol, 70; placebo, 75
% Reversibilty: salmeterol, 3.7; placebo, 4.0
% White: salmeterol, 99; placebo, 98
Pack-years: salmeterol, 43.7; placebo, 43.4
% FEV1 predicted: salmeterol, 44.3; placebo, 44.2
Inclusion criteria: ≥ 10-Pack-year history of cigarette smoking; a history of cough
productive of sputum on most days for at least 3 months of the year, for at least 2
years; documented history of COPD exacerbations each year for the previous 3 years,
including at least one exacerbation in the last year that required oral corticosteroids and/or
antibiotics; a baseline (pre-bronchodilator) FEV1 ≥ 25% to≤ 70% of predicted normal;
poor reversibility of airflowobstruction (defined as an increase < 10%of predictednormal
FEV1 value 30 minutes after inhalation of 400 µg salbutamol) and FEV1/forced vital
capacity (FVC) ratio ≤ 70%
Exclusion criteria: respiratory disorders other than COPD. Patients were also excluded
if they had received systemic corticosteroids, high doses of inhaled corticosteroids or
antibiotics in the 4 weeks before the 2 weeks run-in
Interventions • Salmeterol 50 µg twice daily
• Placebo
Inhaler device: dry powder inhaler
Co-medication: Inhaled salbutamol was used as relief medication throughout the study,
and regular treatment with anticholinergics, mucolytics and theophylline was allowed.
Medications not allowed during the study periodwere inhaled corticosteroids and LABAs
Outcomes HRQoL: Health status was assessed with St George’s Respiratory Questionnaire
COPD exacerbations: acute exacerbations (see notes)
Lung function: FEV1 (at least 6 hours after medication), pretreatment FVC and post-
bronchodilator FEV1 and FVC, morning PEF
Adverse events: any adverse event, non-fatal serious adverse event and all-cause mortality
Other: withdrawal, diary cards recording use of relief medication, symptom scores and
night-time awakenings
Notes Funding: GlaxoSmithKline
Study number: GSK identifier SFCB3024
Definitions: Exacerbationswere defined as worsening of COPD symptoms that required
treatment with antibiotics, oral corticosteroids or both (coded as moderate for this re-
view). Episodes that required corticosteroid treatment or hospital admission were noted
separately
Risk of bias
Bias Authors’ judgement Support for judgement
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Calverley 2003b [TRISTAN] (Continued)
Random sequence generation (selection
bias)
Low risk We used a randomisation schedule gener-
ated by the Patient Allocation for Clinical
Trials (PACT) programme to assign partic-
ipants to study treatment groups
Allocation concealment (selection bias) Low risk Every participating centre was supplied
with a list of participant numbers (assigned
toparticipants at their first visit) and a list of
treatment numbers. Participants who sat-
isfied eligibility criteria were assigned the
next sequential treatment number from the
list
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study drugs were labelled to ensure that
both the participant and the investigator
were unaware of the allocated treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No specific details regarding blinded out-
come assessment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal relatively evenbut high in both
groups (salmeterol, 32.0%, placebo, 38.
8%); the intent-to-treat (ITT) population,
consisting of all participants who were ran-
domly assigned to treatment and received
at least one dose of the study medication,
was used for all analyses of efficacy and sa-
fety. Unclear what method of imputation
was used for each outcome
Selective reporting (reporting bias) Low risk All outcomes stated in the protocol were
reported in detail and could be included in
the meta-analysis
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Calverley 2007 [TORCH]
Methods Design: a multi-centre, randomised, double-blind, parallel-group, placebo-controlled
study
Duration: 36 months (+ 3 weeks run-in period)
Location: 466 centres in 42 countries comprising 190 centres in USA, 134 centres
in Western Europe (Austria, Belgium, Denmark, Finland, France, Germany, Greece,
Iceland, Italy, Netherlands, Norway, Spain, Sweden, United Kingdom), 46 centres in
Eastern Europe (Bulgaria, Croatia, CzechRepublic, Hungary, Estonia, Latvia, Lithuania,
Poland, Romania, Russia, Slovakia, Ukraine), 37 centres in Asia Pacific (China, Hong
Kong, Malaysia, Philippines, Singapore, Taiwan, Thailand) and 59 centres in other
regions (Australia,NewZealand, SouthAfrica,Canada, Argentina, Brazil, Chile,Mexico)
Participants Population: 3087 participants were randomly assigned to salmeterol 50 µg twice daily
(1542) and placebo (1545)
Baseline characteristics:
Mean age (years): salmeterol, 65.1; placebo, 65.0
% Male: salmeterol, 76.3; placebo, 76.3
% White: salmeterol, 82; placebo, 82
Pack-years: salmeterol, 49.3; placebo, 48.6
% FEV1 predicted: salmeterol, 43.6; placebo, 44.1
Inclusion criteria: male or female current or former smokers; history of at least 10 pack-
years; clinical diagnosis of COPD; aged 40 to 80 years inclusive, with pre-bronchodilator
FEV1 < 60% predicted at entry to the study
Exclusion criteria: current diagnosis of asthma; current respiratory disorders other than
COPD; lung volume reduction surgery and/or transplant; serious uncontrolled disease;
evidence of alcohol, drug or solvent abuse, hypersensitivity to ICS, bronchodilators or
lactose; deficiency of alpha1-antitrypsin; exacerbation during run-in period
Interventions • Salmeterol 50 µg twice daily
• Placebo
Inhaler device: dry powder inhaler
Co-medication: Ventolin as relief, inhaled long-acting bronchodilators and long-term
oral corticosteroids (theophyllines long- and short-acting, SABAs and short-acting an-
ticholinergic agents allowed). Medications not allowed during the study period were
inhaled corticosteroids, inhaled long-acting bronchodilators, long-term oral corticos-
teroids and long-term oxygen therapy
Outcomes HRQoL: assessed by St. George’s Respiratory Questionnaire
COPD exacerbations: rates of moderate and severe COPD exacerbations
Lung function: adjusted mean change FEV1
Adverse events: all-cause mortality, non-fatal serious adverse events
Other: withdrawal
Notes Funding: GlaxoSmithKline
Study number: GSK identifier SCO30003; trial registration NCT00268216
Definitions: Exacerbations were defined as symptomatic deterioration requiring treat-
ment with antibiotic agents, systemic corticosteroids, hospitalisation or a combination
of these
Risk of bias
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Calverley 2007 [TORCH] (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk [From protocol] “Subjects will be assigned
to study treatment in accordance with
the randomisation schedule, which will be
generated using the GW computer pro-
gram Patient Allocation for Clinical Trials
(PACT)”
Allocation concealment (selection bias) Low risk [From protocol] “Subjects will be centrally
randomised to one of the four treatment
groups via the System for Central Alloca-
tion of Drug (SCAD) and will be stratified
by smoking status” [’central’ interpreted as
being masked from individual study cen-
tres]
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk [From protocol] “Once the database has
been frozen, the treatment allocations will
be unblinded and all of the analyses detailed
in this document will be performed. The
treatment allocations will be unblinded us-
ing standard GSK systems. The database
will be frozen by BDS Respiratory Data
Management, GSK”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk An independent clinical end point com-
mittee, whose members were unaware of
the treatment assignments, determined the
primary cause of death and whether death
was related to COPD. Unclear for other
outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal rates quite similar but both
high by the end of the 36-month treatment
period. Acceptable methods of imputation
used in all cases. For any participant who
withdraws prematurely from the study, all
available data up to the time of discontin-
uation were included in the analyses. Mor-
tality data were collected for participants
who withdrew early
Selective reporting (reporting bias) Low risk All relevant outcomes stated in the protocol
were reported in detail. Exacerbation data
could not be included with the rest of the
data, as they were given only as rate per
patient-year
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Campbell 2005
Methods Design: randomised, double-blind, placebo-controlled, parallel-group study
Duration: 6 months (+ 3 weeks run-in period)
Location: 73 centres in eight countries (Bulgaria, Hungary, Israel, The Netherlands,
Romania, Spain, Sweden and the UK)
Participants Population: 432 participants were randomly assigned to formoterol 12 µg twice daily
(215) and placebo (217)
Baseline characteristics:
Mean age (years): formoterol, 60; placebo, 60
% Male: formoterol, 61; placebo, 73
% Reversibilty: formoterol, 5.1; placebo, 4.7
Pack-years: formoterol, 37; placebo, 37
% FEV1 predicted: formoterol, 53.0; placebo, 54.1
% taking ICS: formoterol, 47; placebo, 44
Inclusion criteria: older than 40 years of age; clinical diagnosis of COPD with at least
2 years of symptoms, FEV1 40% to 70% predicted, FEV1/slow VC < 70%; history of
at least 10 pack-years
Exclusion criteria: history of asthma or seasonal allergic rhinitis; onset before age 40;
inhaled corticosteroid dose change; oral steroid use or significant COPD exacerbation
in the past month
Interventions • Formoterol 12 µg twice daily
• Placebo
Inhaler device: dry powder inhaler
Co-medication: Allowed medications were terbutaline (0.5 mg) used as reliever [in the
two arms used in the review]; inhaled and nasal corticosteroids without modification
of dosage or frequency of administration. Disallowed medications included domicil-
iary oxygen; disodium cromoglycate; ephedrine; antihistamines; beta-blockers and bron-
chodilators other than the study medication
Outcomes HRQoL: assessed using St George’s Respiratory Questionnaire (SGRQ)
COPD exacerbations: time to first severe exacerbation; number of participants with at
least one exacerbation
Lung function: FEV1 % change, morning PEF, slow VC
Adverse events: non-fatal serious adverse events and all-cause mortality
Other: combined symptom score (CSS), reliever medication use
Notes Funding: AstraZeneca
Study number: unknown
Definitions: Exacerbations were defined as the need for oral steroids, change in dose of
inhaled corticosteroids or the need for antibiotics or hospitalisation [coded as moderate
and severe in the present review]
Risk of bias
Bias Authors’ judgement Support for judgement
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Campbell 2005 (Continued)
Random sequence generation (selection
bias)
Low risk Treatment was randomly assigned in bal-
anced blocks using a computer-generated
scheme
Allocation concealment (selection bias) Low risk Randomisation scheme was provided in
coded envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind treatment period (partici-
pants and investigators)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No specific details regarding blinded out-
come assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk An intention-to-treat approach was used
throughout. Unclear how data were im-
puted, but withdrawal rates were simi-
lar and below 20% in both groups (for-
moterol, 14.0%, placebo, 18.0%)
Selective reporting (reporting bias) Unclear risk No trial protocol could be located against
which to check all preregistered outcomes
as reported
Dahl 2001
Methods Design: multicenter, double-blind, randomised, parallel-group, placebo-controlled
study
Duration: 6 months (+ 2 weeks run-in period)
Location: Denmark, Netherlands, Poland, Russia, UK
Participants Population: 586 participants were randomly assigned to formoterol 12 µg twice daily
(194), formoterol 24 µg twice daily (192) and placebo (200)
Baseline characteristics:
Mean age (years): formoterol 12, 64.3; formoterol 24, 63.5; placebo, 63.4
% Male: formoterol 12, 74.2; formoterol 24, 75.6; placebo, 78.5
Pack-years: formoterol 12, 46.0; formoterol 24, 42.2; placebo, 42.5
% FEV1 predicted: formoterol 12, 46.0; formoterol 24, 45.0; placebo, 43.9
% taking ICS: formoterol 12, 47; formoterol 24, 53; placebo, 54
Inclusion criteria: males and females aged 40 and older; history of at least 10 pack-
years; clinical diagnosis of COPD
Exclusion criteria: history of asthma; respiratory tract infection in the past month; need
for long-term oxygen therapy
Interventions • Formoterol 12 µg twice daily
• Formoterol 24 µg twice daily
• Placebo
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Dahl 2001 (Continued)
Inhaler device: dry powder inhaler
Co-medication: Salbutamol was provided as rescue; inhaled corticosteroids (ICS) were
allowed if stable; short courses of antibiotics, oral corticosteroids and/or oxygen could
be used in case of exacerbation or infection. Initiation or discontinuation of ICS or
recent change in dose was not allowed; neither were parenteral or oral corticosteroids,
theophylline, anticholinergics or other LABAs
Outcomes HRQoL: assessed with St George’s Respiratory Questionnaire (SGRQ)
COPD exacerbations: frequency of level 1, 2 and 3 exacerbations (definitions below)
Lung function: FEV1 area under the curve over 12 hours and at individual time points,
morning PEF
Adverse events: non-fatal serious adverse events and all-cause mortality
Other: withdrawal, vital signs, electrocardiograms and clinical laboratory evaluations,
number of puffs of rescue medication, daily total symptom scores
Notes Funding: Novartis
Study number: unknown
Definitions: First level of exacerbation was defined as days with at least two individual
symptom scores of 2 or greater and/or a reduction in PEF from baseline of greater
than 20%; second level of exacerbation: course of additional therapy (corticosteroids,
antibiotics or oxygen) [coded as moderate for this review]; third level: COPD-related
hospitalisations [coded as severe for this review]
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned to receive one of the
following four regimens [no other details
given but industry sponsored]
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding was obtained by double-dummy
dosing [assumed participants and investi-
gators]
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No specific details regarding blinded out-
come assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Statistical analysis was carried out accord-
ing to the intent-to-treat principle. [Un-
clear how data were imputed across out-
comes. Dropout higher in placebo group
but considered low overall in all three
groups (formoterol 12, 6.7%; formoterol
24, 6.8%, placebo, 14.5%)]
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Dahl 2001 (Continued)
Selective reporting (reporting bias) Unclear risk Moderate exacerbation rates not reported
for each group, but all other outcomes
could be included in the meta-analysis.
Trial protocol could not be located against
which to check all preregistered outcomes
as reported
Dahl 2010
Methods Design: randomised double-blind double-dummy parallel-group study
Duration: 12 months (+ 2 weeks run-in period)
Location: Denmark, UK, Germany, Russia, USA (unclear how many centres)
Participants Population: 867 participants were randomly assigned to formoterol 12 µg twice daily
(435) and placebo (432)
Baseline characteristics:
Mean age (years): formoterol, 64; placebo, 63
% Male: formoterol, 80.2; placebo, 81.5
% Reversibility: formoterol, 10.1; placebo, 10.8
Pack-years: formoterol, 40; placebo, 43
% FEV1 predicted: formoterol, 52.5; placebo, 52.0
% taking ICS: formoterol, 50.9; placebo, 51.9
Inclusion criteria: males and females aged 40 and older; clinical diagnosis of moderate
to severe COPD; history of at least 20 pack-years
Exclusion criteria: history of asthma; current respiratory tract infection or hospitalisa-
tion for COPD exacerbation within the previous 6 weeks
Interventions • Formoterol 12 µg twice daily
• Placebo
Inhaler device: dry powder inhaler
Co-medication: Fixed-dose combinations of inhaled corticosteroids (ICS) plus LABA
were replaced by monotherapy ICS at an equivalent dose and regimen plus salbutamol
as needed. Participants receiving ICS monotherapy continued treatment at a stable dose
throughout the study. Oral corticosteroids were not allowed, or a change in ICS was
noted during the previous month
Outcomes HRQoL: assessed by St George’s Respiratory Questionnaire (SGRQ)
COPD exacerbations: frequency of exacerbations (definition below)
Lung function: trough (predose) FEV1 and PEF, dyspnoea (baseline and transition
scores)
Adverse events: any adverse events and all-cause mortality
Other: withdrawal, use of rescue medication, change in concomitant medications, 6-
minute walk test, ECG, vital signs and haematology
Notes Funding: Novartis
Study number: NCT00393458
Definitions: Exacerbations were defined as onset or worsening of more than one respi-
ratory symptom for > 3 consecutive days (based on diary cards or participants’ reports
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of their health since the previous visit) plus documented proof of intensified treatment
(e.g. systemic steroids, antibiotics or oxygen) and/or hospitalisation or emergency room
visit [coded as moderate and severe]
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned to treatment (1:1:1:1)
with stratification for smoking status (cur-
rent/ex-smoker) using an automated inter-
active system
Allocation concealment (selection bias) Low risk Using an automated interactive system
[concealment assumed by automatisation]
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind double-dummy trial
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Protocol states double-blind for partici-
pant, caregiver, investigator and outcomes
assessor (http://www.clinicaltrials.gov/ct2/
show/NCT00393458)
Incomplete outcome data (attrition bias)
All outcomes
High risk Efficacy results are presented for the mod-
ified intention-to-treat (ITT) population,
including all randomly assigned partici-
pants who received at least one dose of
study drug, but excluding patients from
six sites owing to non-conformance with
good clinical practice. Withdrawal rela-
tively high in both groups (formoterol, 25.
7; placebo, 31.7)
Selective reporting (reporting bias) Low risk Checked paper against protocol. All out-
comes stated in the protocol were reported
Doherty 2012
Methods Design: randomised, double-blind, placebo-controlled trial
Duration: 6 months (+ 2 weeks run-in period)
Location: 164 centres in North, Central and South America, Europe, Africa and Asia
Participants Population: 479 participants were randomly assigned to formoterol 10 µg twice daily
(243) and placebo (236)
Baseline characteristics:
Mean age (years): formoterol, 59.7; placebo, 58.8
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%Male: formoterol, 74.9; placebo, 75.4
% White: formoterol, 68.7; placebo, 65.7
% Reversibility: formoterol, 10.4; placebo, 9.5
Pack-years: formoterol, 45.9; placebo, 43.5
% FEV1 predicted: formoterol, 38.2; placebo, 38.0
Inclusion criteria: males and females aged 40 and older; FEV1/FVC < 70%; PFEV 25%
to 60%; COPD symptoms for at least 24 months; history of at least 10 pack-years
Exclusion criteria: current diagnosis of asthma; marked bronchodilator reversibility;
recent COPD exacerbation; history of lung cancer/surgery; other significant medical
illness
Interventions • Formoterol 10 µg twice daily
• Placebo
Inhaler device: metered dose inhaler
Co-medication: open-label, short-acting beta2-agonist (SABA)/short-acting anticholin-
ergic combination was allowed. All long-acting COPD treatments (LABA, inhaled cor-
ticosteroids, LABA/ICS FDC or long-acting anticholinergics) were disallowed
Outcomes HRQoL: assessed with St George’s Respiratory Questionnaire (including number reach-
ing a minimally clinically important difference)
COPD exacerbations: time to first mild, moderate or severe exacerbation. Number of
people with exacerbations
Lung function: FEV1 area under the curve from 0 to 12 hours postdose (at weeks 13
and 26 LOCF); trough FEV1 (not for LABA placebo comparison)
Adverse events: all-cause mortality and non-fatal serious adverse events
Other: withdrawal, COPD symptom-free nights
Notes Funding: Merck & Co
Study number: NCT00383721
Definitions: A mild exacerbation was defined as a clinically judged deterioration of
COPD symptoms (managed with increased short-acting bronchodilator use: 12+ in-
halations/day of SABA/short-acting anticholinergic, or 2+ nebulised treatments/day of
2.5 mg SABA/short-acting anticholinergic) on any two consecutive days. A moderate
exacerbation was defined as a clinically judged deterioration of COPD with an acute
change in symptoms that required antibiotic and/or oral steroid treatment for lower air-
way disease. A severe exacerbation was defined as a deterioration of COPD that resulted
in emergency treatment or hospitalisation because of COPD
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly assigned in a 1:
1:1:1:1 ratio [industry sponsored]
Allocation concealment (selection bias) Unclear risk Participants who discontinued early were
not replaced [no other details given]
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy. Protocol
states participants and investigators were
blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Protocol and paper do not provide details
about blinding of outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal rates were quite different (for-
moterol, 20.6%; placebo, 28.4%), but ef-
ficacy analyses and safety summaries were
based on the intent-to-treat principle for all
randomly assigned participants
Selective reporting (reporting bias) High risk Quality of life [primary outcome] was not
reported in a way that could be analysed for
the comparison in question. All other stated
and expected outcomes were reported and
analysed
Hanania 2003
Methods Design: randomised, double-blind, placebo-controlled, parallel-group, 24-week clinical
trial
Duration: 6 months (+ 2 weeks run-in period)
Location: 75 centres in the USA, one in Puerto Rico
Participants Population: 362 participants were randomly assigned to salmeterol 50 µg twice daily
(177) and placebo (185)
Baseline characteristics:
Mean age (years): salmeterol, 64.2; placebo, 64.8
% Male: salmeterol, 57.6; placebo, 68.1
% White: salmeterol, 93.2; placebo, 93.5
Pack-years (median): salmeterol, 57; placebo, 56
% FEV1 predicted: salmeterol, 42; placebo, 42
Inclusion criteria: males and females aged 40 and older; clinical diagnosis of COPD;
history of at least 20 pack-years and cough productive of sputum on most days for at
least 3 months of the year for at least 2 years; FEV1/FVC ratio < 70% and baseline FEV1
< 65% predicted but > 0.70 L
Exclusion criteria: current diagnosis of asthma; abnormal clinically significant ECG;
moderate or severe exacerbation during the run-in period; any significant medical dis-
order
Interventions • Salmeterol 50 µg twice daily
• Placebo
Inhaler device: dry powder inhaler
Co-medication: Stable regimens of theophylline were allowed (no change in dose for 1
month before screening) [only 11% were taking these medications]. Disallowed medica-
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tions included oral corticosteroids within the past 6 weeks and long-term oxygen therapy,
and participants discontinued the use of corticosteroids and bronchodilators
Outcomes HRQoL: assessed with the Chronic Respiratory Disease Questionnaire (CRQ). Clini-
cally meaningful difference of 10 points
COPD exacerbations: See ’definitions’
Lung function: morning predose and 2-hour postdose FEV1, morning peak expiratory
flow (PEF), dyspnoea (as assessed by the transition dyspnoea index [TDI])
Adverse events:
Other: withdrawal, supplemental albuterol use, symptoms of chronic bronchitis (as
assessed by the Chronic Bronchitis Symptom Questionnaire [CBSQ])
Notes Funding: GlaxoSmithKline
Study number: GSK identifier SFCA3007
Definitions: Exacerbations were defined by treatment, with moderate exacerbations
requiring treatment with antibiotics and/or corticosteroids, and severe exacerbations
requiring hospitalisation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was stratified by reversibil-
ity (defined as a 12% and 200-mL increase
in FEV1 from baseline after administration
of 400 g albuterol) and investigative site [se-
quence generation not described but study
was industry sponsored]
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind [presumed par-
ticipant and investigator]
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No specific details regarding blinded out-
come assessment
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawal high and even between groups
(formoterol, 31.7%, placebo, 31.9%). To
account for participant withdrawals, end
point was used as the primary time point
and was defined as the last on-treat-
ment post-baseline assessment excluding
any data from the discontinuation visit
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Selective reporting (reporting bias) Low risk All expected and stated outcomes were re-
ported. Quality of life data were not in-
cluded, asQOLwas measured on the CRQ
rather than the SGRQ
Hanrahan 2008
Methods Design: Pooled results from two identically designed phase III multicentre double-
blind, double-dummy, placebo- and active-controlled, parallel-group,multiple-dose ran-
domised trials [Baumgartner 2007 and NCT00064402]
Duration: 3 months (+ 2 weeks run-in period)
Location: 60 sites in the first study and 64 sites in the second study (all in the United
States)
Participants Population: 583 participants were randomly assigned to salmeterol 50 µg twice daily
(290) and placebo (293)
Baseline characteristics:
Mean age (years): salmeterol, 62.8; placebo, 63.2
% Male: salmeterol, 58.6; placebo, 60.4
% White: salmeterol, 93.4; placebo, 96.6
% FEV1 predicted: salmeterol, 40.9; placebo, 41.3
% taking ICS: salmeterol, 28.6; placebo, 23.9
Inclusion criteria: males and females aged 35 and older; primary clinical COPD di-
agnosis; FEV1 < 65% predicted and > 0.70 L; FEV1/FVC < 70%; > 15 pack-years;
breathlessness severity on dyspnoea scale > 2
Exclusion criteria: life-threatening/unstable respiratory status within 30 days; asthma or
any chronic respiratory disease other than COPD; lung resection > 1 full lobe; clinically
significant abnormal electrocardiograms at screening
Interventions • Salmeterol 50 µg twice daily
• Placebo
Inhaler device: metered dose inhaler
Co-medication: Albuterol and ipratropiummetered dose inhaler were provided as rescue
and supplemental medications; corticosteroid or xanthines were allowed if the dose
had been stable for 14 days. Use of non-protocol-specified beta-agonists, continuous
supplemental oxygen and beta-blockers was not permitted during the study period
Outcomes HRQoL: not reported
COPDexacerbations: proportion of participants experiencing protocol-definedCOPD
exacerbations
Lung function: % change in trough FEV1 from baseline and average area under the
curve
Adverse events: all-cause mortality and non-fatal serious adverse events
Other: withdrawal, ECG and Holter monitoring
Notes Funding: Sepracor
Study number: NCT00064402 and NCT00064415
Definitions: Exacerbation was defined as an increase in symptoms leading to any change
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in baseline medication or additional medical attention (e.g. hospitalisation, emergency
room visit)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly assigned to
LABA treatment or placebo [industry
sponsored]
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Protocols state participant, investigator and
outcomes assessor were blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Among 1465 randomly assigned partici-
pants, 1456 took at least 1 dose of double-
blind study medication (ITT participants)
. Withdrawal higher in placebo group (sal-
meterol, 14.5%, placebo, 21.8%)
Selective reporting (reporting bias) High risk SGRQ [primary outcome] named in pro-
tocol but not reported. All other outcome
data provided
Kornmann 2011
Methods Design: randomised, double-blind, placebo-controlled trial
Duration: 6 months (+ 2 weeks run-in period)
Location: 142 centres in 15 countries (Brazil, Canada, Colombia, Czech Republic,
Denmark, Germany, Hungary, Iceland, India, Italy, Norway, Peru, Russia, Slovakia,
Taiwan and Finland)
Participants Population: 669 participants were randomly assigned to salmeterol 50 µg twice daily
(334) and placebo (335)
Baseline characteristics:
Mean age (years): salmeterol, 63; placebo, 64
% Male: salmeterol, 75; placebo, 77
% Reversibility: salmeterol, 11; placebo, 13
Pack-years: salmeterol, 40; placebo, 41
% FEV1 predicted: salmeterol, 53; placebo, 53
% taking ICS: salmeterol, 46; placebo, 40
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Inclusion criteria: Males and females aged 40 and older; diagnosis of moderate to severe
COPD; history of at least 20 pack-years; < 80% and > 30% predicted FEV1; FEV1/
FVC < 0.70
Exclusion criteria: history of asthma; hospitalisation for COPD exacerbation in the 6
weeks beforeVisit 1 or during run-in; requiring oxygen therapy; respiratory tract infection
within 6 weeks before Visit 1 and during the run-in period; concomitant pulmonary
disease; history of long QTc syndrome or QTc interval > 450 ms for males and > 470
ms for females; clinically significant condition
Interventions • Salmeterol 50 µg twice daily
• Placebo
Inhaler device: dry powder inhaler
Co-medication: Concomitant medication with inhaled corticosteroids was allowed if
stable for 1month before screening and remained stable throughout the study; salbutamol
was provided for relief. Participants previously taking fixed combinations of ICS and
LABA were switched to equivalent ICS monotherapy
Outcomes HRQoL: assessed with St George’s Respiratory Questionnaire (including proportion
meeting minimal clinically important difference)
COPD exacerbations: not reported
Lung function: trough FEV1, transition dyspnoea index, morning and evening PEF
Adverse events: all-cause mortality and non-fatal serious adverse events
Other: withdrawal, use of relief medication, days of poor COPD control, vital signs and
ECGs
Notes Funding: Novartis
Study number: NCT00567996
Definitions: Trough FEV1 was defined as average of the 23 hour 10 minute and 23 hour
45 minute postdose FEV1 readings
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly allocated to
treatment in a 1:1:1 ratio (with stratifi-
cation for smoking status) using an auto-
mated system
Allocation concealment (selection bias) Low risk Using an automated system [concealment
assumed by automatisation]
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participant, investigator, outcomes asses-
sor all blind [from protocol]. Blinding
was maintained from randomisation until
database lock unless any participant emer-
gencies arose
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participant, investigator, outcomes asses-
sor all blind [from protocol]. Blinding
was maintained from randomisation until
database lock unless any participant emer-
gencies arose
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal somewhat higher in placebo
group (salmeterol, 15%; placebo, 20.1%).
Efficacy data were analysed for the inten-
tion-to-treat (ITT) population, comprising
all randomly assigned participants who re-
ceived at least one dose of the study drug.
The population for the safety analysis com-
prised all participants who received at least
one dose of the study drug
Selective reporting (reporting bias) High risk FEV1 data given only in graphical form.
No exacerbation data provided. SGRQ re-
ported only as a dichotomous outcome
Mahler 1999
Methods Design: Stratified, randomised, double-blind, double-dummy, placebo-controlled, par-
allel-group clinical trial
Duration: 3 months (+ 2 to 3 weeks run-in period)
Location: multiple sites at clinics and university medical centres throughout the United
States
Participants Population: 278 participants were randomly assigned to salmeterol 42 µg twice daily
(135) and placebo (143)
Baseline characteristics:
Mean age (years): salmeterol, 63.2; placebo, 63.2
% Male: salmeterol, 71.9; placebo, 76.2
% White: salmeterol, 91.9; placebo, 90.9
Pack-years: salmeterol, 60.2; placebo, 60.2
% FEV1 predicted: salmeterol, 42.1; placebo, 40.8
Inclusion criteria: males and females aged 35 and older; history of at least 10 pack-
years; diagnosis of COPD; FEV1 > 0.7 L and < 65% predicted normal; FEV1/FVC <
70%
Exclusion criteria: unstable respiratory status within the previous 4 weeks; history of
asthma or chronic respiratory disease other than COPD; clinically significant concurrent
disease
Interventions • Salmeterol 42 µg twice daily
• Placebo
Inhaler device: dry powder inhaler
Co-medication: Albuterol was allowed for acute symptomatic relief; participants receiv-
ing a stable regimen of oral (< 10 mg prednisone per day) or inhaled corticosteroids
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continued these treatments. Oxygen therapy other than nocturnal use was disallowed,
as were changes in medications for COPD within 4 weeks before the screening visit
and inability to discontinue treatment with theophylline, ipratropium or oral B-agoing
therapy
Outcomes HRQoL: assessed by theChronicRespiratoryDiseaseQuestionnaire (CDRQ), including
the proportion of participants meeting minimal clinically important difference from
baseline
COPD exacerbations: time to first COPD exacerbation; percentage of participants
experiencing one or more exacerbations
Lung function: spirometric measures over 12 hours (FEV1, FVC), area under the 12-
hour curve for FEV1, dyspnoea severity on the transition dyspnoea index
Adverse events: adverse events, vital signs and all-cause mortality
Other: six-minute walk test (6MW) within 4 hours of the morning dose of study med-
ication, participant-rated intensity of breathlessness on the Borg dyspnoea scale before
and after the 6MW, participant self-rating of symptoms, night-time awakenings, sup-
plemental albuterol use, ECG
Notes Funding: GlaxoSmithKline
Study number: GSK identifier SLGA4005
Definitions: Exacerbations were not defined
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified, randomised trial [GSK spon-
sored]
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy [assumed
participant and investigator]
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No specific details regarding blinded out-
come assessment
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawal more than twice as high in the
placebo group (salmeterol, 6.7%, placebo,
16.1%). Analyses were performed on three
groups of participants: all participants, re-
sponsive and non-responsive strata [no
mention of intention-to-treat principle or
imputation]
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Selective reporting (reporting bias) High risk Different FEV1 outcome from other stud-
ies, cannot be included. No serious adverse
event data
Mahler 2002
Methods Design: randomised, double-blind, placebo-controlled, parallel-group,multi-centre trial
Duration: 6 months (+ 2 weeks run-in period)
Location: 65 centres in the United States
Participants Population: 341 participants were randomly assigned to salmeterol 50 µg twice daily
(160) and placebo (181)
Baseline characteristics:
Mean age (years): salmeterol, 63.5; placebo, 64.0
% Male: salmeterol, 64.4; placebo, 75.1
% White: salmeterol, 95.0; placebo, 91.7
Pack-years (median): salmeterol, 52.5; placebo, 60
% FEV1 predicted: salmeterol, 40; placebo, 41
Inclusion criteria: males and females aged 40 and older; history of at least 20 pack-
years; diagnosis of COPD; FEV1 < 65% of predicted but > 0.70 L, FEV1/FVC ratio <
70%; daily cough productive of sputum for 3 months of the year for 2 consecutive years
and dyspnoea
Exclusion criteria: current diagnosis of asthma; abnormal clinically significant ECG;
moderate or severe exacerbation during the run-in period; any significant medical dis-
order
Interventions • Salmeterol 50 µg twice daily
• Placebo
Inhaler device: dry powder inhaler
Co-medication: Albuterol was allowed as needed, as were stable regimens of theo-
phylline. Disallowed medications included oral corticosteroid use in the past 6 weeks,
long-term oxygen therapy, corticosteroids and all bronchodilators
Outcomes HRQoL: assessed on the CRQ
COPD exacerbations: time to exacerbation and proportions of participants experienc-
ing at least one moderate/severe COPD exacerbation
Lung function: AM predose and 2-hour postdose FEV1, serial FEV1 over 12 hours,
morning (AM) peak expiratory flow rate (PEFR)
Adverse events: non-fatal serious adverse events and all-cause mortality
Other: Chronic Bronchitis Symptoms Questionnaire (CBSQ), supplemental albuterol
(MDI or nebules), night-time awakenings requiring the use of albuterol
Notes Funding: GlaxoSmithKline
Study number: GSK identifier SFCA3006
Definitions: Moderate exacerbations were defined as those requiring treatment with
antibiotics and/or corticosteroids, and severe exacerbations were those requiring hospi-
talisation
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was stratified by reversibil-
ity and investigative site to ensure a balance
between treatment groups at each site and
in terms of the numbers of reversible par-
ticipants [no other details, industry spon-
sored]
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind [participant and investiga-
tor]
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No specific details regarding blinded out-
come assessment
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawal high and uneven between
groups (salmeterol, 28%, placebo, 38%).
Analyses based on the intent-to-treat (ITT)
population consisted of all randomly as-
signed participants who had taken at least
one dose of double-blind study drug
Selective reporting (reporting bias) Low risk All stated and expected outcomes were re-
ported in detail and were included, except
quality of life, because the study used a dif-
ferent measure than was used in the other
studies
Nelson 2007
Methods Design: randomised, double-blind, double-dummy, placebo- and active-controlled trial
Duration: 3 months (+ 4 to 14 days run-in period)
Location: 38 centres across the United States
Participants Population: 228 participants were randomly assigned to formoterol 12 µg twice daily
(114) and placebo (114)
Baseline characteristics:
Mean age (years): formoterol, 63.0; placebo, 63.5
% Male: formoterol, 53.5; placebo, 57.0
% White: formoterol, 83.3; placebo, 86.0
% taking other COPD med: formoterol, 33.3; placebo, 37.7
Inclusion criteria: males and females aged 40 and older; diagnosis of COPD; history
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of at least 10 pack-years; FEV1 30% to < 70% predicted; FEV1/FVC ration < 70%
Exclusion criteria: current or past diagnosis of asthma; respiratory tract infection or
acute exacerbation of COPD within the previous month; other significant disease
Interventions • Formoterol 12 µg twice daily
• Placebo
Inhaler device: dry powder inhaler
Co-medication: Albuterol was allowed as rescue medication and the use of inhaled or
oral steroids was permitted if the corticosteroid dose was stable for 1 month. Disallowed
medications included oxygen therapy, non-selective beta-blockers, MAOIs and other
bronchodilators
Outcomes HRQoL: not reported
COPD exacerbations: number of participants experiencing at least one exacerbation
during the study
Lung function: not reported
Adverse events: cardiac adverse events, all-cause mortality and non-fatal serious adverse
events
Other: withdrawal, Holter monitoring, ECG
Notes Funding: Dey Pharma
Study number: NCT00215436
Definitions: Exacerbations were not defined in the paper
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned in a 1:1:1 ratio [no
other details, industry sponsored]
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded electronic ECG and Holter mon-
itor data were assessed by a central labo-
ratory (Quintiles Transnational Corpora-
tion, Mumbai, India) to look for clinically
significant abnormalities according to pre-
determined criteria. Blinded investigators
rated the intensity of each AE and cate-
gorised each for potential relationship to
study medication
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Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawal twice as high in placebo group
as in drug group [formoterol, 10.5%,
placebo, 20.2%]. The safety population
consisted of all participants who received≥
1 dose of study medication [not given for
efficacy population]
Selective reporting (reporting bias) High risk HRQoL, severe exacerbations [primary
outcomes] and FEV1 [secondary] were not
reported
Rennard 2001
Methods Design: randomised, double-blind, placebo-controlled, parallel-group study
Duration: 3 months (+ run-in period of unknown length)
Location: 27 clinical centres in the United States
Participants Population: 267 participants were randomly assigned to salmeterol 42 µg twice daily
(132) and placebo (135)
Baseline characteristics:
Mean age (years): salmeterol, 63.9; placebo, 63.7
% Male: salmeterol, 61.4; placebo, 64.4
% White: salmeterol, 93.2; placebo, 97.0
Inclusion criteria: males and females aged 35 and older; diagnosis of COPD; FEV1 >
0.7 L and < 65% predicted normal; FEV1/FVC < 70%
Exclusion criteria: pulmonary infection within 4 weeks before the study; significant
cardiovascular disease; history of malignancy within the previous two years; significantly
abnormal ECG or lab results; history of hypersensitivity to any beta-agonist or anti-
cholinergic compound
Interventions • Salmeterol 42 µg twice daily
• Placebo
Inhaler device: metered-dose inhaler
Co-medication: up to 14-day courses of oral corticosteroids for exacerbations; partici-
pants using ICS at entry must have maintained a stable regimen for the duration of the
study. Participants were required to discontinue the use of theophylline, ipratropium and
oral beta-agonists for the duration of the study; participants requiring oral corticosteroid
therapy > 10 mg prednisone or continuous oxygen therapy were excluded
Outcomes HRQoL: Quality of life (QOL) was measured using the Chronic Respiratory Disease
Questionnaire (CRQ) and the Pittsburgh Sleep Quality Index (PSQI)
COPD exacerbations: COPD exacerbations
Lung function: FEV1, forced vital capacity (FVC), forced expiratory flow in the middle
half of FVC (FEF25% to 75%) assessments, peak expiratory flow, Transitional Dyspnea
Index (TDI) score, FEV1 area under the curve (AUC) calculated from 12-hour serial
pulmonary function tests (PFTs)
Adverse events:
Other: 6-Minute walk, Borg dyspnoea score, participant self-rating of symptoms, night-
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time awakenings, supplemental albuterol use
Notes Funding: GlaxoSmithKline
Study number: GSK identifier SLGA4004
Definitions: Exacerbations were defined as worsening symptoms of COPD requiring a
change in drug therapy [coded as moderate for this review]
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned to receive 1 of the 3
treatments [no other details provided, in-
dustry sponsored]
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details provided, included outcomes
might be subject to detection bias [self-
rated quality of life, exacerbations, all-cause
mortality, serious adverse events and with-
drawal]
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal quite similar between groups
(salmeterol, 16.7%, placebo, 21.2). Last
observation carried forward (LOCF) analy-
ses were performed on all efficacy measure-
ments to investigate the impact of drop-
outs, and LOCF analyses (data not shown)
were entirely consistent with those pre-
sented here
Selective reporting (reporting bias) Low risk All stated and expected outcomes were re-
ported in a way that could be included in
the meta-analysis
Rennard 2009
Methods Design: randomised, double-blind, double-dummy, parallel-group, active- and placebo-
controlled, multi-centre study
Duration: 12 months (+ 2 weeks run-in period)
Location: 237 sites in the USA, Europe and Mexico
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Participants Population: 976 participants were randomly assigned to formoterol 12 µg twice daily
(495) and placebo (481)
Baseline characteristics:
Mean age (years): formoterol, 62.9; placebo, 62.9
% Male: formoterol, 65.3; placebo, 65.3
% White: formoterol, 92.3; placebo, 91.7
% Reversibility: formoterol, 16.9; placebo, 19.5
Pack-years (median): formoterol, 40; placebo, 40
% FEV1 predicted: formoterol, 39.3; placebo, 40.8
Inclusion criteria: Males and females aged 40 and older; moderate to severe COPD for
2+ years; history of at least 10 pack-years
Exclusion criteria: history of asthma or seasonal rhinitis before age 40; significant/
unstable cardiovascular disorder; significant respiratory tract disorder other than COPD;
homozygous alpha1-antitrypsin deficiency or other clinically significant co-morbidities
precluding participation
Interventions • Formoterol 12 µg twice daily
• Placebo
Inhaler device: dry powder inhaler
Co-medication: Salbutamol was allowed as relief medication. Previous inhaled corticos-
teroids were discontinued, and disallowed medication included long-acting anticholin-
ergics; inhaled LABAs or SABAs (other than salbutamol); oral beta-adrenoreceptor ag-
onists; ephedrine; leukotriene receptor agonists; xanthine derivatives except for short-
term use
Outcomes HRQoL: assessed with St George’s Respiratory Questionnaire (SGRQ)
COPD exacerbations: time to first exacerbation and number per participant-treatment
year
Lung function: predose FEV1, one hour postdose FEV1, morning and evening REF
Adverse events: all-cause mortality and non-fatal serious adverse events
Other: withdrawal, participant-rated symptom scores
Notes Funding: AstraZeneca
Study number: NCT00206167
Definitions: Exacerbations were defined as worsening of COPD requiring an oral cor-
ticosteroid or hospitalisation [coded as moderate and severe for this review]
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Designed to conform with the Declaration
of Helsinki, and consistent with the In-
ternational Conference on Harmonisation
and Good Clinical Practice and applicable
regulatory requirements
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Allocation concealment (selection bias) Low risk Designed to conform with the Declaration
of Helsinki, and consistent with the In-
ternational Conference on Harmonisation
and Good Clinical Practice and applicable
regulatory requirements
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Tomaintain blinding, participants received
both a pressurised metered dose inhaler
(pMDI) and a dry powder inhaler (DPI)
containing active treatment or double-
dummy placebo (PL), as appropriate
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No informationprovided.Outcomes could
be affected by detection bias
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawal even but high in both groups
[formoterol 31.7%, placebo, 36.4%]. The
efficacy analysis set (i.e. intent-to-treat pop-
ulation) included all randomly assigned
participants who received at least one dose
of randomly assigned studymedication and
contributed sufficient data for at least one
co-primary or secondary efficacy end point
to be calculated during the randomly as-
signed treatment period.The safety analysis
population included all randomly assigned
participants who received at least one dose
of randomly assigned studymedication and
from whom any post--random assignment
data were available
Selective reporting (reporting bias) High risk Serial spirometry was reported only for a
subset. Exacerbations not reported in a way
that could be included in the meta-analysis
Rossi 2002
Methods Design: multi-centre, randomised, parallel-group, placebo-controlled study
Duration: 12 months (+ 10 to 21 days run-in period)
Location: 81 centres worldwide
Participants Population: 645 participants were randomly assigned to formoterol 12 µg twice daily
(211), 24 µg twice daily (214) and placebo (220)
Baseline characteristics:
Mean age (years): formoterol 12 µg, 63; formoterol 24 µg, 62; placebo, 63
% Male: formoterol 12 µg, 87.2; formoterol 24 µg, 83.2; placebo, 79.5
% on ICS: formoterol 12 µg, 47; formoterol 24 µg, 47; placebo, 49
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Inclusion criteria: males and females aged 40 and older; diagnosis of COPD; history
of at least 10 pack-years; FEV1 < 70% predicted; FEV1/FVC ration < 0.89
Exclusion criteria: history of asthma; respiratory tract infection in the past month; need
for long-term oxygen therapy
Interventions • Formoterol 12 µg twice daily
• Formoterol 24 µg twice daily
• Placebo
Inhaler device: dry powder inhaler
Co-medication: Stable participants receiving inhaled corticosteroid treatment were in-
structed to remain on that treatment throughout the study; Salbutamol (up to 8 puffs/
d) was allowed as the rescue medication. Short courses of antibiotics, oral corticosteroids
and/or oxygen were permitted in case of exacerbation or respiratory infection up to two
times during the study. All other bronchodilating medications were discontinued
Outcomes HRQoL: assessed with St George’s Respiratory Questionnaire (SGRQ)
COPD exacerbations: frequency of exacerbations, see definitions below
Lung function: standardised AUC for FVC, absolute FEV1 values at all time points,
predose FEV1, morning PEF
Adverse events: all-cause mortality and non-fatal serious adverse events
Other: withdrawal, daily total symptom score, vital signs, ECG
Notes Funding: Novartis
Study number: unknown
Definitions: Mild exacerbation = “bad days,” defined as days with at least two individ-
ual symptom scores of 2 and/or a reduction in PEF from baseline of 20%; moderate
exacerbation = undergo a course of additional therapy (i.e. corticosteroids, antibiotics or
oxygen); severe exacerbation = COPD-related hospitalisations
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, parallel-group study [no spe-
cific details, industry sponsored]
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk F12, F24 and PL were administered in a
double-blind manner
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details provided, unclear whether out-
comes included in the meta-analysis were
subject to detection bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal rates were relatively similar
across the three groups (formoterol 12, 24.
6%, formoterol 24, 18.7%, placebo, 26.
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8%). The statistical analysis was carried out
according to the intent-to-treat principle
Selective reporting (reporting bias) Unclear risk Key expected outcomes were reported (ex-
cept FEV1 [secondary] as AUC outcome)
. No preregistered protocol was available
against which to check all outcomes as re-
ported
SLMF4010 2005
Methods Design: multicentre, randomised, parallel-group, placebo-controlled, double-blind
study
Duration: 6 months (run-in not defined)
Location: 9 centres in France
Participants Population: 34 participants were randomly assigned to salmeterol 50 µg twice daily
(17) and placebo (17)
Baseline characteristics:
Mean age (years): salmeterol, 62.9; placebo, 64.6
% Male: salmeterol, 94.1; placebo, 82.4
% White: salmeterol, 100; placebo, 100
Inclusion criteria: males and females aged 40 and older; history of at least 20 pack-
years; diagnosis of COPD; FEV1 > 60% of theoretical value, FEV1/TLC ratio > 75%
in absolute value and > 85% of theoretical value, FEV1 reversibility > 12% and > 200
mL 20 minutes after 400 µg of salbutamol
Exclusion criteria: history of asthma or allergy including non-respiratory signs
(bronchial cancer, thoracic surgery, etc.); severe cardiovascular disease; exacerbation and/
or other acute respiratory disease within 4 weeks before enrolment
Interventions • Salmeterol 50 µg twice daily
• Placebo
Inhaler device: dry powder inhaler
Co-medication: Disallowed medications included long-term oxygen therapy; inhaled
or systemic corticosteroids and LABAs or theophyllines within 4 weeks of enrolment
Outcomes HRQoL: change in St George’s Respiratory Questionnaire (SGRQ) from visit 1 to 4
and from visit 4 to 6
COPD exacerbations: number experiencing exacerbations during the study period, and
length of hospital stay
Lung function: variations in IC, FRC, FEV1, FIV1 and total lung capacity (post-salbu-
tamol - pre-salbutamol)
Adverse events: non-fatal serious adverse events and all-cause mortality
Other: withdrawal, exercise capacity, use of rescue medication, tobacco status
Notes Funding: GlaxoSmithKline
Study number: GSK identifier SLMF 4010
Definitions: Exacerbations were not well defined but included those leading to hospi-
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talisation [coded as moderate and severe for this review]
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned and stratified on to-
bacco status [no other details, industry
sponsored]
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind [participant and investiga-
tor]
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No specific details regarding blinded out-
come assessment
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawal very high in both groups [41.
2% each]. ITTpopulation included all ran-
domly assigned participants who had re-
ceived at least one dose of studymedication
and for whom the assessment data for at
least one assessment criterionwere available
and were analysed on the basis of treatment
allocated. Safety population consisted of all
randomly assignedparticipantswhohad re-
ceived at least one dose of studymedication
and were analysed on the basis of treatment
really received
Selective reporting (reporting bias) Low risk All stated and expected outcomes could be
included in the analyses
Szafranski 2003
Methods Design: randomised, double-blind, placebo-controlled, parallel-group, multi-centre
study
Duration: 12 months (+ 2 weeks run-in period)
Location: 89 centres from 11 countries (Argentina, Brazil, Denmark, Finland, UK, Italy,
Mexico, Poland, Portugal, South Africa and Spain)
Participants Population: 406 participants were randomly assigned to formoterol 12 µg twice daily
(201) and placebo (205)
Baseline characteristics:
Mean age (years): formoterol, 63; placebo, 65
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%Male: formoterol, 76; placebo, 83
% Reversibility: formoterol, 6; placebo, 5
Pack-years: formoterol, 45; placebo, 45
% FEV1 predicted: formoterol, 36; placebo, 36
Inclusion criteria: males and females aged 40 and older; symptoms for 2+ years; history
of at least 10 pack-years
Exclusion criteria: history of asthma or seasonal rhinitis before 40 years of age; relevant
cardiovascular disorders; use of beta-blockers; current respiratory tract disorders other
than COPD or any other significant diseases or disorders; requiring regular use of oxygen
therapy; exacerbation during run-in
Interventions • Formoterol 12 µg twice daily
• Placebo
Inhaler device: dry powder inhaler
Co-medication: terbutaline (0.5 mg) as reliever. Disallowed medication included par-
enteral steroids, oral steroids, antibiotics and nebulised treatment from 4 weeks before;
inhaled steroids from 2 weeks before; inhaled long-acting beta2-agonists from 48 hours
before; inhaled short-acting beta2-agonists from 6 hours before; other bronchodilators
from 6 to 48 hours before
Outcomes HRQoL: assessed with St George’s Respiratory Questionnaire (SGRQ)
COPD exacerbations: number of severe exacerbations
Lung function: FEV1, vital capacity, morning and evening PEF
Adverse events: all-cause mortality and non-fatal serious adverse events
Other: withdrawal, diary card data, short-acting beta2-agonist use (rescue medication)
, use of antitussives and other COPD medication, COPD symptom scores, night-time
awakenings due to COPD symptoms, health care contacts and sick leave related to
COPD symptoms
Notes Funding: AstraZeneca
Study number: AZ identifier SD-039-CR-0629
Definitions: Exacerbations were defined as intake of a course of oral steroids and/or
antibiotics and/or hospitalisation due to respiratory symptoms [coded as moderate and
severe in this review]
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A total of 812 participants were randomly
assigned [no other details, industry spon-
sored]
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind [presumed participant and
investigator]
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No specific details regarding blinded out-
come assessment
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawal high and uneven between
groups (formoterol, 31.8%, placebo, 43.
9%). An intention-to-treat analysis was
performed
Selective reporting (reporting bias) Unclear risk Quality of life [primary] stated as outcome
but not reported in enough detail to be in-
clude in themeta-analysis. Other outcomes
included
Tashkin 2008 [SHINE]
Methods Design: randomised, double-blind, double-dummy, placebo-controlled, parallel-group,
multicentre study
Duration: 6 months (+ 2 weeks run-in period)
Location: 194 centres in the USA, Czech Republic, the Netherlands, Poland and South
Africa
Participants Population: 584 participants were randomly assigned to formoterol 12 µg twice daily
(284) and placebo (300)
Baseline characteristics:
Mean age (years): formoterol, 63.5; placebo, 63.2
% Male: formoterol, 65.5; placebo, 69.0
% White: formoterol, 92.3; placebo, 94.7
Pack-years (median): formoterol, 40; placebo, 40
% FEV1 predicted: formoterol, 39.6; placebo,41.3
Inclusion criteria: male and female current or former smokers; history of at least 10
pack-years; clinical diagnosis of COPD; 40+ years; symptoms for longer than 2 years; at
least one exacerbation treated with oral corticosteroids and/or antibacterials within 1 to
12 months before screening
Exclusion criteria: history of asthma or seasonal rhinitis before age 40; significant/
unstable cardiovascular disorder; significant respiratory tract disorder other than COPD;
homozygous alpha1-antitrypsin deficiency or other clinically significant co-morbidities
precluding participation
Interventions • Formoterol 12 µg twice daily
• Placebo
Inhaler device: dry powder inhaler
Co-medication: Allowed medications were ephedrine-free antitussives and mucolyt-
ics; nasal corticosteroids; stable-dose non-nebulised ipratropium; cardioselective beta-
adrenoceptor antagonists; salbutamol as rescue; oral steroids, xanthines, inhaled beta-ag-
onists and ipratropium as medication for exacerbations. Medications disallowed during
the study period were long-acting anticholinergics; inhaled LABAs or SABAs (other than
salbutamol); oral beta-adrenoreceptor agonists; ephedrine; leukotriene receptor agonists
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Tashkin 2008 [SHINE] (Continued)
and xanthine derivatives except for short-term use
Outcomes HRQoL: assessed with St George’s Respiratory Questionnaire (SGRQ) including num-
ber of people reaching threshold for minimal clinically important difference from base-
line (4 units)
COPD exacerbations: number per participant-treatment year
Lung function: predose forced expiratory volume in 1 second (FEV1) and 1-hour post-
dose FEV1, dyspnoea, morning and evening PEF
Adverse events: non-fatal serious adverse events and all-cause mortality
Other: withdrawal, breathlessness diary
Notes Funding: AstraZeneca
Study number: AZ identifier D5899C00002; trial registration NCT00206154
Definitions: Exacerbations were defined as requiring treatment with oral corticosteroids
and/or hospitalisation [coded as moderate and severe in this review]
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Eligable participants were randomly as-
signed in balanced blocks according
to a computer-generated randomisation
scheme at each site
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Tomaintain blinding, participants received
both a pressurised metered dose inhaler
(pMDI) and a dry powder inhaler (DPI)
containing active treatment or placebo (PL)
, or combinations of active treatment and
placebo, as appropriate
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ECG results were evaluated by a cardiolo-
gist in a blinded fashion through an inde-
pendent ECG service provider
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal rates were similar (21.5% for-
moterol, 25.7% placebo), and ’the efficacy
analysis set included all randomised pa-
tients who received at least one dose of
study medication and contributed suffi-
cient data for at least one co-primary or sec-
ondary efficacy endpoint’
Selective reporting (reporting bias) Low risk All stated and expected outcomes were re-
ported in full and were included in the
quantitative synthesis
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Tashkin 2012
Methods Design: randomised, double-blind, placebo-controlled trial
Duration: 6 months (+ 2 weeks run-in period)
Location: 131 centres located in South America, Asia, Africa, Europe andNorth America
Participants Population: 421 participants were randomly assigned to formoterol 10 µg twice daily
(209) and placebo (212)
Baseline characteristics:
Mean age (years): formoterol, 59.6; placebo, 58.8
% Male: formoterol, 72.7; placebo, 80.2
% White: formoterol, 77.0; placebo, 73.1
Pack-years: formoterol, 40.3; placebo, 40.29
Inclusion criteria: males and females aged 40 and older; history of at least 10 pack-
years; moderate to severe COPD for at least 2 years; predicted FEV1 between 25% and
60% normal
Exclusion criteria: exacerbation in the four weeks before randomisation; significant
medical illness; diagnosis of asthma, lung cancer or alpha1-antitrypsin deficiency, lobec-
tomy, pneumonectomy, lung volume reduction surgery or ocular problems
Interventions • Formoterol 10 µg twice daily
• Placebo
Inhaler device: metered dose inhaler
Co-medication: Participants were given open-label, short-acting beta2-agonist (SABA)/
short-acting anticholinergic fixed-dose combination to use as relief medication through-
out the study. All long-acting COPD treatments (LABA, ICS, LABA/ICS FDC or long-
acting anticholinergics), supplemental oxygen and beta-blocking agents were not allowed
during the study period
Outcomes HRQoL: assessed with St George’s Respiratory Questionnaire (SQRQ), reported as both
final scores and the number of people experiencing aMCID (improvement or worsening
by 4 units)
COPD exacerbations: rates of moderate or severe exacerbations
Lung function: serial FEV1 postdose, standardised FEV1 area under the curve
Adverse events: non-fatal serious adverse events and all-cause mortality
Other: withdrawal, systemic and ocular effects
Notes Funding: Merck & Co/Schering-Plough
Study number: NCT00383435
Definitions: If COPDexacerbationmet criteria for a severe AE (e.g. was life-threatening,
required hospitalisation or required prolonged hospitalisation), it was recorded as an
adverse event (therefore, exacerbation data were coded as moderate in this review)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The sponsor’s statistician produced a com-
puter-generated randomisation schedule
with treatment codes in blocks using SAS.
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Tashkin 2012 (Continued)
Randomisation was stratified according to
the participant’s smoking status at the time
of randomisation
Allocation concealment (selection bias) Low risk Randomly assigned treatment was pro-
vided to the investigative site by means of
an interactive voice response system at the
time participants were randomly assigned
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Protocol describes the study masking
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Protocol describes the study masking
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal rates 17.7% in formoterol
group and 25% in placebo group. ITTused
Selective reporting (reporting bias) Unclear risk Moderate exacerbations were not reported
for the comparison of interest in this review
[stated in protocol]
Vogelmeier 2008
Methods Design: randomised, partially blinded, placebo-controlled trial
Duration: 6 months (+ 2 weeks run-in)
Location: outpatient and specialist clinics at 86 centres in Germany (30), Italy (19),
Netherlands (9), Russian Federation (9), Poland (7), Czech Republic (4), Spain (4) and
Hungary (4)
Participants Population: 419 participants were randomly assigned to formoterol 10 µg twice daily
(210) and placebo (209)
Baseline characteristics:
Mean age (years): formoterol, 61.8; placebo, 62.5
% Male: formoterol, 75.7; placebo, 77.5
% Reversibility: formoterol, 11.4; placebo, 11.4
Pack-years: formoterol, 35.4; placebo, 40.1
% FEV1 predicted: formoterol, 51.6; placebo, 51.1
% taking ICS: 40.6 to 43.9 across groups
Inclusion criteria: males and females aged 40 and older; history of at least 10 pack-
years; FEV1 < 70% predicted normal; FEV1/FVC < 70%
Exclusion criteria: respiratory tract infection or hospitalised for an acute exacerbation
within the month before screening; clinically significant condition other than COPD
such as ischaemic heart disease
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Vogelmeier 2008 (Continued)
Interventions • Formoterol 10 µg twice daily
• Placebo
Inhaler device: dry powder inhaler
Co-medication: salbutamol as rescue (but not in the 8 hours before a study visit); inhaled
corticosteroids (ICS) were allowed at a stable daily dose. Any participants receiving fixed
combinations of ICS and beta2-agonists were switched to receive the same dose of ICS
and on-demand salbutamol
Outcomes HRQoL: assessed with St Geoge’s Respiratory Questionnaire (SGRQ)
COPD exacerbations: rates of moderate and severe exacerbations
Lung function: FEV1 and FEV measured at 5 minutes, 2 hours and 3 hours postdose,
PEF
Adverse events: all-cause mortality
Other: withdrawal, 6-minute walk test, haematology, blood chemistry, ECG, daily diary
card recoding symptoms, rescue salbutamol use
Notes Funding: Novartis
Study number: NCT00134979
Definitions:Moderate exacerbationwas defined as requiring additional treatment; severe
exacerbations were those leading to hospitalisation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random assignment was not stratified [no
other information givenbut assumed to fol-
low conventional Novartis sequence gener-
ation methods]
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study was double-blind for the treat-
ment comparison used in this review
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No specific details regarding blinded out-
come assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout low and even between groups
(formoterol, 11.9%, placebo, 14.4%). In-
tent-to-treat (ITT) population consisted of
all randomly assigned participants who re-
ceived at least one dose of study medica-
tion. This population was used for efficacy
and safety analyses
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Selective reporting (reporting bias) High risk FEV1 and SGRQ outcomes provided only
in graphical form with inexact P-values
Wadbo 2002
Methods Design: randomised, double-blind, parallel-group study
Duration: 3 months (+ 2 weeks run-in period)
Location: 14 centres in Sweden
Participants Population: 121 participants were randomly assigned to formoterol 24 µg twice daily
(61) and placebo (60)
Baseline characteristics:
Mean age (years): formoterol, 63.6; placebo, 63.6
% Male: formoterol, 54.1; placebo, 50.0
% Reversibility: formoterol, 5.8; placebo, 6.0
% FEV1 predicted: formoterol, 33.3; placebo, 32.6
Inclusion criteria: males and females aged 40 to 75 years; history of at least 10 pack-
years; diagnosis of COPD; history of reduced exercise capacity due to dyspnoea on
exertion; FEV1 < 60% predicted normal and FEV1/FVC < 70%
Exclusion criteria: adult asthma
Interventions • Formoterol 24 µg twice daily
• Placebo
Inhaler device: dry powder inhaler
Co-medication: inhaled short-acting beta2-agonists allowed as reliefmedication, and in-
haled glucocorticoids and mucolytics allowed at a constant dose. No other bronchodila-
tor medication permitted during the study, and participants requiring long-term oxygen
therapy excluded
Outcomes HRQoL: assessed with St George’s Respiratory Questionnaire (SGRQ)
COPD exacerbations: not reported
Lung function: FEV1 and FVC, walking and evening PEF, dyspnoea
Adverse events: non-fatal serious adverse events
Other: withdrawal, 6-minute walk test, blood gas tensions, diary card symptom scores,
use of relief medication
Notes Funding: Lund
Study number: unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants with a walking distance < 300
m were sequentially assigned the lowest
randomisation number, and participants
with a walking distance > 300 m were
sequentially assigned the highest available
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Wadbo 2002 (Continued)
randomisation number
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind study design [participants
and investigators]
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigator- and participant-rated out-
comes [both blind]
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was relatively high but even be-
tween groups (formoterol, 27.9%; placebo,
26.7%). All analyses were performed ac-
cording to the intention-to-treat approach
Selective reporting (reporting bias) High risk Key expected outcomes not reported (mor-
tality and exacerbation rates), and no vari-
ance given for FEV1 outcome
Watkins 2002
Methods Design: randomised, double-blind trial
Duration: 3 months
Participants Population: 182 participants were randomly assigned to salmeterol 50 g twice daily (87)
and placebo (95)
Baseline characteristics: no baseline data reported
Inclusion criteria: no information
Exclusion criteria: no information
Interventions • Salmeterol 50 g twice daily
• Placebo
Inhaler device: dry powder inhaler
Co-medication: no information
Outcomes HRQoL: no information
COPD exacerbations: no information
Lung function: FEV1 area under the curve
Adverse events: no information
Other: no information
Notes Funding: GlaxoSmithKline
Study number: unknown
Only a conference abstractwas available for this report, so no data could be included
in the meta-analysis
Risk of bias
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Watkins 2002 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind [assumed inves-
tigator and participant]
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No informationprovided, but nooutcomes
could be included
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information provided regarding with-
drawal rates or method of imputation
Selective reporting (reporting bias) High risk No full-text paper-only information from
conference abstract. No outcomes could be
included
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Boyd 1995 More than 50% taking other COPDmedications [84% in total-including ICS, oral CS,methylxanthines,
anticholinergics and beta2-agonists]
Celli 2003 More than 50% taking other COPDmedications [55% SABA, 54% ICS/oral CS, 33% anticholinergics,
25% LABAs, 22% xanthines]
Chapman 2002 More than 50% taking other COPD medications [placebo 55% and LABA 68% taking ICS; placebo
17% and LABA 24% taking theophylline]
Dal Negro 2003 More than 50% taking other COPD medications [all treated with theophylline]
Rutten-van Molken 1999 More than 50% taking other COPD medications [81% of salmeterol group and 76% of placebo group
taking ICS, and all maintenance drugs other than the study medication continued at constant dosage]
Steffensen 1996 Entry criteria specified reversible obstructive airways disease, including asthma. Subgroups not reported
Stockley 2006 More than 50% taking other COPDmedications [LABA 86% and placebo 89% in total-including ICS,
anticholinergics and xanthines]
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Characteristics of studies awaiting assessment [ordered by study ID]
Fattore 2005
Methods Design: cost-analysis data were collected alongside a 12-month, multinational, randomised, double-blind, placebo-
controlled trial
Location: Italian National Health Service
Participants 272 participants (mean age = 65.27 years) equally distributed in four treatment groups [two of which received
formoterol and placebo]
Interventions • Formoterol (? dose)
• Placebo
Outcomes Average total cost per participant per year
Notes Unclear which 12-month trial this ran alongside
Characteristics of ongoing studies [ordered by study ID]
NCT01437397
Trial name or title Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol
Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAC)
Methods Design: randomised, double-blind, parallel-group, efficacy study
Conducted at 208 study centres in four countries (Australia, Canada, New Zealand and the United States)
Participants Inclusion criteria: current or former cigarette smokers at least 40 years of age with a cigarette smoking history
of at least 10 pack-years; a diagnosis of stable moderate to severe COPD and stable airway obstruction as
defined by the GOLD guidelines
Exclusion criteria: patients who had been hospitalised for an acute COPD exacerbation within three months
before visit 1; also, patients with any respiratory tract infection or COPD exacerbation in the 6 weeks before
visit 1; any clinically significant respiratory conditions other thanCOPD; clinical history that suggests that the
patient has asthma as opposed to COPD; long-term use of oxygen therapy > 15 hours/d; clinically significant
cardiovascular condition; history of hypersensitivity reaction to inhaled anticholinergics
Interventions • Formoterol 12 µg twice daily
• Placebo twice daily
The study also randomly assigned people to three aclidinium groups that were not relevant to the review
Outcomes Primary: morning predose (trough) forced expiratory volume in one second (FEV1) at week 24; time frame:
change from baseline (week 0) to 24 weeks. Morning one-hour postdose FEV1 at week 24; time frame: change
from baseline (Week 0) to 24 weeks
Secondary: change from baseline in St George’s Respiratory Questionnaire (SGRQ) total score, improvement
in Transition Dyspnea Index (TDI) score
Starting date First received on clinicaltrials.gov September 19, 2011
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NCT01437397 (Continued)
Contact information Funded by Forest Laboratories, no contact information listed
Notes Completed but no results posted. Final data collection for primary outcome in February 2013
NCT01572792
Trial name or title Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fu-
marate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With
Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
Methods Design: randomised, double-blind, parallel-group, safety/efficacy study
Conducted at 208 study centres in four countries (Australia, Canada, New Zealand and the United States)
Participants To be included in the extension phase, participants had to complete the treatment phase of the lead-in study
(LAC-MD-31/NCT01437397) and provide written informed consent
Interventions All participants remained in the same treatment group as for the lead-in study (NCT01437397) and continued
on one of the four treatment arms or placebo
• Formoterol 12 µg twice daily
• Placebo twice daily
The study also randomly assigned people to three aclidinium groups that were not relevant to the review
Outcomes Primary: adverse events, clinical laboratory parameters, vital sign measurement, and electrocardiogram pa-
rameters
Starting date First received on clinicaltrials.gov April 4, 2012
Contact information Funded by Forest Laboratories, no contact information listed
Notes Completed but no results posted. Final data collection for primary outcome in June 2013
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D A T A A N D A N A L Y S E S
Comparison 1. All LABA versus placebo [subgrouped by drug]
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Quality of life (SGRQ total
score)
17 11397 Mean Difference (IV, Random, 95% CI) -2.32 [-3.09, -1.54]
1.1 Formoterol 12 µg twice
daily
11 5587 Mean Difference (IV, Random, 95% CI) -2.66 [-3.84, -1.48]
1.2 Formoterol 24 µg twice
daily
3 627 Mean Difference (IV, Random, 95% CI) -2.51 [-4.51, -0.51]
1.3 Salmeterol 50 µg twice
daily
5 5183 Mean Difference (IV, Random, 95% CI) -1.64 [-2.78, -0.50]
2 Quality of life (number of people
achieving the MCID on the
SGRQ)
3 1871 Odds Ratio (M-H, Fixed, 95% CI) 1.58 [1.32, 1.90]
2.1 Formoterol 12 µg twice
daily
1 397 Odds Ratio (M-H, Fixed, 95% CI) 3.11 [2.06, 4.70]
2.2 Salmeterol 50 µg twice
daily
2 1474 Odds Ratio (M-H, Fixed, 95% CI) 1.33 [1.08, 1.64]
3 Quality of life (CRQ) 4 1193 Mean Difference (IV, Fixed, 95% CI) 3.10 [1.22, 4.98]
3.1 Salmeterol 50 µg twice
daily
4 1193 Mean Difference (IV, Fixed, 95% CI) 3.10 [1.22, 4.98]
4 Severe exacerbations
(hospitalisations)
7 3804 Odds Ratio (M-H, Fixed, 95% CI) 0.73 [0.56, 0.95]
4.1 Formoterol 12 µg twice
daily
6 2418 Odds Ratio (M-H, Fixed, 95% CI) 0.75 [0.55, 1.02]
4.2 Formoterol 24 µg twice
daily
2 581 Odds Ratio (M-H, Fixed, 95% CI) 0.28 [0.11, 0.73]
4.3 Salmeterol 50 µg twice
daily
1 805 Odds Ratio (M-H, Fixed, 95% CI) 0.99 [0.52, 1.86]
5 Severe/moderate exacerbations
(hospitalisation or course of
meds or ER visit
7 3968 Odds Ratio (M-H, Fixed, 95% CI) 0.88 [0.76, 1.02]
5.1 Formoterol 12 µg twice
daily
4 2682 Odds Ratio (M-H, Fixed, 95% CI) 0.87 [0.73, 1.04]
5.2 Salmeterol 50 µg twice
daily
3 1286 Odds Ratio (M-H, Fixed, 95% CI) 0.90 [0.69, 1.16]
6 Moderate exacerbations (course
of antibiotics and/or steroids)
7 3375 Odds Ratio (M-H, Fixed, 95% CI) 0.73 [0.61, 0.87]
6.1 Formoterol 12 µg twice
daily
3 968 Odds Ratio (M-H, Fixed, 95% CI) 0.74 [0.51, 1.05]
6.2 Formoterol 24 µg twice
daily
1 324 Odds Ratio (M-H, Fixed, 95% CI) 0.59 [0.35, 0.97]
6.3 Salmeterol 50 µg twice
daily
4 2083 Odds Ratio (M-H, Fixed, 95% CI) 0.75 [0.60, 0.94]
7 Mortality (all-cause) 23 14079 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.90 [0.75, 1.08]
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7.1 Formoterol 12 µg twice
daily
13 6343 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.41 [0.87, 2.30]
7.2 Formoterol 24 µg twice
daily
2 615 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.54 [0.07, 285.14]
7.3 Salmeterol 50 µg twice
daily
10 7121 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.83 [0.69, 1.01]
8 People with one or more
non-fatal serious adverse event
20 12446 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.83, 1.14]
8.1 Formoterol 12 µg twice
daily
10 4829 Odds Ratio (M-H, Random, 95% CI) 1.20 [0.99, 1.45]
8.2 Formoterol 24 µg twice
daily
3 737 Odds Ratio (M-H, Random, 95% CI) 0.42 [0.23, 0.77]
8.3 Salmeterol 50 µg twice
daily
9 6880 Odds Ratio (M-H, Random, 95% CI) 0.93 [0.78, 1.10]
9 Predose FEV1 (mL) 13 6125 Mean Difference (IV, Random, 95% CI) 72.92 [48.02, 97.82]
9.1 Formoterol 12 µg twice
daily
6 3222 Mean Difference (IV, Random, 95% CI) 44.68 [29.39, 59.97]
9.2 Salmeterol 50 µg twice
daily
7 2903 Mean Difference (IV, Random, 95% CI) 101.01 [59.84, 142.
18]
10 Withdrawal 25 14763 Odds Ratio (M-H, Fixed, 95% CI) 0.74 [0.69, 0.80]
10.1 Formoterol 12 µg twice
daily
14 6597 Odds Ratio (M-H, Fixed, 95% CI) 0.76 [0.68, 0.86]
10.2 Formoterol 24 µg twice
daily
4 1001 Odds Ratio (M-H, Fixed, 95% CI) 0.81 [0.58, 1.14]
10.3 Salmeterol 50 µg twice
daily
10 7165 Odds Ratio (M-H, Fixed, 95% CI) 0.72 [0.65, 0.80]
Comparison 2. Formoterol 12 µg versus placebo [subgrouped by trial duration]
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Quality of life (SGRQ) 11 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 3 months 3 1627 Mean Difference (IV, Random, 95% CI) -3.86 [-5.25, -2.46]
1.2 6 months 5 2427 Mean Difference (IV, Random, 95% CI) -1.14 [-2.51, 0.23]
1.3 12 months 5 3079 Mean Difference (IV, Random, 95% CI) -3.24 [-4.77, -1.71]
2 Severe exacerbations
(hospitalisations)
6 2614 Odds Ratio (M-H, Fixed, 95% CI) 0.73 [0.54, 0.98]
2.1 3 months 1 353 Odds Ratio (M-H, Fixed, 95% CI) 0.47 [0.08, 2.60]
2.2 6 months 3 1319 Odds Ratio (M-H, Fixed, 95% CI) 0.53 [0.26, 1.08]
2.3 12 months 2 942 Odds Ratio (M-H, Fixed, 95% CI) 0.80 [0.57, 1.12]
3 Moderate exacerbations (course
of antibiotics and/or steroids)
3 1078 Odds Ratio (M-H, Fixed, 95% CI) 0.78 [0.56, 1.07]
3.1 3 months 1 228 Odds Ratio (M-H, Fixed, 95% CI) 0.76 [0.27, 2.12]
3.2 6 months 1 419 Odds Ratio (M-H, Fixed, 95% CI) 0.53 [0.28, 0.99]
3.3 12 months 1 431 Odds Ratio (M-H, Fixed, 95% CI) 0.92 [0.62, 1.37]
4 Mortality (all-cause) 13 6553 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.45 [0.89, 2.37]
4.1 3 months 5 1927 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.22 [0.64, 7.70]
4.2 6 months 4 1946 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.25 [0.98, 5.16]
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4.3 12 months 4 2680 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.94 [0.47, 1.88]
5 Patients with one or more serious
adverse event
10 5039 Odds Ratio (M-H, Fixed, 95% CI) 1.20 [1.00, 1.43]
5.1 3 months 2 799 Odds Ratio (M-H, Fixed, 95% CI) 1.21 [0.57, 2.58]
5.2 6 months 4 1916 Odds Ratio (M-H, Fixed, 95% CI) 1.10 [0.78, 1.55]
5.3 12 months 4 2324 Odds Ratio (M-H, Fixed, 95% CI) 1.23 [1.00, 1.52]
6 Predose FEV1 (mL) 6 3222 Mean Difference (IV, Fixed, 95% CI) 44.68 [29.39, 59.97]
6.1 3 months 1 407 Mean Difference (IV, Fixed, 95% CI) 40.0 [16.29, 63.71]
6.2 6 months 3 1437 Mean Difference (IV, Fixed, 95% CI) 44.41 [18.63, 70.18]
6.3 12 months 2 1378 Mean Difference (IV, Fixed, 95% CI) 53.46 [21.74, 85.17]
7 Withdrawal 14 6894 Odds Ratio (M-H, Fixed, 95% CI) 0.77 [0.69, 0.86]
7.1 3 months 4 1368 Odds Ratio (M-H, Fixed, 95% CI) 0.69 [0.50, 0.94]
7.2 6 months 5 2335 Odds Ratio (M-H, Fixed, 95% CI) 0.72 [0.59, 0.89]
7.3 12 months 5 3191 Odds Ratio (M-H, Fixed, 95% CI) 0.81 [0.70, 0.94]
Comparison 3. Formoterol 24 µg versus placebo [subgrouped by trial duration]
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Quality of life (SGRQ) 3 707 Mean Difference (IV, Fixed, 95% CI) -2.32 [-4.52, -0.13]
1.1 3 months 2 376 Mean Difference (IV, Fixed, 95% CI) -2.04 [-4.65, 0.56]
1.2 12 months 1 331 Mean Difference (IV, Fixed, 95% CI) -3.0 [-7.06, 1.06]
2 Severe exacerbations
(hospitalisations)
2 777 Odds Ratio (M-H, Fixed, 95% CI) 0.28 [0.12, 0.67]
2.1 3 months 1 343 Odds Ratio (M-H, Fixed, 95% CI) 0.50 [0.09, 2.75]
2.2 12 months 1 434 Odds Ratio (M-H, Fixed, 95% CI) 0.24 [0.09, 0.65]
3 Moderate exacerbations (course
of antibiotics and/or steroids)
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 12 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Mortality (all-cause) 2 825 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.60 [0.15, 383.12]
4.1 3 months 1 391 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 12 months 1 434 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.60 [0.15, 383.12]
5 People with one or more
non-fatal serious adverse events
3 947 Odds Ratio (M-H, Fixed, 95% CI) 0.53 [0.36, 0.79]
5.1 3 months 2 513 Odds Ratio (M-H, Fixed, 95% CI) 0.36 [0.14, 0.94]
5.2 12 months 1 434 Odds Ratio (M-H, Fixed, 95% CI) 0.58 [0.38, 0.89]
6 Withdrawal 4 1297 Odds Ratio (M-H, Fixed, 95% CI) 0.79 [0.59, 1.05]
6.1 3 months 3 863 Odds Ratio (M-H, Fixed, 95% CI) 0.92 [0.64, 1.33]
6.2 12 months 1 434 Odds Ratio (M-H, Fixed, 95% CI) 0.63 [0.40, 0.99]
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Comparison 4. Salmeterol 50 µg versus placebo [subgrouped by trial duration]
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Quality of life (SGRQ) 5 5183 Mean Difference (IV, Random, 95% CI) -1.64 [-2.78, -0.50]
1.1 6 months 3 1405 Mean Difference (IV, Random, 95% CI) -3.10 [-6.03, -0.17]
1.2 12 months 1 733 Mean Difference (IV, Random, 95% CI) -1.10 [-2.35, 0.15]
1.3 36 months 1 3045 Mean Difference (IV, Random, 95% CI) -1.0 [-2.00, 2.14]
2 Severe exacerbations
(hospitalisations)
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 6 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Moderate exacerbations (course
of antibiotics and/or steroids)
4 2083 Odds Ratio (M-H, Fixed, 95% CI) 0.75 [0.60, 0.94]
3.1 3 months 2 545 Odds Ratio (M-H, Fixed, 95% CI) 0.71 [0.49, 1.03]
3.2 6 months 1 805 Odds Ratio (M-H, Fixed, 95% CI) 0.84 [0.63, 1.12]
3.3 12 months 1 733 Odds Ratio (M-H, Fixed, 95% CI) 0.40 [0.17, 0.92]
4 Mortality (all-cause) 10 7121 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.83 [0.69, 1.01]
4.1 3 months 3 1132 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.14 [0.00, 6.98]
4.2 6 months 5 2211 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.56 [0.22, 1.46]
4.3 12 months 1 733 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.43 [0.12, 1.50]
4.4 36 months 1 3045 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.87 [0.71, 1.06]
5 People with one or more
non-fatal serious adverse events
9 6880 Odds Ratio (M-H, Fixed, 95% CI) 0.94 [0.83, 1.06]
5.1 3 months 2 850 Odds Ratio (M-H, Fixed, 95% CI) 0.81 [0.45, 1.46]
5.2 6 months 5 2211 Odds Ratio (M-H, Fixed, 95% CI) 0.74 [0.55, 1.01]
5.3 12 months 1 733 Odds Ratio (M-H, Fixed, 95% CI) 1.29 [0.88, 1.91]
5.4 36 months 1 3086 Odds Ratio (M-H, Fixed, 95% CI) 0.96 [0.83, 1.11]
6 Predose FEV1 (mL) 7 2903 Mean Difference (IV, Random, 95% CI) 101.01 [59.84, 142.
18]
6.1 3 months 2 765 Mean Difference (IV, Random, 95% CI) 146.86 [114.38,
179.34]
6.2 6 months 4 1405 Mean Difference (IV, Random, 95% CI) 87.93 [39.05, 136.
80]
6.3 12 months 1 733 Mean Difference (IV, Random, 95% CI) 59.0 [28.52, 89.48]
7 Withdrawal 10 7165 Odds Ratio (M-H, Fixed, 95% CI) 0.72 [0.65, 0.80]
7.1 3 months 3 1132 Odds Ratio (M-H, Fixed, 95% CI) 0.60 [0.44, 0.83]
7.2 6 months 5 2211 Odds Ratio (M-H, Fixed, 95% CI) 0.72 [0.59, 0.88]
7.3 12 months 1 733 Odds Ratio (M-H, Fixed, 95% CI) 0.74 [0.55, 1.01]
7.4 36 months 1 3089 Odds Ratio (M-H, Fixed, 95% CI) 0.74 [0.64, 0.86]
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Comparison 5. [Sensitivity analysis-ICS use] All LABA versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Quality of life (SGRQ) 12 8520 Mean Difference (IV, Fixed, 95% CI) -1.53 [-2.08, -0.98]
1.1 Formoterol 12 µg twice
daily
7 3782 Mean Difference (IV, Fixed, 95% CI) -2.16 [-3.04, -1.27]
1.2 Formoterol 24 µg twice
daily
1 121 Mean Difference (IV, Fixed, 95% CI) -1.50 [-4.62, 1.62]
1.3 Salmeterol 50 µg twice
daily
4 4617 Mean Difference (IV, Fixed, 95% CI) -1.12 [-1.84, -0.39]
2 Severe exacerbations
(hospitalisations)
3 1795 Odds Ratio (M-H, Fixed, 95% CI) 0.85 [0.62, 1.16]
2.1 Formoterol 12 µg twice
daily
2 990 Odds Ratio (M-H, Fixed, 95% CI) 0.81 [0.57, 1.15]
2.2 Salmeterol 50 µg twice
daily
1 805 Odds Ratio (M-H, Fixed, 95% CI) 0.99 [0.52, 1.86]
Comparison 6. [Sensitivity analysis-attrition] All LABA versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Quality of life (SGRQ) 13 9114 Mean Difference (IV, Fixed, 95% CI) -1.60 [-2.15, -1.05]
1.1 Formoterol 12 µg twice
daily
8 3338 Mean Difference (IV, Fixed, 95% CI) -2.07 [-3.06, -1.08]
1.2 Formoterol 24 µg twice
daily
3 627 Mean Difference (IV, Fixed, 95% CI) -2.25 [-4.56, 0.06]
1.3 Salmeterol 50 µg twice
daily
4 5149 Mean Difference (IV, Fixed, 95% CI) -1.31 [-2.01, -0.61]
85Long-acting beta2-agonists for chronic obstructive pulmonary disease (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.1. Comparison 1 All LABA versus placebo [subgrouped by drug], Outcome 1 Quality of life
(SGRQ total score).
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 1 All LABA versus placebo [subgrouped by drug]
Outcome: 1 Quality of life (SGRQ total score)
Study or subgroup LABA Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Formoterol 12 g twice daily
Bogdan 2011 (1) 199 38.2 (14.5) 206 42.9 (14.5) 4.7 % -4.70 [ -7.52, -1.88 ]
Calverley 2003a 255 0.8 (17) 256 4.7 (17) 4.5 % -3.90 [ -6.85, -0.95 ]
Campbell 2005 215 -3.81 (13.5737) 217 -4.61 (13.5737) 5.3 % 0.80 [ -1.76, 3.36 ]
Dahl 2001 (2) 181 41.7 (11.8) 86 46.8 (11.8) 4.3 % -5.10 [ -8.13, -2.07 ]
Dahl 2010 435 -5.7 (15.0231) 432 -1.7 (15.0231) 6.8 % -4.00 [ -6.00, -2.00 ]
Doherty 2012 (3) 243 -4.93 (14.5) 236 -2.88 (14.5) 5.2 % -2.05 [ -4.65, 0.55 ]
Rennard 2009 495 -2.9 (13.3) 481 -1.5 (12.7) 8.0 % -1.40 [ -3.03, 0.23 ]
Rossi 2002 159 40.9 (17.8) 80 45.3 (18.7) 2.1 % -4.40 [ -9.34, 0.54 ]
Szafranski 2003 201 -3.6 (15) 205 -0.03 (15) 4.5 % -3.57 [ -6.49, -0.65 ]
Tashkin 2008 [SHINE] 284 -1.24 (11.35) 300 -1.02 (12.41) 7.0 % -0.22 [ -2.15, 1.71 ]
Tashkin 2012 209 -6.19 (15.2) 212 -2.88 (15.2) 4.5 % -3.31 [ -6.21, -0.41 ]
Subtotal (95% CI) 2876 2711 57.0 % -2.66 [ -3.84, -1.48 ]
Heterogeneity: Tau2 = 2.12; Chi2 = 23.11, df = 10 (P = 0.01); I2 =57%
Test for overall effect: Z = 4.44 (P < 0.00001)
2 Formoterol 24 g twice daily
Dahl 2001 169 43.5 (11.8) 86 46.8 (11.8) 4.2 % -3.30 [ -6.36, -0.24 ]
Rossi 2002 171 42.3 (19) 80 45.3 (18.7) 2.0 % -3.00 [ -7.99, 1.99 ]
Wadbo 2002 61 0 (8.59) 60 1.5 (8.9034) 4.1 % -1.50 [ -4.62, 1.62 ]
Subtotal (95% CI) 401 226 10.4 % -2.51 [ -4.51, -0.51 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.70, df = 2 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 2.46 (P = 0.014)
3 Salmeterol 50 g twice daily
Brusasco 2003 405 -2.8 (14.087) 400 -1.5 (14) 7.0 % -1.30 [ -3.24, 0.64 ]
Calverley 2003b [TRISTAN] (4) 372 45.2 (7.7149) 361 46.3 (9.5) 9.4 % -1.10 [ -2.35, 0.15 ]
Calverley 2007 [TORCH] 1521 -0.8 (14.0772) 1524 0.2 (14.0772) 10.3 % -1.00 [ -2.00, 0.00 ]
-10 -5 0 5 10
Favours LABA Favours placebo
data for Bogdan 2011, Dahl 2001, Rossi 2002, and Calverley 2003b [TRISTAN] are entered as endpoint scores.
(Continued . . . )
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(. . . Continued)
Study or subgroup LABA Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Kornmann 2011 292 -5.6 (15.4) 274 -1.5 (14.9) 5.4 % -4.10 [ -6.60, -1.60 ]
SLMF4010 2005 17 -7.1 (15.2555) 17 2.7 (16.0801) 0.5 % -9.80 [ -20.34, 0.74 ]
Subtotal (95% CI) 2607 2576 32.6 % -1.64 [ -2.78, -0.50 ]
Heterogeneity: Tau2 = 0.73; Chi2 = 7.76, df = 4 (P = 0.10); I2 =48%
Test for overall effect: Z = 2.81 (P = 0.0049)
Total (95% CI) 5884 5513 100.0 % -2.32 [ -3.09, -1.54 ]
Heterogeneity: Tau2 = 1.27; Chi2 = 36.00, df = 18 (P = 0.01); I2 =50%
Test for overall effect: Z = 5.83 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.60, df = 2 (P = 0.45), I2 =0.0%
-10 -5 0 5 10
Favours LABA Favours placebo
data for Bogdan 2011, Dahl 2001, Rossi 2002, and Calverley 2003b [TRISTAN] are entered as endpoint scores.
(1) Last available score with imputed SD (based on other studies). Change from baseline data and endpoint data were pooled in the analysis. Most studies reported
change from baseline but
(2) SDs calculated from ANCOVA confidence intervals
(3) SDs for Doherty 2012 and Szafranski 2003 were imputed based on population variance and that of other arms within the studies
(4) Adjusted mean at endpoint
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Analysis 1.2. Comparison 1 All LABA versus placebo [subgrouped by drug], Outcome 2 Quality of life
(number of people achieving the MCID on the SGRQ).
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 1 All LABA versus placebo [subgrouped by drug]
Outcome: 2 Quality of life (number of people achieving the MCID on the SGRQ)
Study or subgroup LABA Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Formoterol 12 g twice daily
Bogdan 2011 131/191 85/206 14.2 % 3.11 [ 2.06, 4.70 ]
Subtotal (95% CI) 191 206 14.2 % 3.11 [ 2.06, 4.70 ]
Total events: 131 (LABA), 85 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 5.39 (P < 0.00001)
2 Salmeterol 50 g twice daily
Brusasco 2003 175/405 157/400 49.6 % 1.18 [ 0.89, 1.56 ]
Kornmann 2011 162/334 127/335 36.1 % 1.54 [ 1.13, 2.10 ]
Subtotal (95% CI) 739 735 85.8 % 1.33 [ 1.08, 1.64 ]
Total events: 337 (LABA), 284 (Placebo)
Heterogeneity: Chi2 = 1.61, df = 1 (P = 0.20); I2 =38%
Test for overall effect: Z = 2.71 (P = 0.0068)
Total (95% CI) 930 941 100.0 % 1.58 [ 1.32, 1.90 ]
Total events: 468 (LABA), 369 (Placebo)
Heterogeneity: Chi2 = 14.55, df = 2 (P = 0.00069); I2 =86%
Test for overall effect: Z = 4.90 (P < 0.00001)
Test for subgroup differences: Chi2 = 12.95, df = 1 (P = 0.00), I2 =92%
0.2 0.5 1 2 5
Favours placebo Favours LABA
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Analysis 1.3. Comparison 1 All LABA versus placebo [subgrouped by drug], Outcome 3 Quality of life
(CRQ).
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 1 All LABA versus placebo [subgrouped by drug]
Outcome: 3 Quality of life (CRQ)
Study or subgroup LABA Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Salmeterol 50 g twice daily
Hanania 2003 (1) 177 6.4 (18) 185 5 (15) 30.3 % 1.40 [ -2.02, 4.82 ]
Mahler 1999 135 7.1 (16.2665) 143 2.1 (15.5457) 25.3 % 5.00 [ 1.26, 8.74 ]
Mahler 2002 (2) 160 8 (18) 181 5 (15) 28.2 % 3.00 [ -0.54, 6.54 ]
Rennard 2001 109 10.3 (19.7322) 103 6.8 (14.7159) 16.3 % 3.50 [ -1.17, 8.17 ]
Total (95% CI) 581 612 100.0 % 3.10 [ 1.22, 4.98 ]
Heterogeneity: Chi2 = 1.97, df = 3 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 3.23 (P = 0.0012)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours placebo Favours LABA
(1) Standard deviations were not reported, and were imputed based on the SDs reported in Mahler 1999 and Rennard 2001
(2) Standard deviations were not reported, and were imputed based on the SDs reported in Mahler 1999 and Rennard 2001
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Analysis 1.4. Comparison 1 All LABA versus placebo [subgrouped by drug], Outcome 4 Severe
exacerbations (hospitalisations).
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 1 All LABA versus placebo [subgrouped by drug]
Outcome: 4 Severe exacerbations (hospitalisations)
Study or subgroup LABA Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Formoterol 12 g twice daily
Vogelmeier 2008 1/210 3/209 2.3 % 0.33 [ 0.03, 3.18 ]
Doherty 2012 5/243 12/236 9.3 % 0.39 [ 0.14, 1.13 ]
Dahl 2001 2/181 2/86 2.1 % 0.47 [ 0.06, 3.39 ]
Rossi 2002 10/211 10/110 9.8 % 0.50 [ 0.20, 1.23 ]
Tashkin 2012 6/209 7/212 5.3 % 0.87 [ 0.29, 2.62 ]
Calverley 2003a 73/255 79/256 44.0 % 0.90 [ 0.61, 1.31 ]
Subtotal (95% CI) 1309 1109 72.9 % 0.75 [ 0.55, 1.02 ]
Total events: 97 (LABA), 113 (Placebo)
Heterogeneity: Chi2 = 3.88, df = 5 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.85 (P = 0.064)
2 Formoterol 24 g twice daily
Rossi 2002 5/214 10/110 10.1 % 0.24 [ 0.08, 0.72 ]
Dahl 2001 2/171 2/86 2.1 % 0.50 [ 0.07, 3.59 ]
Subtotal (95% CI) 385 196 12.2 % 0.28 [ 0.11, 0.73 ]
Total events: 7 (LABA), 12 (Placebo)
Heterogeneity: Chi2 = 0.40, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 2.60 (P = 0.0092)
3 Salmeterol 50 g twice daily
Brusasco 2003 20/405 20/400 15.0 % 0.99 [ 0.52, 1.86 ]
Subtotal (95% CI) 405 400 15.0 % 0.99 [ 0.52, 1.86 ]
Total events: 20 (LABA), 20 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
Total (95% CI) 2099 1705 100.0 % 0.73 [ 0.56, 0.95 ]
Total events: 124 (LABA), 145 (Placebo)
Heterogeneity: Chi2 = 8.88, df = 8 (P = 0.35); I2 =10%
Test for overall effect: Z = 2.36 (P = 0.018)
Test for subgroup differences: Chi2 = 4.70, df = 2 (P = 0.10), I2 =57%
0.05 0.2 1 5 20
Favours LABA Favours placebo
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Analysis 1.5. Comparison 1 All LABA versus placebo [subgrouped by drug], Outcome 5 Severe/moderate
exacerbations (hospitalisation or course of meds or ER visit.
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 1 All LABA versus placebo [subgrouped by drug]
Outcome: 5 Severe/moderate exacerbations (hospitalisation or course of meds or ER visit
Study or subgroup LABA Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Formoterol 12 g twice daily
Bogdan 2011 8/199 17/208 4.1 % 0.47 [ 0.20, 1.12 ]
Campbell 2005 35/215 34/217 7.3 % 1.05 [ 0.63, 1.75 ]
Dahl 2010 126/435 145/432 26.8 % 0.81 [ 0.61, 1.08 ]
Rennard 2009 177/495 179/481 30.2 % 0.94 [ 0.72, 1.22 ]
Subtotal (95% CI) 1344 1338 68.5 % 0.87 [ 0.73, 1.04 ]
Total events: 346 (LABA), 375 (Placebo)
Heterogeneity: Chi2 = 3.03, df = 3 (P = 0.39); I2 =1%
Test for overall effect: Z = 1.54 (P = 0.12)
2 Salmeterol 50 g twice daily
Hanrahan 2008 41/290 44/293 9.7 % 0.93 [ 0.59, 1.48 ]
Mahler 2002 100/160 118/181 10.8 % 0.89 [ 0.57, 1.39 ]
Hanania 2003 55/177 63/185 11.0 % 0.87 [ 0.56, 1.36 ]
Subtotal (95% CI) 627 659 31.5 % 0.90 [ 0.69, 1.16 ]
Total events: 196 (LABA), 225 (Placebo)
Heterogeneity: Chi2 = 0.04, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.41)
Total (95% CI) 1971 1997 100.0 % 0.88 [ 0.76, 1.02 ]
Total events: 542 (LABA), 600 (Placebo)
Heterogeneity: Chi2 = 3.10, df = 6 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.73 (P = 0.083)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.85), I2 =0.0%
0.2 0.5 1 2 5
Favours LABA Favours placebo
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Analysis 1.6. Comparison 1 All LABA versus placebo [subgrouped by drug], Outcome 6 Moderate
exacerbations (course of antibiotics and/or steroids).
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 1 All LABA versus placebo [subgrouped by drug]
Outcome: 6 Moderate exacerbations (course of antibiotics and/or steroids)
Study or subgroup LABA Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Formoterol 12 g twice daily
Nelson 2007 (1) 7/114 9/114 2.9 % 0.76 [ 0.27, 2.12 ]
Vogelmeier 2008 17/210 30/209 9.4 % 0.53 [ 0.28, 0.99 ]
Rossi 2002 68/211 38/110 11.5 % 0.90 [ 0.55, 1.47 ]
Subtotal (95% CI) 535 433 23.8 % 0.74 [ 0.51, 1.05 ]
Total events: 92 (LABA), 77 (Placebo)
Heterogeneity: Chi2 = 1.77, df = 2 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 1.68 (P = 0.093)
2 Formoterol 24 g twice daily
Rossi 2002 49/214 37/110 12.8 % 0.59 [ 0.35, 0.97 ]
Subtotal (95% CI) 214 110 12.8 % 0.59 [ 0.35, 0.97 ]
Total events: 49 (LABA), 37 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.06 (P = 0.039)
3 Salmeterol 50 g twice daily
Calverley 2003b [TRISTAN] 8/372 19/361 6.4 % 0.40 [ 0.17, 0.92 ]
Rennard 2001 38/132 41/135 9.8 % 0.93 [ 0.55, 1.57 ]
Mahler 1999 28/135 47/143 12.3 % 0.53 [ 0.31, 0.92 ]
Brusasco 2003 142/405 156/400 34.7 % 0.84 [ 0.63, 1.12 ]
Subtotal (95% CI) 1044 1039 63.3 % 0.75 [ 0.60, 0.94 ]
Total events: 216 (LABA), 263 (Placebo)
Heterogeneity: Chi2 = 5.01, df = 3 (P = 0.17); I2 =40%
Test for overall effect: Z = 2.56 (P = 0.010)
Total (95% CI) 1793 1582 100.0 % 0.73 [ 0.61, 0.87 ]
Total events: 357 (LABA), 377 (Placebo)
Heterogeneity: Chi2 = 7.59, df = 7 (P = 0.37); I2 =8%
Test for overall effect: Z = 3.57 (P = 0.00035)
Test for subgroup differences: Chi2 = 0.78, df = 2 (P = 0.68), I2 =0.0%
0.2 0.5 1 2 5
Favours LABA Favours placebo
(1) Nelson 2007 and Mahler 1999 did not explicitly define exacerbations. Rates were more in keeping with ’moderate’ than ’severe’.
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Analysis 1.7. Comparison 1 All LABA versus placebo [subgrouped by drug], Outcome 7 Mortality (all-
cause).
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 1 All LABA versus placebo [subgrouped by drug]
Outcome: 7 Mortality (all-cause)
Study or subgroup LABA Placebo
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Formoterol 12 g twice daily
Bogdan 2011 0/199 0/208 0.0 [ 0.0, 0.0 ]
Nelson 2007 0/114 0/114 0.0 [ 0.0, 0.0 ]
Dahl 2001 0/192 0/100 0.0 [ 0.0, 0.0 ]
Vogelmeier 2008 0/210 1/209 0.13 [ 0.00, 6.79 ]
Tashkin 2008 [SHINE] 1/284 1/300 1.06 [ 0.07, 16.95 ]
Campbell 2005 2/215 0/217 7.49 [ 0.47, 120.19 ]
Rossi 2002 3/211 0/110 4.62 [ 0.42, 50.53 ]
Tashkin 2012 3/209 1/212 2.78 [ 0.39, 19.86 ]
Doherty 2012 4/243 2/236 1.90 [ 0.38, 9.52 ]
Dahl 2010 3/435 4/432 0.74 [ 0.17, 3.29 ]
Rennard 2009 4/495 4/481 0.97 [ 0.24, 3.90 ]
Szafranski 2003 6/201 9/205 0.67 [ 0.24, 1.89 ]
Calverley 2003a 13/255 5/256 2.52 [ 0.98, 6.45 ]
Subtotal (95% CI) 3263 3080 1.41 [ 0.87, 2.30 ]
Total events: 39 (LABA), 27 (Placebo)
Heterogeneity: Chi2 = 8.77, df = 9 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 1.38 (P = 0.17)
2 Formoterol 24 g twice daily
Dahl 2001 0/191 0/100 0.0 [ 0.0, 0.0 ]
Rossi 2002 1/214 0/110 4.54 [ 0.07, 285.14 ]
Subtotal (95% CI) 405 210 4.54 [ 0.07, 285.14 ]
Total events: 1 (LABA), 0 (Placebo)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
3 Salmeterol 50 g twice daily
SLMF4010 2005 0/17 0/17 0.0 [ 0.0, 0.0 ]
0.002 0.1 1 10 500
Favours LABA Favours placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup LABA Placebo
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Mahler 1999 0/135 0/143 0.0 [ 0.0, 0.0 ]
Hanania 2003 0/177 0/185 0.0 [ 0.0, 0.0 ]
Hanrahan 2008 0/293 0/294 0.0 [ 0.0, 0.0 ]
Rennard 2001 0/132 1/135 0.14 [ 0.00, 6.98 ]
Mahler 2002 0/160 3/181 0.15 [ 0.02, 1.46 ]
Kornmann 2011 0/334 3/335 0.13 [ 0.01, 1.30 ]
Calverley 2003b [TRISTAN] 3/372 7/361 0.43 [ 0.12, 1.50 ]
Brusasco 2003 6/405 5/400 1.19 [ 0.36, 3.90 ]
Calverley 2007 [TORCH] 205/1521 232/1524 0.87 [ 0.71, 1.06 ]
Subtotal (95% CI) 3546 3575 0.83 [ 0.69, 1.01 ]
Total events: 214 (LABA), 251 (Placebo)
Heterogeneity: Chi2 = 7.03, df = 5 (P = 0.22); I2 =29%
Test for overall effect: Z = 1.82 (P = 0.068)
Total (95% CI) 7214 6865 0.90 [ 0.75, 1.08 ]
Total events: 254 (LABA), 278 (Placebo)
Heterogeneity: Chi2 = 20.23, df = 16 (P = 0.21); I2 =21%
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Chi2 = 4.44, df = 2 (P = 0.11), I2 =55%
0.002 0.1 1 10 500
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Analysis 1.8. Comparison 1 All LABA versus placebo [subgrouped by drug], Outcome 8 People with one or
more non-fatal serious adverse event.
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 1 All LABA versus placebo [subgrouped by drug]
Outcome: 8 People with one or more non-fatal serious adverse event
Study or subgroup LABA Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Formoterol 12 g twice daily
Bogdan 2011 7/199 4/208 1.5 % 1.86 [ 0.54, 6.45 ]
Calverley 2003a 85/255 66/256 8.6 % 1.44 [ 0.98, 2.11 ]
Campbell 2005 13/215 9/217 2.8 % 1.49 [ 0.62, 3.56 ]
Dahl 2001 8/192 5/100 1.7 % 0.83 [ 0.26, 2.59 ]
Doherty 2012 19/243 21/236 4.4 % 0.87 [ 0.45, 1.66 ]
Rennard 2009 88/495 58/481 9.2 % 1.58 [ 1.10, 2.26 ]
Rossi 2002 23/211 17/110 4.2 % 0.67 [ 0.34, 1.31 ]
Szafranski 2003 39/201 42/205 6.6 % 0.93 [ 0.57, 1.52 ]
Tashkin 2008 [SHINE] 23/284 25/300 5.1 % 0.97 [ 0.54, 1.75 ]
Tashkin 2012 17/209 12/212 3.4 % 1.48 [ 0.69, 3.17 ]
Subtotal (95% CI) 2504 2325 47.5 % 1.20 [ 0.99, 1.45 ]
Total events: 322 (LABA), 259 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 9.84, df = 9 (P = 0.36); I2 =9%
Test for overall effect: Z = 1.81 (P = 0.070)
2 Formoterol 24 g twice daily
Dahl 2001 3/192 4/100 1.0 % 0.38 [ 0.08, 1.74 ]
Rossi 2002 15/214 16/110 3.6 % 0.44 [ 0.21, 0.93 ]
Wadbo 2002 3/61 7/60 1.2 % 0.39 [ 0.10, 1.59 ]
Subtotal (95% CI) 467 270 5.8 % 0.42 [ 0.23, 0.77 ]
Total events: 21 (LABA), 27 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 2.79 (P = 0.0052)
3 Salmeterol 50 g twice daily
Brusasco 2003 49/405 56/400 8.0 % 0.85 [ 0.56, 1.28 ]
Calverley 2003b [TRISTAN] 69/372 54/361 8.4 % 1.29 [ 0.88, 1.91 ]
Calverley 2007 [TORCH] 617/1542 633/1544 15.2 % 0.96 [ 0.83, 1.11 ]
0.02 0.1 1 10 50
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(. . . Continued)
Study or subgroup LABA Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hanania 2003 5/177 11/185 1.9 % 0.46 [ 0.16, 1.35 ]
Hanrahan 2008 11/290 19/293 3.5 % 0.57 [ 0.27, 1.22 ]
Kornmann 2011 19/334 26/335 4.8 % 0.72 [ 0.39, 1.32 ]
Mahler 2002 7/160 11/181 2.3 % 0.71 [ 0.27, 1.87 ]
Rennard 2001 10/132 7/135 2.2 % 1.50 [ 0.55, 4.06 ]
SLMF4010 2005 1/17 3/17 0.4 % 0.29 [ 0.03, 3.13 ]
Subtotal (95% CI) 3429 3451 46.7 % 0.93 [ 0.78, 1.10 ]
Total events: 788 (LABA), 820 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 9.15, df = 8 (P = 0.33); I2 =13%
Test for overall effect: Z = 0.90 (P = 0.37)
Total (95% CI) 6400 6046 100.0 % 0.97 [ 0.83, 1.14 ]
Total events: 1131 (LABA), 1106 (Placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 32.05, df = 21 (P = 0.06); I2 =34%
Test for overall effect: Z = 0.35 (P = 0.72)
Test for subgroup differences: Chi2 = 11.91, df = 2 (P = 0.00), I2 =83%
0.02 0.1 1 10 50
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Analysis 1.9. Comparison 1 All LABA versus placebo [subgrouped by drug], Outcome 9 Predose FEV1 (mL).
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 1 All LABA versus placebo [subgrouped by drug]
Outcome: 9 Predose FEV1 (mL)
Study or subgroup LABA Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Formoterol 12 g twice daily
Bogdan 2011 199 50 (122) 208 10 (122) 11.3 % 40.00 [ 16.29, 63.71 ]
Calverley 2003a (1) 255 -97.5 (300) 256 -156.8 (300) 8.1 % 59.30 [ 7.28, 111.32 ]
Campbell 2005 215 72.5 (334.3) 217 -21.7 (334.3) 7.0 % 94.20 [ 31.15, 157.25 ]
Dahl 2010 (2) 435 1330 (300.5) 432 1280 (300.5) 9.5 % 50.00 [ 9.99, 90.01 ]
Tashkin 2008 [SHINE] 284 50 (190) 300 10 (210) 10.4 % 40.00 [ 7.55, 72.45 ]
Tashkin 2012 (3) 209 0 (300) 212 -17 (300) 7.6 % 17.00 [ -40.32, 74.32 ]
Subtotal (95% CI) 1597 1625 53.9 % 44.68 [ 29.39, 59.97 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.87, df = 5 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 5.73 (P < 0.00001)
2 Salmeterol 50 g twice daily
Calverley 2003b [TRISTAN] 372 1323 (212) 361 1264 (209) 10.6 % 59.00 [ 28.52, 89.48 ]
Hanania 2003 178 91 (300) 185 1 (300) 7.1 % 90.00 [ 28.27, 151.73 ]
Hanrahan 2008 276 223.1 (218.2) 275 80.4 (204.1) 10.1 % 142.70 [ 107.42, 177.98 ]
Kornmann 2011 333 90 (430) 335 -20 (430) 6.8 % 110.00 [ 44.78, 175.22 ]
Mahler 2002 159 107 (460) 181 -4 (460) 4.3 % 111.00 [ 13.00, 209.00 ]
Rennard 2001 109 150 (323.65) 105 -20 (297.16) 5.2 % 170.00 [ 86.80, 253.20 ]
SLMF4010 2005 17 -94 (239.1) 17 -30 (235) 2.0 % -64.00 [ -223.37, 95.37 ]
Subtotal (95% CI) 1444 1459 46.1 % 101.01 [ 59.84, 142.18 ]
Heterogeneity: Tau2 = 1830.26; Chi2 = 19.57, df = 6 (P = 0.003); I2 =69%
Test for overall effect: Z = 4.81 (P < 0.00001)
Total (95% CI) 3041 3084 100.0 % 72.92 [ 48.02, 97.82 ]
Heterogeneity: Tau2 = 1279.35; Chi2 = 41.38, df = 12 (P = 0.00004); I2 =71%
Test for overall effect: Z = 5.74 (P < 0.00001)
Test for subgroup differences: Chi2 = 6.32, df = 1 (P = 0.01), I2 =84%
-200 -100 0 100 200
Favours placebo Favours LABA
as endpoint scores.
(1) SD imputed by calculating the mean SD for change reported in the other included studies (mean SD for LABA and placebo were both 0.3))
(2) Change from baseline data and endpoint data were pooled in the analysis. Most studies reported change from baseline but data for Dahl 2010, and Calverley 2003b
[TRISTAN] are entered
(3) SD imputed as for Calverley 2003a
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Analysis 1.10. Comparison 1 All LABA versus placebo [subgrouped by drug], Outcome 10 Withdrawal.
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 1 All LABA versus placebo [subgrouped by drug]
Outcome: 10 Withdrawal
Study or subgroup LABA Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Formoterol 12 g twice daily
Aalbers 2002 30/166 13/86 0.9 % 1.24 [ 0.61, 2.52 ]
Bogdan 2011 17/199 22/208 1.2 % 0.79 [ 0.41, 1.54 ]
Calverley 2003a 111/255 106/256 3.7 % 1.09 [ 0.77, 1.55 ]
Campbell 2005 30/215 39/217 2.1 % 0.74 [ 0.44, 1.24 ]
Dahl 2001 13/194 15/100 1.2 % 0.41 [ 0.19, 0.89 ]
Dahl 2010 112/435 137/432 6.4 % 0.75 [ 0.56, 1.00 ]
Doherty 2012 50/243 67/236 3.4 % 0.65 [ 0.43, 1.00 ]
Nelson 2007 16/114 30/114 1.6 % 0.46 [ 0.23, 0.90 ]
Rennard 2009 157/495 175/481 7.6 % 0.81 [ 0.62, 1.06 ]
Rossi 2002 52/211 30/110 1.9 % 0.87 [ 0.52, 1.47 ]
Szafranski 2003 64/201 90/205 3.8 % 0.60 [ 0.40, 0.90 ]
Tashkin 2008 [SHINE] 61/284 77/300 3.7 % 0.79 [ 0.54, 1.16 ]
Tashkin 2012 37/209 53/212 2.7 % 0.65 [ 0.40, 1.03 ]
Vogelmeier 2008 25/210 30/209 1.7 % 0.81 [ 0.46, 1.42 ]
Subtotal (95% CI) 3431 3166 41.6 % 0.76 [ 0.68, 0.86 ]
Total events: 775 (LABA), 884 (Placebo)
Heterogeneity: Chi2 = 13.45, df = 13 (P = 0.41); I2 =3%
Test for overall effect: Z = 4.59 (P < 0.00001)
2 Formoterol 24 g twice daily
Aalbers 2002 27/177 14/87 1.0 % 0.94 [ 0.46, 1.90 ]
Dahl 2001 23/192 14/100 1.0 % 0.84 [ 0.41, 1.71 ]
Rossi 2002 40/214 29/110 1.9 % 0.64 [ 0.37, 1.11 ]
Wadbo 2002 17/61 16/60 0.7 % 1.06 [ 0.48, 2.37 ]
Subtotal (95% CI) 644 357 4.7 % 0.81 [ 0.58, 1.14 ]
Total events: 107 (LABA), 73 (Placebo)
0.2 0.5 1 2 5
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(. . . Continued)
Study or subgroup LABA Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 1.31, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 1.22 (P = 0.22)
3 Salmeterol 50 g twice daily
Brusasco 2003 76/405 103/400 5.2 % 0.67 [ 0.48, 0.93 ]
Calverley 2003b [TRISTAN] 119/372 140/361 6.0 % 0.74 [ 0.55, 1.01 ]
Calverley 2007 [TORCH] 582/1544 694/1545 27.0 % 0.74 [ 0.64, 0.86 ]
Hanania 2003 57/177 59/185 2.4 % 1.01 [ 0.65, 1.58 ]
Hanrahan 2008 44/293 64/294 3.4 % 0.64 [ 0.42, 0.97 ]
Kornmann 2011 50/334 70/335 3.7 % 0.67 [ 0.45, 0.99 ]
Mahler 1999 9/135 23/143 1.3 % 0.37 [ 0.17, 0.84 ]
Mahler 2002 45/160 69/181 2.9 % 0.64 [ 0.40, 1.00 ]
Rennard 2001 22/132 29/135 1.5 % 0.73 [ 0.40, 1.35 ]
SLMF4010 2005 7/17 7/17 0.3 % 1.00 [ 0.26, 3.92 ]
Subtotal (95% CI) 3569 3596 53.7 % 0.72 [ 0.65, 0.80 ]
Total events: 1011 (LABA), 1258 (Placebo)
Heterogeneity: Chi2 = 6.26, df = 9 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 6.24 (P < 0.00001)
Total (95% CI) 7644 7119 100.0 % 0.74 [ 0.69, 0.80 ]
Total events: 1893 (LABA), 2215 (Placebo)
Heterogeneity: Chi2 = 21.80, df = 27 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 7.80 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.83, df = 2 (P = 0.66), I2 =0.0%
0.2 0.5 1 2 5
Favours LABA Favours placebo
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Analysis 2.1. Comparison 2 Formoterol 12 µg versus placebo [subgrouped by trial duration], Outcome 1
Quality of life (SGRQ).
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 2 Formoterol 12 g versus placebo [subgrouped by trial duration]
Outcome: 1 Quality of life (SGRQ)
Study or subgroup Formoterol 12 g Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 3 months
Bogdan 2011 (1) 199 38.2 (14.5) 206 42.9 (14.5) 24.5 % -4.70 [ -7.52, -1.88 ]
Dahl 2001 181 41.7 (16.8) 174 46.8 (17.6) 15.2 % -5.10 [ -8.68, -1.52 ]
Dahl 2010 435 38.1 (13.5208) 432 41.3 (13.5208) 60.3 % -3.20 [ -5.00, -1.40 ]
Subtotal (95% CI) 815 812 100.0 % -3.86 [ -5.25, -2.46 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.32, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 5.41 (P < 0.00001)
2 6 months
Calverley 2003a 255 0.2 (17) 256 2 (17) 16.2 % -1.80 [ -4.75, 1.15 ]
Campbell 2005 215 -3.81 (13.5737) 217 -4.61 (13.5737) 19.8 % 0.80 [ -1.76, 3.36 ]
Doherty 2012 243 -4.93 (14.5) 236 -2.88 (14.5) 19.4 % -2.05 [ -4.65, 0.55 ]
Tashkin 2008 [SHINE] 284 -1.24 (11.35) 300 -1.02 (12.41) 28.2 % -0.22 [ -2.15, 1.71 ]
Tashkin 2012 209 -6.19 (15.2) 212 -2.88 (15.2) 16.5 % -3.31 [ -6.21, -0.41 ]
Subtotal (95% CI) 1206 1221 100.0 % -1.14 [ -2.51, 0.23 ]
Heterogeneity: Tau2 = 0.78; Chi2 = 5.86, df = 4 (P = 0.21); I2 =32%
Test for overall effect: Z = 1.62 (P = 0.10)
3 12 months
Calverley 2003a 255 0.8 (17) 256 4.7 (17) 18.2 % -3.90 [ -6.85, -0.95 ]
Dahl 2010 435 -6.7 (22.5346) 432 -1.7 (22.5346) 17.7 % -5.00 [ -8.00, -2.00 ]
Rennard 2009 495 -2.9 (13.3) 481 -1.5 (12.7) 34.1 % -1.40 [ -3.03, 0.23 ]
Rossi 2002 159 40.9 (17.8) 160 45.3 (18.7) 11.6 % -4.40 [ -8.41, -0.39 ]
Szafranski 2003 201 -3.6 (15) 205 -0.03 (15) 18.4 % -3.57 [ -6.49, -0.65 ]
Subtotal (95% CI) 1545 1534 100.0 % -3.24 [ -4.77, -1.71 ]
Heterogeneity: Tau2 = 1.10; Chi2 = 6.30, df = 4 (P = 0.18); I2 =37%
Test for overall effect: Z = 4.15 (P = 0.000034)
Test for subgroup differences: Chi2 = 8.07, df = 2 (P = 0.02), I2 =75%
-10 -5 0 5 10
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entered as endpoint scores.
(1) Change from baseline data and endpoint data were pooled in the analysis. Most studies reported change from baseline but data for Bogdan 2011, Dahl 2001, Dahl
2010, and Rossi 2002 are
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Analysis 2.2. Comparison 2 Formoterol 12 µg versus placebo [subgrouped by trial duration], Outcome 2
Severe exacerbations (hospitalisations).
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 2 Formoterol 12 g versus placebo [subgrouped by trial duration]
Outcome: 2 Severe exacerbations (hospitalisations)
Study or subgroup Formoterol 12 g Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 3 months
Dahl 2001 2/181 4/172 4.0 % 0.47 [ 0.08, 2.60 ]
Subtotal (95% CI) 181 172 4.0 % 0.47 [ 0.08, 2.60 ]
Total events: 2 (Formoterol 12 g), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.39)
2 6 months
Vogelmeier 2008 1/210 3/209 3.0 % 0.33 [ 0.03, 3.18 ]
Tashkin 2012 6/209 7/212 6.7 % 0.87 [ 0.29, 2.62 ]
Doherty 2012 5/243 12/236 11.8 % 0.39 [ 0.14, 1.13 ]
Subtotal (95% CI) 662 657 21.5 % 0.53 [ 0.26, 1.08 ]
Total events: 12 (Formoterol 12 g), 22 (Placebo)
Heterogeneity: Chi2 = 1.23, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.74 (P = 0.082)
3 12 months
Rossi 2002 10/211 20/220 18.5 % 0.50 [ 0.23, 1.09 ]
Calverley 2003a 73/255 79/256 55.9 % 0.90 [ 0.61, 1.31 ]
Subtotal (95% CI) 466 476 74.4 % 0.80 [ 0.57, 1.12 ]
Total events: 83 (Formoterol 12 g), 99 (Placebo)
Heterogeneity: Chi2 = 1.77, df = 1 (P = 0.18); I2 =44%
Test for overall effect: Z = 1.30 (P = 0.19)
Total (95% CI) 1309 1305 100.0 % 0.73 [ 0.54, 0.98 ]
Total events: 97 (Formoterol 12 g), 125 (Placebo)
Heterogeneity: Chi2 = 4.22, df = 5 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 2.07 (P = 0.038)
Test for subgroup differences: Chi2 = 1.29, df = 2 (P = 0.52), I2 =0.0%
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Analysis 2.3. Comparison 2 Formoterol 12 µg versus placebo [subgrouped by trial duration], Outcome 3
Moderate exacerbations (course of antibiotics and/or steroids).
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 2 Formoterol 12 g versus placebo [subgrouped by trial duration]
Outcome: 3 Moderate exacerbations (course of antibiotics and/or steroids)
Study or subgroup Formoterol 12 g Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 3 months
Nelson 2007 7/114 9/114 9.8 % 0.76 [ 0.27, 2.12 ]
Subtotal (95% CI) 114 114 9.8 % 0.76 [ 0.27, 2.12 ]
Total events: 7 (Formoterol 12 g), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
2 6 months
Vogelmeier 2008 17/210 30/209 32.2 % 0.53 [ 0.28, 0.99 ]
Subtotal (95% CI) 210 209 32.2 % 0.53 [ 0.28, 0.99 ]
Total events: 17 (Formoterol 12 g), 30 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.01 (P = 0.045)
3 12 months
Rossi 2002 68/211 75/220 58.0 % 0.92 [ 0.62, 1.37 ]
Subtotal (95% CI) 211 220 58.0 % 0.92 [ 0.62, 1.37 ]
Total events: 68 (Formoterol 12 g), 75 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
Total (95% CI) 535 543 100.0 % 0.78 [ 0.56, 1.07 ]
Total events: 92 (Formoterol 12 g), 114 (Placebo)
Heterogeneity: Chi2 = 2.16, df = 2 (P = 0.34); I2 =7%
Test for overall effect: Z = 1.55 (P = 0.12)
Test for subgroup differences: Chi2 = 2.16, df = 2 (P = 0.34), I2 =7%
0.2 0.5 1 2 5
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Analysis 2.4. Comparison 2 Formoterol 12 µg versus placebo [subgrouped by trial duration], Outcome 4
Mortality (all-cause).
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 2 Formoterol 12 g versus placebo [subgrouped by trial duration]
Outcome: 4 Mortality (all-cause)
Study or subgroup Formoterol 12 g Placebo
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 3 months
Dahl 2001 0/192 0/200 0.0 [ 0.0, 0.0 ]
Nelson 2007 0/114 0/114 0.0 [ 0.0, 0.0 ]
Bogdan 2011 0/199 0/208 0.0 [ 0.0, 0.0 ]
Tashkin 2012 3/209 1/212 2.78 [ 0.39, 19.86 ]
Doherty 2012 4/243 2/236 1.90 [ 0.38, 9.52 ]
Subtotal (95% CI) 957 970 2.22 [ 0.64, 7.70 ]
Total events: 7 (Formoterol 12 g), 3 (Placebo)
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.25 (P = 0.21)
2 6 months
Vogelmeier 2008 0/210 1/209 0.13 [ 0.00, 6.79 ]
Tashkin 2008 [SHINE] 1/284 1/300 1.06 [ 0.07, 16.95 ]
Campbell 2005 2/215 0/217 7.49 [ 0.47, 120.19 ]
Calverley 2003a 13/255 5/256 2.52 [ 0.98, 6.45 ]
Subtotal (95% CI) 964 982 2.25 [ 0.98, 5.16 ]
Total events: 16 (Formoterol 12 g), 7 (Placebo)
Heterogeneity: Chi2 = 3.04, df = 3 (P = 0.38); I2 =1%
Test for overall effect: Z = 1.92 (P = 0.055)
3 12 months
Rossi 2002 3/211 0/220 7.79 [ 0.81, 75.27 ]
Dahl 2010 3/435 4/432 0.74 [ 0.17, 3.29 ]
Rennard 2009 4/495 4/481 0.97 [ 0.24, 3.90 ]
Szafranski 2003 6/201 9/205 0.67 [ 0.24, 1.89 ]
Subtotal (95% CI) 1342 1338 0.94 [ 0.47, 1.88 ]
Total events: 16 (Formoterol 12 g), 17 (Placebo)
Heterogeneity: Chi2 = 3.83, df = 3 (P = 0.28); I2 =22%
Test for overall effect: Z = 0.16 (P = 0.87)
Total (95% CI) 3263 3290 1.45 [ 0.89, 2.37 ]
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(. . . Continued)
Study or subgroup Formoterol 12 g Placebo
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Total events: 39 (Formoterol 12 g), 27 (Placebo)
Heterogeneity: Chi2 = 9.98, df = 9 (P = 0.35); I2 =10%
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Chi2 = 3.02, df = 2 (P = 0.22), I2 =34%
0.005 0.1 1 10 200
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Analysis 2.5. Comparison 2 Formoterol 12 µg versus placebo [subgrouped by trial duration], Outcome 5
Patients with one or more serious adverse event.
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 2 Formoterol 12 g versus placebo [subgrouped by trial duration]
Outcome: 5 Patients with one or more serious adverse event
Study or subgroup Formoterol 12 g Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 3 months
Bogdan 2011 7/199 4/208 1.7 % 1.86 [ 0.54, 6.45 ]
Dahl 2001 8/192 9/200 3.7 % 0.92 [ 0.35, 2.44 ]
Subtotal (95% CI) 391 408 5.4 % 1.21 [ 0.57, 2.58 ]
Total events: 15 (Formoterol 12 g), 13 (Placebo)
Heterogeneity: Chi2 = 0.76, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
2 6 months
Campbell 2005 13/215 9/217 3.7 % 1.49 [ 0.62, 3.56 ]
Tashkin 2012 17/209 12/212 4.8 % 1.48 [ 0.69, 3.17 ]
Doherty 2012 19/243 21/236 8.6 % 0.87 [ 0.45, 1.66 ]
Tashkin 2008 [SHINE] 23/284 25/300 9.8 % 0.97 [ 0.54, 1.75 ]
Subtotal (95% CI) 951 965 26.9 % 1.10 [ 0.78, 1.55 ]
Total events: 72 (Formoterol 12 g), 67 (Placebo)
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(. . . Continued)
Study or subgroup Formoterol 12 g Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 1.71, df = 3 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.59)
3 12 months
Rossi 2002 23/211 33/220 12.6 % 0.69 [ 0.39, 1.23 ]
Szafranski 2003 39/201 42/205 14.7 % 0.93 [ 0.57, 1.52 ]
Calverley 2003a 85/255 66/256 19.2 % 1.44 [ 0.98, 2.11 ]
Rennard 2009 88/495 58/481 21.2 % 1.58 [ 1.10, 2.26 ]
Subtotal (95% CI) 1162 1162 67.8 % 1.23 [ 1.00, 1.52 ]
Total events: 235 (Formoterol 12 g), 199 (Placebo)
Heterogeneity: Chi2 = 7.61, df = 3 (P = 0.05); I2 =61%
Test for overall effect: Z = 1.95 (P = 0.052)
Total (95% CI) 2504 2535 100.0 % 1.20 [ 1.00, 1.43 ]
Total events: 322 (Formoterol 12 g), 279 (Placebo)
Heterogeneity: Chi2 = 10.41, df = 9 (P = 0.32); I2 =14%
Test for overall effect: Z = 2.00 (P = 0.045)
Test for subgroup differences: Chi2 = 0.32, df = 2 (P = 0.85), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours formoterol 12 g Favours placebo
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Analysis 2.6. Comparison 2 Formoterol 12 µg versus placebo [subgrouped by trial duration], Outcome 6
Predose FEV1 (mL).
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 2 Formoterol 12 g versus placebo [subgrouped by trial duration]
Outcome: 6 Predose FEV1 (mL)
Study or subgroup Formoterol 12 g Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 3 months
Bogdan 2011 199 50 (122) 208 10 (122) 41.6 % 40.00 [ 16.29, 63.71 ]
Subtotal (95% CI) 199 208 41.6 % 40.00 [ 16.29, 63.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.31 (P = 0.00094)
2 6 months
Campbell 2005 215 72.5 (334.3) 217 -21.7 (334.3) 5.9 % 94.20 [ 31.15, 157.25 ]
Tashkin 2008 [SHINE] 284 50 (190) 300 10 (210) 22.2 % 40.00 [ 7.55, 72.45 ]
Tashkin 2012 209 0 (300) 212 -17 (300) 7.1 % 17.00 [ -40.32, 74.32 ]
Subtotal (95% CI) 708 729 35.2 % 44.41 [ 18.63, 70.18 ]
Heterogeneity: Chi2 = 3.35, df = 2 (P = 0.19); I2 =40%
Test for overall effect: Z = 3.38 (P = 0.00073)
3 12 months
Calverley 2003a 255 -97.5 (300) 256 -156.8 (300) 8.6 % 59.30 [ 7.28, 111.32 ]
Dahl 2010 (1) 435 1330 (300.5) 432 1280 (300.5) 14.6 % 50.00 [ 9.99, 90.01 ]
Subtotal (95% CI) 690 688 23.2 % 53.46 [ 21.74, 85.17 ]
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 3.30 (P = 0.00095)
Total (95% CI) 1597 1625 100.0 % 44.68 [ 29.39, 59.97 ]
Heterogeneity: Chi2 = 3.87, df = 5 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 5.73 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.44, df = 2 (P = 0.80), I2 =0.0%
-200 -100 0 100 200
Favours placebo Favours formoterol 12 g
Change from baseline data and endpoint data were pooled in the analysis. Only Dahl 2010 were entered as endpoint scores.
(1) Data was also presented for 3 months but omitted in this analysis to avoid double counting. Sensitivity analyses with the study included in both time-points did not
change conclusions.
106Long-acting beta2-agonists for chronic obstructive pulmonary disease (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.7. Comparison 2 Formoterol 12 µg versus placebo [subgrouped by trial duration], Outcome 7
Withdrawal.
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 2 Formoterol 12 g versus placebo [subgrouped by trial duration]
Outcome: 7 Withdrawal
Study or subgroup Formoterol 12 g Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 3 months
Bogdan 2011 17/199 22/208 2.8 % 0.79 [ 0.41, 1.54 ]
Aalbers 2002 30/166 27/173 3.1 % 1.19 [ 0.67, 2.11 ]
Nelson 2007 16/114 30/114 3.7 % 0.46 [ 0.23, 0.90 ]
Dahl 2001 13/194 29/200 3.8 % 0.42 [ 0.21, 0.84 ]
Subtotal (95% CI) 673 695 13.5 % 0.69 [ 0.50, 0.94 ]
Total events: 76 (Formoterol 12 g), 108 (Placebo)
Heterogeneity: Chi2 = 7.08, df = 3 (P = 0.07); I2 =58%
Test for overall effect: Z = 2.32 (P = 0.020)
2 6 months
Vogelmeier 2008 25/210 30/209 3.8 % 0.81 [ 0.46, 1.42 ]
Campbell 2005 30/215 39/217 4.8 % 0.74 [ 0.44, 1.24 ]
Tashkin 2012 37/209 53/212 6.2 % 0.65 [ 0.40, 1.03 ]
Doherty 2012 50/243 67/236 7.7 % 0.65 [ 0.43, 1.00 ]
Tashkin 2008 [SHINE] 61/284 77/300 8.4 % 0.79 [ 0.54, 1.16 ]
Subtotal (95% CI) 1161 1174 31.0 % 0.72 [ 0.59, 0.89 ]
Total events: 203 (Formoterol 12 g), 266 (Placebo)
Heterogeneity: Chi2 = 0.81, df = 4 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 3.12 (P = 0.0018)
3 12 months
Rossi 2002 52/211 59/220 6.2 % 0.89 [ 0.58, 1.38 ]
Calverley 2003a 111/255 106/256 8.6 % 1.09 [ 0.77, 1.55 ]
Szafranski 2003 64/201 90/205 8.7 % 0.60 [ 0.40, 0.90 ]
Dahl 2010 112/435 137/432 14.6 % 0.75 [ 0.56, 1.00 ]
Rennard 2009 157/495 175/481 17.4 % 0.81 [ 0.62, 1.06 ]
Subtotal (95% CI) 1597 1594 55.6 % 0.81 [ 0.70, 0.94 ]
Total events: 496 (Formoterol 12 g), 567 (Placebo)
Heterogeneity: Chi2 = 5.43, df = 4 (P = 0.25); I2 =26%
Test for overall effect: Z = 2.73 (P = 0.0063)
0.2 0.5 1 2 5
Favours formoterol 12 g Favours placebo
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(. . . Continued)
Study or subgroup Formoterol 12 g Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total (95% CI) 3431 3463 100.0 % 0.77 [ 0.69, 0.86 ]
Total events: 775 (Formoterol 12 g), 941 (Placebo)
Heterogeneity: Chi2 = 14.62, df = 13 (P = 0.33); I2 =11%
Test for overall effect: Z = 4.61 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.40, df = 2 (P = 0.50), I2 =0.0%
0.2 0.5 1 2 5
Favours formoterol 12 g Favours placebo
Analysis 3.1. Comparison 3 Formoterol 24 µg versus placebo [subgrouped by trial duration], Outcome 1
Quality of life (SGRQ).
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 3 Formoterol 24 g versus placebo [subgrouped by trial duration]
Outcome: 1 Quality of life (SGRQ)
Study or subgroup Formoterol 24 g Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 3 months
Dahl 2001 (1) 169 43.5 (19.4) 86 46.8 (17.6) 21.5 % -3.30 [ -8.03, 1.43 ]
Wadbo 2002 61 0 (8.59) 60 1.5 (8.9034) 49.4 % -1.50 [ -4.62, 1.62 ]
Subtotal (95% CI) 230 146 70.9 % -2.04 [ -4.65, 0.56 ]
Heterogeneity: Chi2 = 0.39, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.54 (P = 0.12)
2 12 months
Rossi 2002 171 42.3 (19) 160 45.3 (18.7) 29.1 % -3.00 [ -7.06, 1.06 ]
Subtotal (95% CI) 171 160 29.1 % -3.00 [ -7.06, 1.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
Total (95% CI) 401 306 100.0 % -2.32 [ -4.52, -0.13 ]
Heterogeneity: Chi2 = 0.54, df = 2 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 2.08 (P = 0.038)
Test for subgroup differences: Chi2 = 0.15, df = 1 (P = 0.70), I2 =0.0%
-10 -5 0 5 10
Favours formoterol 24 g Favours placebo
(1) Dahl 2001 and Rossi 2002 data are endpoint scores, and Wadbo 2002 was presented as change from baseline
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Analysis 3.2. Comparison 3 Formoterol 24 µg versus placebo [subgrouped by trial duration], Outcome 2
Severe exacerbations (hospitalisations).
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 3 Formoterol 24 g versus placebo [subgrouped by trial duration]
Outcome: 2 Severe exacerbations (hospitalisations)
Study or subgroup Formoterol 24 g Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 3 months
Dahl 2001 2/171 4/172 17.0 % 0.50 [ 0.09, 2.75 ]
Subtotal (95% CI) 171 172 17.0 % 0.50 [ 0.09, 2.75 ]
Total events: 2 (Formoterol 24 g), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
2 12 months
Rossi 2002 5/214 20/220 83.0 % 0.24 [ 0.09, 0.65 ]
Subtotal (95% CI) 214 220 83.0 % 0.24 [ 0.09, 0.65 ]
Total events: 5 (Formoterol 24 g), 20 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.81 (P = 0.0050)
Total (95% CI) 385 392 100.0 % 0.28 [ 0.12, 0.67 ]
Total events: 7 (Formoterol 24 g), 24 (Placebo)
Heterogeneity: Chi2 = 0.53, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 2.89 (P = 0.0038)
Test for subgroup differences: Chi2 = 0.52, df = 1 (P = 0.47), I2 =0.0%
0.05 0.2 1 5 20
Favours formoterol 24 g Favours placebo
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Analysis 3.3. Comparison 3 Formoterol 24 µg versus placebo [subgrouped by trial duration], Outcome 3
Moderate exacerbations (course of antibiotics and/or steroids).
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 3 Formoterol 24 g versus placebo [subgrouped by trial duration]
Outcome: 3 Moderate exacerbations (course of antibiotics and/or steroids)
Study or subgroup Formoterol 24 g Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 12 months
Rossi 2002 49/214 75/220 0.57 [ 0.38, 0.88 ]
0.2 0.5 1 2 5
Favours formoterol 24 g Favours placebo
Analysis 3.4. Comparison 3 Formoterol 24 µg versus placebo [subgrouped by trial duration], Outcome 4
Mortality (all-cause).
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 3 Formoterol 24 g versus placebo [subgrouped by trial duration]
Outcome: 4 Mortality (all-cause)
Study or subgroup Formoterol 24 g Placebo
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 3 months
Dahl 2001 0/191 0/200 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 191 200 0.0 [ 0.0, 0.0 ]
Total events: 0 (Formoterol 24 g), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
2 12 months
Rossi 2002 1/214 0/220 7.60 [ 0.15, 383.12 ]
Subtotal (95% CI) 214 220 7.60 [ 0.15, 383.12 ]
Total events: 1 (Formoterol 24 g), 0 (Placebo)
0.002 0.1 1 10 500
Favours formoterol 24 g Favours placebo
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(. . . Continued)
Study or subgroup Formoterol 24 g Placebo
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
Total (95% CI) 405 420 7.60 [ 0.15, 383.12 ]
Total events: 1 (Formoterol 24 g), 0 (Placebo)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours formoterol 24 g Favours placebo
Analysis 3.5. Comparison 3 Formoterol 24 µg versus placebo [subgrouped by trial duration], Outcome 5
People with one or more non-fatal serious adverse events.
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 3 Formoterol 24 g versus placebo [subgrouped by trial duration]
Outcome: 5 People with one or more non-fatal serious adverse events
Study or subgroup Formoterol 24 g Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 3 months
Wadbo 2002 3/61 7/60 9.4 % 0.39 [ 0.10, 1.59 ]
Dahl 2001 3/192 9/200 12.2 % 0.34 [ 0.09, 1.26 ]
Subtotal (95% CI) 253 260 21.6 % 0.36 [ 0.14, 0.94 ]
Total events: 6 (Formoterol 24 g), 16 (Placebo)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 2.08 (P = 0.038)
2 12 months
Rossi 2002 48/214 73/220 78.4 % 0.58 [ 0.38, 0.89 ]
Subtotal (95% CI) 214 220 78.4 % 0.58 [ 0.38, 0.89 ]
Total events: 48 (Formoterol 24 g), 73 (Placebo)
Heterogeneity: not applicable
0.05 0.2 1 5 20
Favours formoterol 24 g Favours placebo
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(. . . Continued)
Study or subgroup Formoterol 24 g Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 2.49 (P = 0.013)
Total (95% CI) 467 480 100.0 % 0.53 [ 0.36, 0.79 ]
Total events: 54 (Formoterol 24 g), 89 (Placebo)
Heterogeneity: Chi2 = 0.81, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 3.16 (P = 0.0016)
Test for subgroup differences: Chi2 = 0.80, df = 1 (P = 0.37), I2 =0.0%
0.05 0.2 1 5 20
Favours formoterol 24 g Favours placebo
Analysis 3.6. Comparison 3 Formoterol 24 µg versus placebo [subgrouped by trial duration], Outcome 6
Withdrawal.
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 3 Formoterol 24 g versus placebo [subgrouped by trial duration]
Outcome: 6 Withdrawal
Study or subgroup Formoterol 24 g Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 3 months
Wadbo 2002 17/61 16/60 10.9 % 1.06 [ 0.48, 2.37 ]
Aalbers 2002 27/177 27/173 21.6 % 0.97 [ 0.54, 1.74 ]
Dahl 2001 23/192 29/200 23.3 % 0.80 [ 0.45, 1.44 ]
Subtotal (95% CI) 430 433 55.8 % 0.92 [ 0.64, 1.33 ]
Total events: 67 (Formoterol 24 g), 72 (Placebo)
Heterogeneity: Chi2 = 0.37, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.65)
2 12 months
Rossi 2002 40/214 59/220 44.2 % 0.63 [ 0.40, 0.99 ]
Subtotal (95% CI) 214 220 44.2 % 0.63 [ 0.40, 0.99 ]
Total events: 40 (Formoterol 24 g), 59 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.01 (P = 0.045)
0.2 0.5 1 2 5
Favours formoterol 24 g Favours placebo
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(. . . Continued)
Study or subgroup Formoterol 24 g Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total (95% CI) 644 653 100.0 % 0.79 [ 0.59, 1.05 ]
Total events: 107 (Formoterol 24 g), 131 (Placebo)
Heterogeneity: Chi2 = 2.01, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.62 (P = 0.10)
Test for subgroup differences: Chi2 = 1.64, df = 1 (P = 0.20), I2 =39%
0.2 0.5 1 2 5
Favours formoterol 24 g Favours placebo
Analysis 4.1. Comparison 4 Salmeterol 50 µg versus placebo [subgrouped by trial duration], Outcome 1
Quality of life (SGRQ).
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 4 Salmeterol 50 g versus placebo [subgrouped by trial duration]
Outcome: 1 Quality of life (SGRQ)
Study or subgroup Salmeterol 50 g Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 6 months
Brusasco 2003 405 -2.8 (14.087) 400 -1.5 (14) 19.9 % -1.30 [ -3.24, 0.64 ]
Kornmann 2011 292 -5.6 (15.4) 274 -1.5 (14.9) 14.5 % -4.10 [ -6.60, -1.60 ]
SLMF4010 2005 17 -7.1 (15.2555) 17 2.7 (16.0801) 1.1 % -9.80 [ -20.34, 0.74 ]
Subtotal (95% CI) 714 691 35.6 % -3.10 [ -6.03, -0.17 ]
Heterogeneity: Tau2 = 3.52; Chi2 = 4.89, df = 2 (P = 0.09); I2 =59%
Test for overall effect: Z = 2.07 (P = 0.038)
2 12 months
Calverley 2003b [TRISTAN] (1) 372 45.2 (7.7149) 361 46.3 (9.5) 29.9 % -1.10 [ -2.35, 0.15 ]
Subtotal (95% CI) 372 361 29.9 % -1.10 [ -2.35, 0.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.72 (P = 0.086)
3 36 months
Calverley 2007 [TORCH] 1521 -0.8 (14.0772) 1524 0.2 (14.0772) 34.5 % -1.00 [ -2.00, 0.00 ]
-20 -10 0 10 20
Favours salmeterol 50 g Favours placebo
(Continued . . . )
113Long-acting beta2-agonists for chronic obstructive pulmonary disease (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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Study or subgroup Salmeterol 50 g Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 1521 1524 34.5 % -1.00 [ -2.00, 0.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.96 (P = 0.050)
Total (95% CI) 2607 2576 100.0 % -1.64 [ -2.78, -0.50 ]
Heterogeneity: Tau2 = 0.73; Chi2 = 7.76, df = 4 (P = 0.10); I2 =48%
Test for overall effect: Z = 2.81 (P = 0.0049)
Test for subgroup differences: Chi2 = 1.79, df = 2 (P = 0.41), I2 =0.0%
-20 -10 0 10 20
Favours salmeterol 50 g Favours placebo
(1) All data except Calverley 2003b [TRISTAN] (endpoint scores) are presented as change from baseline
Analysis 4.2. Comparison 4 Salmeterol 50 µg versus placebo [subgrouped by trial duration], Outcome 2
Severe exacerbations (hospitalisations).
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 4 Salmeterol 50 g versus placebo [subgrouped by trial duration]
Outcome: 2 Severe exacerbations (hospitalisations)
Study or subgroup Salmeterol 50 g Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 6 months
Brusasco 2003 20/405 20/400 0.99 [ 0.52, 1.86 ]
0.2 0.5 1 2 5
Favours salmeterol 50 g Favours placebo
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Analysis 4.3. Comparison 4 Salmeterol 50 µg versus placebo [subgrouped by trial duration], Outcome 3
Moderate exacerbations (course of antibiotics and/or steroids).
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 4 Salmeterol 50 g versus placebo [subgrouped by trial duration]
Outcome: 3 Moderate exacerbations (course of antibiotics and/or steroids)
Study or subgroup Salmeterol 50 g Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 3 months
Rennard 2001 38/132 41/135 15.5 % 0.93 [ 0.55, 1.57 ]
Mahler 1999 28/135 47/143 19.5 % 0.53 [ 0.31, 0.92 ]
Subtotal (95% CI) 267 278 35.0 % 0.71 [ 0.49, 1.03 ]
Total events: 66 (Salmeterol 50 g), 88 (Placebo)
Heterogeneity: Chi2 = 2.04, df = 1 (P = 0.15); I2 =51%
Test for overall effect: Z = 1.80 (P = 0.072)
2 6 months
Brusasco 2003 142/405 156/400 54.8 % 0.84 [ 0.63, 1.12 ]
Subtotal (95% CI) 405 400 54.8 % 0.84 [ 0.63, 1.12 ]
Total events: 142 (Salmeterol 50 g), 156 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.25)
3 12 months
Calverley 2003b [TRISTAN] 8/372 19/361 10.2 % 0.40 [ 0.17, 0.92 ]
Subtotal (95% CI) 372 361 10.2 % 0.40 [ 0.17, 0.92 ]
Total events: 8 (Salmeterol 50 g), 19 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.17 (P = 0.030)
Total (95% CI) 1044 1039 100.0 % 0.75 [ 0.60, 0.94 ]
Total events: 216 (Salmeterol 50 g), 263 (Placebo)
Heterogeneity: Chi2 = 5.01, df = 3 (P = 0.17); I2 =40%
Test for overall effect: Z = 2.56 (P = 0.010)
Test for subgroup differences: Chi2 = 2.98, df = 2 (P = 0.23), I2 =33%
0.1 0.2 0.5 1 2 5 10
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Analysis 4.4. Comparison 4 Salmeterol 50 µg versus placebo [subgrouped by trial duration], Outcome 4
Mortality (all-cause).
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 4 Salmeterol 50 g versus placebo [subgrouped by trial duration]
Outcome: 4 Mortality (all-cause)
Study or subgroup Salmeterol 50 g Placebo
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 3 months
Mahler 1999 0/135 0/143 0.0 [ 0.0, 0.0 ]
Hanrahan 2008 0/293 0/294 0.0 [ 0.0, 0.0 ]
Rennard 2001 0/132 1/135 0.14 [ 0.00, 6.98 ]
Subtotal (95% CI) 560 572 0.14 [ 0.00, 6.98 ]
Total events: 0 (Salmeterol 50 g), 1 (Placebo)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
2 6 months
Hanania 2003 0/177 0/185 0.0 [ 0.0, 0.0 ]
SLMF4010 2005 0/17 0/17 0.0 [ 0.0, 0.0 ]
Mahler 2002 0/160 3/181 0.15 [ 0.02, 1.46 ]
Kornmann 2011 0/334 3/335 0.13 [ 0.01, 1.30 ]
Brusasco 2003 6/405 5/400 1.19 [ 0.36, 3.90 ]
Subtotal (95% CI) 1093 1118 0.56 [ 0.22, 1.46 ]
Total events: 6 (Salmeterol 50 g), 11 (Placebo)
Heterogeneity: Chi2 = 4.33, df = 2 (P = 0.11); I2 =54%
Test for overall effect: Z = 1.19 (P = 0.23)
3 12 months
Calverley 2003b [TRISTAN] 3/372 7/361 0.43 [ 0.12, 1.50 ]
Subtotal (95% CI) 372 361 0.43 [ 0.12, 1.50 ]
Total events: 3 (Salmeterol 50 g), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
4 36 months
Calverley 2007 [TORCH] 205/1521 232/1524 0.87 [ 0.71, 1.06 ]
Subtotal (95% CI) 1521 1524 0.87 [ 0.71, 1.06 ]
Total events: 205 (Salmeterol 50 g), 232 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
0.002 0.1 1 10 500
Favours salmeterol 50 g Favours placebo
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Study or subgroup Salmeterol 50 g Placebo
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Total (95% CI) 3546 3575 0.83 [ 0.69, 1.01 ]
Total events: 214 (Salmeterol 50 g), 251 (Placebo)
Heterogeneity: Chi2 = 7.03, df = 5 (P = 0.22); I2 =29%
Test for overall effect: Z = 1.82 (P = 0.068)
Test for subgroup differences: Chi2 = 2.69, df = 3 (P = 0.44), I2 =0.0%
0.002 0.1 1 10 500
Favours salmeterol 50 g Favours placebo
Analysis 4.5. Comparison 4 Salmeterol 50 µg versus placebo [subgrouped by trial duration], Outcome 5
People with one or more non-fatal serious adverse events.
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 4 Salmeterol 50 g versus placebo [subgrouped by trial duration]
Outcome: 5 People with one or more non-fatal serious adverse events
Study or subgroup Salmeterol 50 g Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 3 months
Rennard 2001 10/132 7/135 1.2 % 1.50 [ 0.55, 4.06 ]
Hanrahan 2008 11/290 19/293 3.3 % 0.57 [ 0.27, 1.22 ]
Subtotal (95% CI) 422 428 4.5 % 0.81 [ 0.45, 1.46 ]
Total events: 21 (Salmeterol 50 g), 26 (Placebo)
Heterogeneity: Chi2 = 2.29, df = 1 (P = 0.13); I2 =56%
Test for overall effect: Z = 0.70 (P = 0.49)
2 6 months
SLMF4010 2005 1/17 3/17 0.5 % 0.29 [ 0.03, 3.13 ]
Mahler 2002 7/160 11/181 1.8 % 0.71 [ 0.27, 1.87 ]
Hanania 2003 5/177 11/185 1.9 % 0.46 [ 0.16, 1.35 ]
Kornmann 2011 19/334 26/335 4.5 % 0.72 [ 0.39, 1.32 ]
Brusasco 2003 49/405 56/400 9.1 % 0.85 [ 0.56, 1.28 ]
0.02 0.1 1 10 50
Favours salmeterol 50 g Favours placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup Salmeterol 50 g Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 1093 1118 17.8 % 0.74 [ 0.55, 1.01 ]
Total events: 81 (Salmeterol 50 g), 107 (Placebo)
Heterogeneity: Chi2 = 1.76, df = 4 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.93 (P = 0.054)
3 12 months
Calverley 2003b [TRISTAN] 69/372 54/361 8.2 % 1.29 [ 0.88, 1.91 ]
Subtotal (95% CI) 372 361 8.2 % 1.29 [ 0.88, 1.91 ]
Total events: 69 (Salmeterol 50 g), 54 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
4 36 months
Calverley 2007 [TORCH] 617/1542 633/1544 69.5 % 0.96 [ 0.83, 1.11 ]
Subtotal (95% CI) 1542 1544 69.5 % 0.96 [ 0.83, 1.11 ]
Total events: 617 (Salmeterol 50 g), 633 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
Total (95% CI) 3429 3451 100.0 % 0.94 [ 0.83, 1.06 ]
Total events: 788 (Salmeterol 50 g), 820 (Placebo)
Heterogeneity: Chi2 = 9.15, df = 8 (P = 0.33); I2 =13%
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Chi2 = 5.25, df = 3 (P = 0.15), I2 =43%
0.02 0.1 1 10 50
Favours salmeterol 50 g Favours placebo
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Analysis 4.6. Comparison 4 Salmeterol 50 µg versus placebo [subgrouped by trial duration], Outcome 6
Predose FEV1 (mL).
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 4 Salmeterol 50 g versus placebo [subgrouped by trial duration]
Outcome: 6 Predose FEV1 (mL)
Study or subgroup Salmeterol 50 g Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 3 months
Hanrahan 2008 276 223.1 (218.2) 275 80.4 (204.1) 20.5 % 142.70 [ 107.42, 177.98 ]
Rennard 2001 109 150 (323.65) 105 -20 (297.16) 12.1 % 170.00 [ 86.80, 253.20 ]
Subtotal (95% CI) 385 380 32.6 % 146.86 [ 114.38, 179.34 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.35, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 8.86 (P < 0.00001)
2 6 months
Hanania 2003 178 91 (300) 185 1 (300) 15.6 % 90.00 [ 28.27, 151.73 ]
Kornmann 2011 333 90 (430) 335 -20 (430) 15.0 % 110.00 [ 44.78, 175.22 ]
Mahler 2002 159 107 (460) 181 -4 (460) 10.2 % 111.00 [ 13.00, 209.00 ]
SLMF4010 2005 17 -94 (239.1) 17 -30 (235) 5.2 % -64.00 [ -223.37, 95.37 ]
Subtotal (95% CI) 687 718 46.1 % 87.93 [ 39.05, 136.80 ]
Heterogeneity: Tau2 = 681.60; Chi2 = 4.12, df = 3 (P = 0.25); I2 =27%
Test for overall effect: Z = 3.53 (P = 0.00042)
3 12 months
Calverley 2003b [TRISTAN] (1) 372 1323 (212) 361 1264 (209) 21.3 % 59.00 [ 28.52, 89.48 ]
Subtotal (95% CI) 372 361 21.3 % 59.00 [ 28.52, 89.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.79 (P = 0.00015)
Total (95% CI) 1444 1459 100.0 % 101.01 [ 59.84, 142.18 ]
Heterogeneity: Tau2 = 1830.26; Chi2 = 19.57, df = 6 (P = 0.003); I2 =69%
Test for overall effect: Z = 4.81 (P < 0.00001)
Test for subgroup differences: Chi2 = 15.15, df = 2 (P = 0.00), I2 =87%
-200 -100 0 100 200
Favours placebo Favours salmeterol 50 g
(1) All data except that from Calverley 2003b [TRISTAN] (endpoint scores) were entered as change from baseline
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Analysis 4.7. Comparison 4 Salmeterol 50 µg versus placebo [subgrouped by trial duration], Outcome 7
Withdrawal.
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 4 Salmeterol 50 g versus placebo [subgrouped by trial duration]
Outcome: 7 Withdrawal
Study or subgroup Salmeterol 50 g Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 3 months
Mahler 1999 9/135 23/143 2.4 % 0.37 [ 0.17, 0.84 ]
Rennard 2001 22/132 29/135 2.8 % 0.73 [ 0.40, 1.35 ]
Hanrahan 2008 44/293 64/294 6.3 % 0.64 [ 0.42, 0.97 ]
Subtotal (95% CI) 560 572 11.5 % 0.60 [ 0.44, 0.83 ]
Total events: 75 (Salmeterol 50 g), 116 (Placebo)
Heterogeneity: Chi2 = 1.79, df = 2 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 3.11 (P = 0.0019)
2 6 months
SLMF4010 2005 7/17 7/17 0.5 % 1.00 [ 0.26, 3.92 ]
Hanania 2003 57/177 59/185 4.5 % 1.01 [ 0.65, 1.58 ]
Mahler 2002 45/160 69/181 5.4 % 0.64 [ 0.40, 1.00 ]
Kornmann 2011 50/334 70/335 6.9 % 0.67 [ 0.45, 0.99 ]
Brusasco 2003 76/405 103/400 9.8 % 0.67 [ 0.48, 0.93 ]
Subtotal (95% CI) 1093 1118 27.1 % 0.72 [ 0.59, 0.88 ]
Total events: 235 (Salmeterol 50 g), 308 (Placebo)
Heterogeneity: Chi2 = 3.17, df = 4 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 3.21 (P = 0.0013)
3 12 months
Calverley 2003b [TRISTAN] 119/372 140/361 11.2 % 0.74 [ 0.55, 1.01 ]
Subtotal (95% CI) 372 361 11.2 % 0.74 [ 0.55, 1.01 ]
Total events: 119 (Salmeterol 50 g), 140 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.92 (P = 0.055)
4 36 months
Calverley 2007 [TORCH] 582/1544 694/1545 50.2 % 0.74 [ 0.64, 0.86 ]
Subtotal (95% CI) 1544 1545 50.2 % 0.74 [ 0.64, 0.86 ]
Total events: 582 (Salmeterol 50 g), 694 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.07 (P = 0.000046)
Total (95% CI) 3569 3596 100.0 % 0.72 [ 0.65, 0.80 ]
0.2 0.5 1 2 5
Favours salmeterol 50 g Favours placebo
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(. . . Continued)
Study or subgroup Salmeterol 50 g Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 1011 (Salmeterol 50 g), 1258 (Placebo)
Heterogeneity: Chi2 = 6.26, df = 9 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 6.24 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.40, df = 3 (P = 0.71), I2 =0.0%
0.2 0.5 1 2 5
Favours salmeterol 50 g Favours placebo
Analysis 5.1. Comparison 5 [Sensitivity analysis-ICS use] All LABA versus placebo, Outcome 1 Quality of
life (SGRQ).
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 5 [Sensitivity analysis ICS use] All LABA versus placebo
Outcome: 1 Quality of life (SGRQ)
Study or subgroup LABA Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Formoterol 12 g twice daily
Bogdan 2011 (1) 199 38.2 (14.5) 206 42.9 (14.5) 3.8 % -4.70 [ -7.52, -1.88 ]
Calverley 2003a 255 0.8 (17) 256 4.7 (17) 3.5 % -3.90 [ -6.85, -0.95 ]
Doherty 2012 (2) 243 -4.93 (14.5) 236 -2.88 (14.5) 4.5 % -2.05 [ -4.65, 0.55 ]
Rennard 2009 495 -2.9 (13.3) 481 -1.5 (12.7) 11.5 % -1.40 [ -3.03, 0.23 ]
Szafranski 2003 201 -3.6 (15) 205 -0.03 (15) 3.6 % -3.57 [ -6.49, -0.65 ]
Tashkin 2008 [SHINE] 284 -1.24 (11.35) 300 -1.02 (12.41) 8.2 % -0.22 [ -2.15, 1.71 ]
Tashkin 2012 209 -6.19 (15.2) 212 -2.88 (15.2) 3.6 % -3.31 [ -6.21, -0.41 ]
Subtotal (95% CI) 1886 1896 38.7 % -2.16 [ -3.04, -1.27 ]
Heterogeneity: Chi2 = 10.68, df = 6 (P = 0.10); I2 =44%
Test for overall effect: Z = 4.76 (P < 0.00001)
2 Formoterol 24 g twice daily
-20 -10 0 10 20
Favours LABA Favours placebo
as endpoint scores.
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(. . . Continued)
Study or subgroup LABA Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Wadbo 2002 61 0 (8.59) 60 1.5 (8.9034) 3.1 % -1.50 [ -4.62, 1.62 ]
Subtotal (95% CI) 61 60 3.1 % -1.50 [ -4.62, 1.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
3 Salmeterol 50 g twice daily
Brusasco 2003 405 -2.8 (14.087) 400 -1.5 (14) 8.1 % -1.30 [ -3.24, 0.64 ]
Calverley 2003b [TRISTAN] 372 45.2 (7.7149) 361 46.3 (9.5) 19.3 % -1.10 [ -2.35, 0.15 ]
Calverley 2007 [TORCH] 1521 -0.8 (14.0772) 1524 0.2 (14.0772) 30.5 % -1.00 [ -2.00, 0.00 ]
SLMF4010 2005 17 -7.1 (15.2555) 17 2.7 (16.0801) 0.3 % -9.80 [ -20.34, 0.74 ]
Subtotal (95% CI) 2315 2302 58.2 % -1.12 [ -1.84, -0.39 ]
Heterogeneity: Chi2 = 2.70, df = 3 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 3.02 (P = 0.0025)
Total (95% CI) 4262 4258 100.0 % -1.53 [ -2.08, -0.98 ]
Heterogeneity: Chi2 = 16.55, df = 11 (P = 0.12); I2 =34%
Test for overall effect: Z = 5.44 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.17, df = 2 (P = 0.20), I2 =37%
-20 -10 0 10 20
Favours LABA Favours placebo
as endpoint scores.
(1) Change from baseline data and endpoint data were pooled in the analysis. Most studies reported change from baseline but data for Bogdan 2011 and Calverley 2003b
[TRISTAN] are entered
(2) SDs for Doherty 2012 and Szafranski 2003 were imputed based on population variance and that of other arms within the studies
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Analysis 5.2. Comparison 5 [Sensitivity analysis-ICS use] All LABA versus placebo, Outcome 2 Severe
exacerbations (hospitalisations).
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 5 [Sensitivity analysis ICS use] All LABA versus placebo
Outcome: 2 Severe exacerbations (hospitalisations)
Study or subgroup LABA Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Formoterol 12 g twice daily
Doherty 2012 5/243 12/236 13.7 % 0.39 [ 0.14, 1.13 ]
Calverley 2003a 73/255 79/256 64.4 % 0.90 [ 0.61, 1.31 ]
Subtotal (95% CI) 498 492 78.1 % 0.81 [ 0.57, 1.15 ]
Total events: 78 (LABA), 91 (Placebo)
Heterogeneity: Chi2 = 2.09, df = 1 (P = 0.15); I2 =52%
Test for overall effect: Z = 1.16 (P = 0.24)
2 Salmeterol 50 g twice daily
Brusasco 2003 20/405 20/400 21.9 % 0.99 [ 0.52, 1.86 ]
Subtotal (95% CI) 405 400 21.9 % 0.99 [ 0.52, 1.86 ]
Total events: 20 (LABA), 20 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
Total (95% CI) 903 892 100.0 % 0.85 [ 0.62, 1.16 ]
Total events: 98 (LABA), 111 (Placebo)
Heterogeneity: Chi2 = 2.35, df = 2 (P = 0.31); I2 =15%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Chi2 = 0.28, df = 1 (P = 0.59), I2 =0.0%
0.2 0.5 1 2 5
Favours LABA Favours placebo
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Analysis 6.1. Comparison 6 [Sensitivity analysis-attrition] All LABA versus placebo, Outcome 1 Quality of
life (SGRQ).
Review: Long-acting beta2-agonists for chronic obstructive pulmonary disease
Comparison: 6 [Sensitivity analysis attrition] All LABA versus placebo
Outcome: 1 Quality of life (SGRQ)
Study or subgroup LABA Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Formoterol 12 g twice daily
Bogdan 2011 (1) 199 38.2 (14.5) 206 42.9 (14.5) 3.8 % -4.70 [ -7.52, -1.88 ]
Calverley 2003a 255 0.8 (17) 256 4.7 (17) 3.5 % -3.90 [ -6.85, -0.95 ]
Campbell 2005 215 -3.81 (13.5737) 217 -4.61 (13.5737) 4.7 % 0.80 [ -1.76, 3.36 ]
Dahl 2001 181 41.7 (16.8) 86 46.8 (17.6) 1.5 % -5.10 [ -9.55, -0.65 ]
Doherty 2012 (2) 243 -4.93 (14.5) 236 -2.88 (14.5) 4.5 % -2.05 [ -4.65, 0.55 ]
Rossi 2002 159 40.9 (17.8) 80 45.3 (18.7) 1.3 % -4.40 [ -9.34, 0.54 ]
Tashkin 2008 [SHINE] 284 -1.24 (11.35) 300 -1.02 (12.41) 8.2 % -0.22 [ -2.15, 1.71 ]
Tashkin 2012 209 -6.19 (15.2) 212 -2.88 (15.2) 3.6 % -3.31 [ -6.21, -0.41 ]
Subtotal (95% CI) 1745 1593 31.2 % -2.07 [ -3.06, -1.08 ]
Heterogeneity: Chi2 = 16.51, df = 7 (P = 0.02); I2 =58%
Test for overall effect: Z = 4.09 (P = 0.000043)
2 Formoterol 24 g twice daily
Dahl 2001 169 43.5 (19.4) 86 46.8 (17.6) 1.4 % -3.30 [ -8.03, 1.43 ]
Rossi 2002 171 42.3 (19) 80 45.3 (18.7) 1.2 % -3.00 [ -7.99, 1.99 ]
Wadbo 2002 61 0 (8.59) 60 1.5 (8.9034) 3.1 % -1.50 [ -4.62, 1.62 ]
Subtotal (95% CI) 401 226 5.7 % -2.25 [ -4.56, 0.06 ]
Heterogeneity: Chi2 = 0.50, df = 2 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.91 (P = 0.056)
3 Salmeterol 50 g twice daily
Brusasco 2003 405 -2.8 (14.087) 400 -1.5 (14) 8.1 % -1.30 [ -3.24, 0.64 ]
Calverley 2003b [TRISTAN] (3) 372 45.2 (7.7149) 361 46.3 (9.5) 19.4 % -1.10 [ -2.35, 0.15 ]
Calverley 2007 [TORCH] 1521 -0.8 (14.0772) 1524 0.2 (14.0772) 30.6 % -1.00 [ -2.00, 0.00 ]
Kornmann 2011 292 -5.6 (15.4) 274 -1.5 (14.9) 4.9 % -4.10 [ -6.60, -1.60 ]
Subtotal (95% CI) 2590 2559 63.0 % -1.31 [ -2.01, -0.61 ]
Heterogeneity: Chi2 = 5.27, df = 3 (P = 0.15); I2 =43%
-10 -5 0 5 10
Favours LABA Favours placebo
data for Bogdan 2011, Dahl 2001, Rossi 2002, and Calverley 2003b [TRISTAN] are entered as endpoint scores.
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(. . . Continued)
Study or subgroup LABA Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Test for overall effect: Z = 3.69 (P = 0.00023)
Total (95% CI) 4736 4378 100.0 % -1.60 [ -2.15, -1.05 ]
Heterogeneity: Chi2 = 24.10, df = 14 (P = 0.04); I2 =42%
Test for overall effect: Z = 5.67 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.82, df = 2 (P = 0.40), I2 =0.0%
-10 -5 0 5 10
Favours LABA Favours placebo
data for Bogdan 2011, Dahl 2001, Rossi 2002, and Calverley 2003b [TRISTAN] are entered as endpoint scores.
(1) Last available score with imputed SD (based on other studies). Change from baseline data and endpoint data were pooled in the analysis. Most studies reported
change from baseline but
(2) SDs for Doherty 2012 and Szafranski 2003 were imputed based on population variance and that of other arms within the studies
(3) Adjusted mean at endpoint
A D D I T I O N A L T A B L E S
Table 1. Length of included studies with summary demographics
Trial length Study IDs Mean age, years,
median (range)
Male, %,
median (range)
3 months Aalbers 2002; Bogdan 2011; Dahl
2001; Hanrahan 2008;
Mahler 1999; Nelson 2007; Rennard
2001; Wadbo 2002;
Watkins 2002
63.5 (62 to 67) 66.5 (52 to 87)
6 months Brusasco 2003; Campbell 2005;
Doherty 2012; Hanania 2003;
Kornmann 2011; Mahler 2002;
SLMF4010 2005;
Tashkin 2008 [SHINE]; Tashkin
2012; Vogelmeier 2008
63 (59 to 65) 75 (63 to 88)
12 months Calverley 2003a; Calverley 2003b
[TRISTAN]; Dahl 2010;
Rennard 2009;Rossi 2002; Szafranski
2003
63.5 (63 to 64) 77.5 (75 to 80)
36 months Calverley 2007 [TORCH] 65 (N/A) 76
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Table 2. Baseline severity within the included studies
FEV1 % predicted at baseline Study IDs Mean baseline SGRQ,
median (range)
30% ≤ mean < 40% Brusasco 2003; Calverley 2003a; Doherty 2012;
Szafranski 2003; Wadbo 2002
50 (47 to 53)
40% ≤ mean < 50% Calverley 2003b [TRISTAN]; Calverley 2007
[TORCH];
Dahl 2010; Hanania 2003; Hanrahan 2008;
Mahler 1999;
Mahler 2002; Rennard 2009; Tashkin 2008
[SHINE]
50 (48 to 55)
50% ≤ mean < 60% Aalbers 2002; Bogdan 2011; Campbell 2005;
Dahl 2010; Kornmann 2011; Vogelmeier 2008
45 (44 to 49)
Five studies did not report mean % predicted FEV1 at baseline; 10 of the studies presented here did not
provide baseline SGRQ.
A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
CENTRAL (The Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
EMBASE (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (Ebsco) Monthly
AMED (Ebsco) Monthly
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Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE Search strategy used to identify trials for the CAGR
COPD search
1. Lung Diseases, Obstructive/
2. exp Pulmonary Disease, Chronic Obstructive/
3. emphysema$.mp.
4. (chronic$ adj3 bronchiti$).mp.
5. (obstruct$ adj3 (pulmonary or lung$ or airway$ or airflow$ or bronch$ or respirat$)).mp.
6. COPD.mp.
7. COAD.mp.
8. COBD.mp.
9. AECB.mp.
10. or/1-9
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
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11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases
Appendix 2. Search strategy for Clinicaltrials.gov
search terms: formoterol OR salmeterol OR LABA OR long-acting OR “long acting”
condition: COPD
study type: interventional studies
C O N T R I B U T I O N S O F A U T H O R S
Chris Mavergames and Kayleigh Kew assessed studies for inclusion. Chris, Julia Walters and Kayleigh extracted data from the papers
and assessed studies for risk of bias. Kayleigh analysed the data and wrote the review, with input from Julia.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• NIHR, UK.
Programme grant funding
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Studies were analysed in four trial duration subgroups rather than the two stated in the protocol (≤ one year or > one year ). It was
not deemed appropriate to organise subgroups according to severity at baseline because the study populations were similar, and so this
was not performed. An additional sensitivity analysis related to the use of other medications during the trials was conducted to deal
with several studies in which the proportion of participants taking inhaled steroids fell just above or just below the 50% cut-off for
exclusion.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Inhalation; Adrenergic beta-2 Receptor Agonists [∗administration & dosage]; Drug Administration Schedule; Pul-
monary Disease, Chronic Obstructive [drug therapy; mortality]; Quality of Life; Randomized Controlled Trials as Topic
MeSH check words
Female; Humans; Male
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